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Phosphofructokinase (ATP: D-fructose 6-phosphate 1-transferase, EC
2.7.1.11) catalyses the phosphorylation of fructose 6-phosphate to fructose 1,6-
bisphosphate, and is a key regulatory enzyme in glycolysis. Sequence conservation
between mammalian PFK and PFK from E.coli, B. stearothermophilus and S.citri,
and between the amino and carboxyl halves of the mammalian enzymes suggests
that mammalian PFK has evolved from a prokaryotic progenitor by a process of
gene duplication and fusion.
The aim of this project was to obtain detailed structural information describing
PFK from humans and from the parasitic filarial nematode Onchocerca volvulus and
so facilitate the design of inhibitors specific for the filarial enzyme. Five Onchocerca
volvulus cDNA libraries were probed with oligonucleotides, heterologous DNA from
E.coli, rabbit muscle and human muscle PFK. Redundant oligonucleotides were
used in a polymerase chain reaction to try to clone part of the parasite's PFK.
Antisera to E.coli and Ascaris suum PFK were used to screen libraries for
expression of PFK. The lack of good quality DNA libraries and the unexpected gene
structure and codon usage of the parasite did not allow the isolation of DNA
encoding O. volvulus PFK.
In man, PFK is under the control of three structural loci encoding subunits for
muscle, liver and platelet types. They are located on separate chromosomes and
are regulated independently. During the course of this project, the muscle and liver
type DNA sequences were reported from other laboratories. The partial sequence of
the platelet type is reported here, and its chromosomal location is confirmed. The
sequence codes for three hundred amino acids and comprises 80% of the carboxyl
domain in comparison to the muscle and liver types.
The structure, function and evolution of PFK is discussed, based on detailed
crystal structure information for PFK from E.coli and B. stearothermophilus and the
amino acid sequences of PFK from other sources
xi
1.1
CHAPTER ONE
INTRODUCTION
HISTORICAL BACKGROUND
6-Phosphofructo-1 -Kinase (EC 2.7.1.11) irreversibly catalyses the
transfer of a phospho group from ATP to the p anomer of frucfese 1-
phosphate to form the p anomer of fructose 1,6 bisphosphate.
2-
OPOCH
3 2
ATP
"OPOCH
3 2 0 ch
H 'a. h
2-
Figure 1. The phosphorylation of fructose 6-phosphate to generate
fructose 1,6-bisphosphate
This phosphorylation was first described in erythroct/fesby Dische in
1935 and then in muscle by Ostern etal. in 1936. Negelein (1936) observed
that administration of epinephrine to frog muscle caused the accumulation of
hexosemonophosphates and a small increase in lactic acid. He proposed
that PFK was a possible regulatory enzyme of glycolysis. Engelhardt &
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Sakov (1943) suggested that inactivation of PFK by O2 was responsible for
the Pasteur effect. Aisenberg etal. (1957) proposed that an intermediate of
oxidative phosphorylation accumulated when glucose was metabolised
aerobically which inhibited PFK. Lardy & Parks (1956) noted that ATP had a
strong inhibitory effect on PFK and that this might play an important part in
carbohydrate metabolism. Since then, PFK has been extensively studied in
a variety of organisms and our knowledge, although still incomplete, has
been expanded to give a greater appreciation of the properties, structure
and regulation of this complex glycolytic enzyme. In the introduction, I will try
to describe the complex behaviour of PFK in vitro and in vivo. There is a
wealth of experimental detail and analysis available for PFK, some of which
is contradictory. The isoenzymes of mammalian PFK have different attributes
and sometimes behave in contradictory ways. Different tissues have varying
levels of isoenzymes and vary according to developmental stages.
In general, prokaryotic PFK's are controlled by a small number of
effector molecules whereas PFK's from more complex organisms are
regulated by a relatively large number of effector molecules. Plant cells also
contain a pyrophosphate dependent PFK which shows little homology to
PFK-1 except at the catalytic site, and it has not been included in this
description. Eukaryotic PFK's undergo association-dissociation reactions
and exist in a variety of polymeric states. The structure of PFK from bacteria
has been investigated in E. coliand B. stearothermophilus. It consists of
large and small domains which have central cores of (3 sheet surrounded
by a helices as seen in Figure 2.
2
I
Figure2.R bbondiagramofmonom r
ofBPFK.Alphahelixisgreen,b tsh t
isorangeandcoilblue.Thmino carboxylterminiiarema k dNndC respectively.
Eukaryotic phosphofructokinases are usually more than twice the
size of their bacterial counterparts and appear to be the result of the gene
duplication and fusion of a prokaryotic ancestral gene. The amino and
carboxyl halves of an eukaryotic PFK have probably the same size and
conformation of a bacterial PFK and so an eukaryotic monomer will
resemble a prokaryotic dimer. The amino half of the eukaryotic enzymes
retains essentially the same function as a prokaryotic enzyme while the
carboxyl half has evolved new sites for binding effector molecules
(Poormann etal., 1984).
1.2 KNOWN DISTRIBUTION OF PFK
PFK has been isolated from a large number of plant, bacterial
verte brate and non verte brate species (Bloxham & Lardy, 1973). DNA
sequences for genes encoding PFK are known for Escherichia coli (Daldal,
1983; Hellinga & Evans, 1985), Bacillus stearothermophilus (French &
Chang, 1987), Thermus thermophilus (Xu et al., 1991), Saccharomyces
cerevisiae (Heinisch, 1986; Heinisch et al., 1989), Spiroplasma citri
(Chevalier et al., 1990), rabbit muscle (Lee et al., 1987), mouse liver
(Gehnrich etal., 1988), human muscle (Nakajima etal., 1987) and human
liver (Levanon etal., 1989; Elson etal., 1990). Partial amino acid sequences
are known for sheep heart and sheep muscle (Sutherland, K. PhD thesis,
University of Auckland, 1989). Multiple forms of PFK were found in the rat
(Lowry & Passoneau, 1964). De-Faria et al. (1976) isolated PFK from
several diverse sources in the phylum chordata. These included human, bat,
cayman, cobra, turtle, frog and carp. Multiple forms were identified by their
electrophoretic mobility. Striated muscle and liver showed mostly single
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forms whereas cardiac muscle and brain had a higher frequency of multiple
forms. Glycolysis has been thought of as a virtually ubiquitous pathway and
it could therefore be assumed that PFK would also be an ubiquitous
enzyme. This has been put into doubt by the recent discovery that some
archaebacteria do not have the normal complement of glycolytic enzymes
(Danson, 1988). Thermoplasma acidophilum possesses operational
glycolysis, but lacks PFK-1, F1,6BP'ase, F1,6BP Aldolase, glyceraldehyde 3-
P dehydrogenase and phosphoglycerate mutase (Budgen & Danson, 1986).
1.3 PFK IN MAMMALS
The description of a new type of glycogen storage disease in skeletal
muscle (Tarui etal., 1965; Layzer etai, 1967) led to the idea of isoenzymes
of PFK. Tarui's disease is a recessively inherited trait which shows the
almost complete absence of PFK in muscle. Half of the normal levels of PFK
are present in red blood cells but normal levels are found in white cells.
Previous kinetic studies on crude extracts from the rat also indicated the
possibility of isoenzymes (Lowry & Passoneau, 1964).
The proposal that erythrocyte and muscle PFK were isoenzymes
sharing partial structural identity was put forward to explain this inherited
defect (Tarui, 1967; Layzer et al., 1967; Tarui et al., 1969). Normal levels of
PFK in other tissues led Layzer & Conway (1970) to propose the existence
of multiple isoenzymes composed of three separate types of PFK subunits
which are under separate genetic control. Immunochemical studies
supported this hypothesis (Tarui et al., 1969; Layzer & Conway, 1970;
Layzer, 1971).
The study of PFK from a variety of animal species provided conclusive
evidence for the existence of isoenzymes of PFK in the rat (Taylor & Bew,
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1970;Tanaka et al., 1971; Kasten et al., 1983; Dunaway & Kasten, 1985;
Vora etal., 1985b), rabbit (Tarui etal., 1972; Tsai & Kemp, 1973), chicken
(Kono etal., 1973), rabbit, mouse, guinea pig, rat (Gonzalez et al., 1975) and
a variety of chordates (de Faria etal., 1976).
1.3.1 Tissue distribution of isoenzymes in humans
Evidence supports the existence of three isoenzymes in humans. The
isoenzymes are distinguished as muscle (M), liver (L) and platelet (P) forms.
The subunits of these isoenzymes are encoded by three separate structural
genes (Vora, 1982).
Anti-PFK antibodies generally tend to be isoenzyme specific, but not
species specific. Thus, antibodies raised against homotetramers will
completely precipitate that isoenzyme and will also show cross species
specificity (Gonzalez et al., 1975; Vora ., 1982). Anti-liver PFK antibody
show no cross reactivity with muscle or platelet homotetramers (Oskam et
al., 1985; Vora et al., 1981) and anti-muscle PFK antibody shows virtually no
cross reactivity with liver homotetramers (Tsai & Kemp, 1973). Structural
similarities between the muscle and platelet subunits is assumed to account
for the cross reactivity of anti muscle antibody to platelet PFK (Vora et al.,
1981). Subunit specific antibodies have been raised against human PFK
isoenzymes (Dunaway et al., 1988) and have been used to study the relative
amounts of homo and heterotetramers in human tissues. Only adult muscle
showed the presence of a single subunit, the muscle subunit. Other tissues
showed various amounts of all three subunits. Table 1 gives the percentage
of each subunit present in various tissues determined by densitometric
scanning of immunoblots of subunits resolved by SDS-PAGE (Dunaway et
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al., 1988).
The properties of the native enzymes indicate that the PFK isoenzyme
pools in human tissues can be very complex and are not simple
combinations of two or three homotetrameric isoenzymes, but complex
mixtures of homo and heterotetramers.Dunaway et al. (1988) quantified the
isoenzymic content of various human tissues by immunotitration with
subunit-specific antibodies, stepwise elution from QAE Sephadex, scanning
densitometry of silver stained gels and immunoblots.
Table 1 Quantification of the PFK subunits in human tissue
From Dunaway et al. (1988)
LIVER MUSCLE PLATELET
STAIN BLOT STAIN BLOT STAIN BLOT
TISSUE. SUBUNIT... % % % % % %
SKELETAL MUSCLE
HEART VENTRICLE
HEART ATRIA
CEREBRAL CORTEX
LIVER
FIBROBLAST
ERYTHROCYTE
PLATELET
PLACENTA
UMBILICAL CORD
ND ND 100
3±0.5 2.5 91±7
14±2 15.9 76±3
15±2 14.2 55±3
62±5 61.6 29±3
21 ±2 21.8 16±3
54±4 56.0 43±3
42+3 39.8 19+3
81 ±6 83.0 12+2
57±4 60.0 16±2
100.0 ND ND
93.0 7±2 4.5
77.7 10±2 6.4
58.4 30±4 27.4
28.9 10±2 9.5
17.0 63±6 61.2
40.3 5±1 3.7
22.5 38+2 37.7
10.5 8+2 6.5
10.0 27±3 30.0
Nakajima et al. (1990c) reported the presence of HLPFK mRNA in
human muscle, in conflict with the isoenzyme specific antibody work of a
variety of authors (Vora, 1952.; Dunaway et al., 1988). MLPFK mRNA
has also been reported in mouse muscle (Gehnrich et al., 1988). This does
not necessarily show that the liver monomer is present in muscle, as the
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amount of a gene product (protein), is finely regulated by transcription,
translation and post-translational modification.
1.3.2 Structural properties of isoenzymes in humans
The subunit molecular masses of the isoenzymes have been
determined by SDS-PAGE. Muscle was reported as 85 kDa (Karadsheh et
al., 1977; Cottreau et al., 1979) and 80kDa (Kaur & Layzer, 1977). The
amino acid sequence of the muscle enzyme indicates a molecular mass of
85,050 (Nakajima et al., 1987; Sharma et al., 1989). The liver subunit was
reported as 80 kDa (Karadshesh et al., 1977; Cottreau et al., 1979). The
platelet isoenzyme was reported as 85 kDa. The subsequent cloning of the
human muscle and liver genes gives a more precise figure for subunit mass.
The liver subunit amino acid sequence suggests a Mr of 85,146 (Levanon
etal., 1989).
1.3.2.1 Aggregation of isoenzymes
PFK subunits have a tendency to self associate into oligomeric forms
larger than the tetramer, which is the lowest active form of the enzyme. This
process is influenced by a variety of factors such as pH, enzyme
concentration, metabolic activators and inhibitors, and structural cellular
components (Paetkau & Lardy, 1967; Layzer et al., 1969; Brand & Soling,
1974; Reinhart & Lardy 1980b; Aaronson & Frieden, 1972).
The liver enzyme was reported to self associate more readily
than the muscle enzyme (Kemp, 1971; Trujillo & Deal, 1977; Reinhart &
Lardy, 1980b). The rabbit brain isoenzyme, which is 50% platelet form does
not aggregate beyond a tetramer at pH 8.0 (Foe & Kemp, 1985).
At low protein concentrations, PFK dissociates into non-active forms
smaller than the active tetramer (Layzer etal., 1969; Hulme & Tipton, 1971;
Underwood & Newsholme, 1965; Reinhart & Lardy, 1980b). This process
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can be reversed and is prevented by the presence of activators such as
AMR Dissociation of the enzyme is promoted by inhibitors such as ATP
(Hofer, 1971; Hulme & Tipton, 1971; Reinhart & Lardy, 1980b).
The dissociation constant of large aggregates of rat liver PFK is lower
in the presence of saturating F6P than it is in the presence of saturating
MgATP. In the absence of either substrate PFK dissociates past the active
tetramer with a concomitant loss of activity. MgATP promotes tetramer
formation more readily than F6P. This suggests that the monomer-dimer
population has a lower affinity for F6P than MgATP, but the opposite is the
case for the aggregated population (Ramaiah & Tejwani, 1970, 1973;
Reinhart, 1980; Reinhart & Lardy, 1980a,b.)
Crystallographic and kinetic studies (Berger & Evans, 1990)
indicated that the allosteric and cooperative behaviour of PFK is due to a
reversible transition between two states that differ in affinity for F6P by a
factor of at least 2,000. Increasing amounts of F6P increases the fraction of
the high affinity R state. In the absence of F6P the low affinity T state
predominates.
The use of a reactive thiol group to monitor the transitions between R
and T states suggested that allosteric transitions were readily made at
protein concentrations where the enzyme existed as a tetramer or higher
polymer and that dissociation to dimers was not required for the inhibited
conformation (Kemp, 1969a).This thiol group has been isolated and
sequenced (Simpson et ai, 1977). It is a highly reactive cysteine group
corresponding to position 88 in RMPFK and position 73 in BPFK. This
residue is important for catalytic activity and is conserved in most
phosphofructokinases.
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1.3.3 PHYSICAL PROPERTIES OF ISOENZYMES
The pH optima have been reported for PFK's from a variety of
mammalian species. Most have an optimum at slightly alkaline pH (Layzer
eta!., 1969; Staal etal., 1972; Dunaway et ai, 1972; Massey & Deal, 1973;
Balinsky et at., 1979). PFK from Erlich ascites tumour has a lower pH
optimum of 7.1 (Sumi & Ui, 1972) which fits in with the high rates of
glycolysis and concomitant decrease in pH observed in some tumour cells.
The isoelectric points are reported to be at pH 6.6 for the muscle form,
pH 5.0 for the erythrocyte form (M + L subunits) and pH 4.6 for the form in
erythrocytes from patients with Taruis disease (L subunits only) (Kaur &
Layzer, 1977).
Electron microscopy of pig liver PFK (Foe & Trujillo, 1980) shows that
particles ranging in size from tetramers to long flexible chains of tetramers
are present. Tetramers are square planar and approximately 11 OA on a
side. The individual subunits are roughly spherical with a mean radius of
28A. The chains are formed by end to end association of tetramers and the
geometry of association implied a D2 symmetry (see Section 6.3) with
distinct isologous bonding domains for dimer, tetramer and chain formation.
Electron microscopy of rabbit muscle PFK indicated a subunit volume
of 101nm3 and the appearance of a conical shape with rounded off corners
and edges of a rectangular prism (Hesterberg et a!., 1981). Structural
features within the tetramer were interpreted as being due to the four
individual subunits being approximately 4 x 6 x 6 nm (tapered to a
trapezoidal shape) and arranged with D2 dihedral symmetry. This is
consistent with the observation by Klotz et at. (1975) that essentially all
tetrameric proteins of known structure display D2 symmetry.
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1.3.4 GENETICS OF ISOENZYMES
The genes for the liver, muscle and platelet type subunits have been
assigned to chromosomes 21, 1 and 10, respectively (Weil etal., 1980; Vora
& Francke, 1981; Vora etal., 1982; Vora etal., 1983). In addition to the three
recognised loci, Ashley et al. (1987) identified another possible locus for a
PFK gene. They used a mouse PFK cDNA probe to search a human
astrocytoma cDNA library to isolate a human PFK cDNA probe which they
referred to as human PFKX. They assigned PFKX to chromosome 12 by
using the cDNA for slot blot hybridisation to sorted human chromosomes
and by Southern blot analysis of DNA from mouse/human somatic cell
hybrids. They assigned the homologous mouse gene to chromosome 15,
using a panel of hamster/mouse somatic cell hybrids. S1 nuclease
protection assays indicated that PFKX is expressed in human fibroblasts and
brain. Northern blot analysis of RNA from various adult mouse tissues
showed a high level in mouse testes. Further reports on this particular work
have not appeared in the literature and the work was presented as an
abstract. It may be that this group have isolated the gene for another PFK
isoenzyme, such as an embryonic or foetal form, or even a processed
pseudogene. Sequence data and perhaps expression of the putative
isoenzyme would greatly clarify this work.
Although the three PFKs have similar structures, functions and
cellular locations they are not tightly clustered on a specific chromosome.
This may be the result of gene duplication followed by translocation and/or
early tetraploidisation of the karyotype (Ohno, 1970). HPPFK and HK have
been localised to the same region of chromosome 10 in humans (Schwarz
et al., 1984) and are considered to be syntenic but later studies suggest
otherwise (see Section 6.4). This is of interest as high levels of PFK and HK
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are noted in certain tumour cells in addition to an elevated rate of glycolysis.
PFK and PK are linked in the mycoplasma Spiroplasma citri to form a single
transcriptional unit (Chevalier etai, 1990).
1.4 KINETIC AND ALLOSTERIC PROPERTIES OF PFK
PFK activity is affected to the greatest extent by its substrates ATP and
F6P, and the products F1,6BP and ADP. More than 30 presumptive
regulatory effectors have been reported. The significance of effector
regulation in vivo is still a subject of controversy. Table 2 lists the known
effectors of PFK.
Table 2. EFFECTORS OF PHOSPHOFRUCTOKINASE
INHIBITORS ACTIVATORS DEINHIBITORS
ATPO) cAMP(6) cAMPW
CITRATE*2) AMP*3) AMP(6)
Mg2+(12) Pj(6) Pj(6)
Ca2+(5) ADP(6) ADP(6)
PHOSPHOCREATINE*15) nh4+*8) F6PP)
GLYCERATE 3-P(3) M1,6BP*12) M1.6BP02)
GLYCERATE 2.3BP*3) K+(8)
GLYCERATE 1,3BP(3) F1,6BP(9) F1,6BP(9)
GLYCERATE 2-P(3) F2,6BP*1°) F2,6BP(10)
OLEATE/PALM ITATEC14) R1,5BP(H) R1,5BP(11)
3\5'-CGMP(12) G1.6BP01) G1,6BP(H)
H+W OH'W
GSSG*16) GSH06)
S042-(17)
TCA cycle intermediates^)
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CALMODULINS CALMODULINS)
ACETYL CoA(oxidised)(14)
ACTINO3) ACTINC3)
(1) Section 1.4.2.1 (9) Section 1.4.1.3
(10) 1.4.3
(11) 1.4.1.4
(12) 1.4.1.5
(13) 1.4.5
(14) Tejwani (1978)
(15) Connet (1989)
(16) Gilbert (1982)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
1.4.2.2
1.4.2.4
1.4.2.3
1.4.6
1.4.1.1
1.1
1.4.1.2
(17) Akkermann, etal. (1974)
In general, prokaryotic PFK is controlled by a small number of effector
molecules. These are the activators Mg.ADP and Mg.GDP, and the inhibitor
PEP (Sols, 1981).
1.4.1.1 Activation of mammalian PFK by adenine nucleotides
PFK is activated by ADP and AMP both of which can also relieve ATP
inhibition (Underwood & Newsholme, 1965; Brock, 1969; Kemp, 1971; Tsai
& Kemp, 1974). In the absence of Mg2+, ADP binds more tightly than other
nucleotides to the activating site, but in the presence of Mg2+ the affinity for
ADP is greatly reduced (Kemp & Krebs, 1967). The activating site is very
specific for the adenine ring (Kemp & Krebs, 1967) but will also bind a
variety of phosphorylated derivatives of adenosine besides AMP, cyclic AMP
and ADP, e.g. ADP-ribose and NADH (Gottschalk & Kemp, 1981).
In the absence of ADP, the binding of F6P is highly cooperative with a
Hill coefficient of 3.8 . The positive homotropic interactions are lowered on
the addition of the allosteric effector ADP, with the Hill coefficient dropping to
1.4 at 0.8 mM ADP. (Blangy et al., 1968). ADP thus binds preferentially to
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the R state. The effector site (site C) binds ADP and also PEP in E. coli PFK
(Evans et al., 1981). It lies in a deep cleft formed by the small domains of
two subunits. The phosphate residues of these effectors are bound by
positively charged side chains from both subunits of the enzyme. (See
Section 1.6.1).
Rat liver PFK requires higher concentrations of AMP and ADP to
achieve an increase of activity comparable to that observed for the rat
muscle enzyme (Kemp, 1971). The relative insensitivity of the liver enzyme
to these effectors is due to a higher affinity for ATP at the inhibitory site
(Lowry & Passoneau, 1966). Even near saturating concentrations of these
effectors fail to increase the affinity of the enzyme for F6P in the presence of
3mM MgATP and thus the enzyme does not appear to function properly at
physiological F6P levels (Reinhardt & Lardy, 1980a). It is only when the
effects of all the positive effectors (FBP, AMP, and Pj) synergistically combine,
that the affinity for F6P appears to approach the level sufficient to account for
physiological activity.
The platelet isoenzyme is less sensitive to stimulation by AMP than
the muscle and liver enzymes. Pj stimulates the platelet enzyme less than
the liver enzyme which is less sensitive than the muscle enzyme (Foe &
Kemp, 1985).
cAMP is an activator of PFK at even lower concentrations than AMP or
ADP (Kemp 1971; Tsai & Kemp, 1974). The liver enzyme is less sensitive to
activation by cAMP than the muscle enzyme (Kemp, 1971).
1.4.1.2 Activation by NH4+ and K+
NH4+ and (NH4)2S04 have been found to increase PFK activity and
relieve ATP inhibition (Underwood & Newsholme, 1965; Brock, 1969; Kemp,
1971; Tejwani etal., 1973). The concentration of NH4+ ions rises in certain
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tissues during anoxia (Lowry & Passoneau, 1966). This may be of
physiological significance in these tissues. NH4+ increases the affinity of the
enzyme for F6P (Kemp & Krebs, 1967; Dunaway & Weber, 1974a) but does
not change the affinity for ATP or MgATP (Pettigrew & Frieden, 1979a).
Potassium ions are essential for enzyme activity (Uyeda & Racker,
1965; Lowry & Passoneau, 1966; Paetkau & Lardy, 1967; Kemp 1971). The
activators K+ and NH4+ increase Vmax without greatly affecting inhibition by
ATP for the human skeletal muscle isoenzyme (Kemp & Foe, 1983 ),
whereas the primary mode of action of the physiological activators (AMP,
F16BP and inorganic phosphate) and inhibitors (MgATP, citrate and H+) in
rats is to alter the Km for F6P with little or no effect on Vmax. Cys-73 in
B.stearothermophilus may be important for binding of monovalent cations.
1.4.1.3 Activation by F16BP
F16BP activates PFK in the same manner as ADP by decreasing the
apparent affinity of the inhibitory site for ATP or MgATP (Pettigrew & Frceden,
1979a), resulting in the loss of ATP inhibition (Bloxham & Lardy, 1973). The
synergistic effect of the three activators F16BP, AMP and Pj leads to the
assumption that different binding sites exist for the three ligands (Lowry &
Passoneau, 1966; Reinhart & Lardy, 1980a). Hers and Hue (1983) have
suggested however that F16BP could be considered as an inhibitor at high
concentrations.
1.4.1.4 Activation by Ribose 1,5BP
Glycolytic flux in the brain is activated several fold within a few
seconds after the initiation of ischemia by decapitation. Analysis of brain
samples showed that within 2-5 seconds, F6P decreases by 60%, and
F16BP increases 7-fold, consistent with activation of PFK. None of the
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known activators of PFK, including F16BP, F26BP, G16BP or AMP, can
account for this rapid activation. Ogushi et at. (1990) reported that R15BP
forms rapidly during the initiation of glycolytic flux and disappears within 20
seconds. Ishikawa et al. (1990) found that R15BP was the second most
potent activator of rat PFK in vitro with F26BP being the most potent, and that
R15BP was more potent than F16BP. Other mammalian PFKs show similar
affinities for F26BP but vary in their affinities for R15BP. Rat liver PFK had 3-
fold less affinity for R15BP than the rat brain enzyme or RMPFK and this
may reflect the physiological roles of the isoenzymes. However, R15BP has
only been shown to occur in the brain and it is not possible to assess its
importance in other cells.
1.4.1.5 Activation by other sugar bisphosphates
Sugar bisphosphates such as mannose 1,6-bisphosphate and
glucose 1,6-bisphosphate have been postulated to be regulators of PFK
(Rose & Warms, 1974; Uyeda, 1979; Passoneau & Lowry, 1963). More
recent work suggests that control of PFK is primarily achieved by variation in
the levels of fructose 2,6-bisphosphate, (see Section 1.4.3).
1.4.2 INHIBITION OF PFK
Prokaryotic PFK is inhibited by PEP, but the mammalian
enzymes have a large number of inhibitors. Each isoenzyme has a separate
response to inhibitors and the responses vary according to the organism
(Meinhofer et al., 1980). ATP acts synergistically with other inhibitors
(Mathias & Kemp, 1972).
1.4.2.1 Inhibition of PFK by ATP
ATP is a substrate of PFK but will inhibit the enzyme if present at
sufficiently high levels (Underwood & Newsholme, 1965). ATP binds to a site
distinct from the catalytic site as well as to the catalytic site itself (Colombo
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et al., 1975). The human isoenzymes vary in their response to ATP
concentration (Dunaway et al.* 1988). In the absence of F26BP, the muscle
homotetramer is least susceptible to ATP inhibition and the muscle-rich
isoenzymes are less susceptible to ATP inhibition than isoenzyme pools
from platelets and fibroblasts which contain a high percentage of platelet
type subunit. The same trend is seen in the presence of F26BP although
F26BP is a potent antagonist of ATP inhibition. Regardless of the presence
of F26BP, ATP inhibition is more pronounced as the concentrations of P
subunit in a heterotetramer increases and ATP sensitivity may be an intrinsic
property of this subunit, (Dunaway etal., 1988)
The degree of inhibition by a fixed concentration of ATP and the
concentration at which inhibition occurs is a function of the pH and F6P
concentration (Ui, 1966; Brock, 1969; Dunaway & Weber, 1974a; Pettigrew &
Fr/eden, 1979b).
Below pH 7.5, PFK shows a strong sigmoidal dependence on the
concentration of F6P and to inhibition by ATP at high concentrations, and
also on the allosteric interaction of a number of effectors. At pH 8.0 however,
the enzyme displays typical hyperbolic kinetics with respect to F6P and ATP
and is not altered by allosteric effectors (Lowry & Passoneau, 1966;
Pettigrew & Frieden, 1979b; Uyeda et al., 1983). Decreased sensitivity to
ATP occurs at alkaline pH, with the muscle enzyme showing less sensitivity
than liver enzyme (Tsai & Kemp, 1974).
ATP inhibition can be relieved by the addition of F6P (Underwood &
Newsholme, 1965) but the situation is complicated by the additional effects
of F26BP. The liver enzyme requires at least twice as much F6P as the
muscle enzyme to give half maximal velocities under any conditions (Kemp,
1971; Tsai & Kemp, 1974).
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ATP is thought to lower the affinity of PFK for F6P (Underwood &
Newsholme, 1965). It is likely that the liver enzyme has a greater affinity for
ATP than the muscle enzyme at the ATP inhibitory site. This would explain
why the liver enzyme shows susceptibility to ATP inhibition at a lower ATP
concentration than the muscle enzyme (Kemp, 1971).
1.4.2.2 Inhibition by TCA cycle intermediates
PFK is inhibited by a number of TCA cycle intermediates. These are
a-oxoglutarate, succinate, malate, acetyl CoA, fumarate and
citrate (Underwood & Newsholme, 1965). Citrate is by far the most important
inhibitor and acts synergistically with ATP (Underwood & Newsholm, 1965;
Uyeda, 1979). In rabbits, the muscle enzyme is more sensitive to citrate
inhibition than the platelet form, which in turn is more sensitive than the liver
form (Foe & Kemp, 1985). The human platelet enzyme however, is reported
as being more sensitive to citrate inhibition than the muscle or liver enzymes
(Meinhofer et al., 1980).
Inhibition is believed to occur by reducing the affinity of the enzyme
for F6P (Pettigrew & Fneden, 1979b). This would account for F6P relieving
inhibition of muscle PFK at lower concentrations than that needed for liver
PFK, as muscle PFK has a higher affinity for F6P.
Citrate levels increase when acetyl CoA levels rise. Acetyl CoA
condenses with oxaloacetate to form citrate. When glycolysis increases and
citric acid cycle intermediates are not consumed as a source of biosynthetic
precursors, citrate acts as a negative feedback on glycolysis by inhibiting
PFK (Passoneau & Lowry, 1963), and thereby enhances the coordination of
glycolysis, ATP production, and TCA cycle intermediate levels (Foe & Kemp,
1985).
1.4.2.3 Inhibition by decreasing pH
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Low pH decreases the affinity of PFK for F6P (Trivedi & Danforth,
1966; Reinhart, 1985) as well as causing dissociation below the active
tetramer (Paetkau & Lardy, 1967; Hofer & Pette, 1968; Mansour, 1972). The
process can be reversed by increasing pH (Hofer & Pette, 1963) and by the
addition of ligands (Alpers et al., 1971; Lad et al., 1973) which give an
increase in activity and a higher molecular weight of the active enzyme.
Inhibition by low pH is greater at higher ATP concentration. This can be
counteracted in the human erythrocyte by increasing the concentration of
F6P (Layzer, et al., 1969). With frog muscle PFK, increases in F6P
concentration displace the pH curve toward the acid side (Trivedi &
Danforth, 1966) but this does not occur with HMPFK.
As muscle contracts, the pH rises at first because of hydrolysis of
creatine phosphate and this may promote activity of PFK. Later as the
concentration of lactic acid increases, pH falls (Karpatkin et al., 1964). This
decrease in pH inhibits the activity of PFK so stopping lactate production
before the pH becomes low enough to damage the cell (Danforth, 1965).
Bock and Frieden (1974; 1976a; 1976b) proposed a mechanism for
pH inactivation and cold lability of PFK based on the alteration of the pK of
an ionisable group on the enzyme. The model requires that pH and
temperature changes are linked and that different enzyme forms are
involved in inactivation and reactivation which proceed by kinetically
different pathways. This transition takes place in the pH range 6-7 and so
one or more histidines are proposed to be subject to the
protonation/deprotonation equilibrium, (Bock etal., 1975). This is supported
by the loss of three protons during the formation of a tetramer from
monomers between pH 6.0-8.55, since the ionisable residues have an
apparent pKa of 6.9 (Luther & Lee, 1986q).
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Different ligands are proposed to bind to protonated or unprotonated
forms of the enzyme and shift the apparent pK for the activation or
inactivation process (Bock & Frieden, 1976b).
ATP and MgATP increase the pK by 0.1 units whereas F6P decreases
it by 0.3 units. At high concentrations of ATP the behaviour is more complex
which suggests that more than one ATP binding site is present. The
presence of ATP also increases the rate of F6P reactivation. Bock &
Frieden's protonation/deprotonation model accords with the Monod, Wyman
and Changeux model for allosteric proteins and with the Frieden model of R
and T states of allosteric enzymes having two substrates (Pettigrew &
Frieden, 1977). Although the protonated form may deactivate to inactive
dimeric forms, this will be slow in the absence of effectors which promote
dissociation, such as citrate, and may account for the oscillatory behaviour
due to PFK seen in vivo (Goldhammer & Paradies, 1979).
Positive modulators such as F26BP, G16BP and AMP counteract pH
mediated ATP inhibition and stabilise the unprotonated form of the enzyme
against citrate inhibition (Dobson et al., 1986). These modulators must
reverse pH inhibition of PFK as several cases are reported where PFK is still
active when the pH is below that reported to be inhibitory to the enzyme
(Newsholme & Crabtree, 1978; Meyer etal., 1982; Bailey & Seymour, 1983).
Decreasing pH increases the Km for F6P. Studies on rabbit muscle
PFK indicated that decreasing pH decreased the apparent dissociation
constant forMg.ATP (Pettigrew & Frieden, 1979a; Kitajima etal., 1983). This
may reflect a difference in the allosteric regulation of the L and M
isoenzymes (Reinhart, 1985) which agrees with observations that unlike the
muscle enzyme, liver PFK exhibits significant cooperativity and MgATP
inhibition at high pH (Reinhart & Lardy, 1980a).
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1.4.2.4 Inhibition by phosphate esters
The muscle enzyme is inhibited by PEP, glycerate 3-P glycerate 2-P,
glycerate 2,3-P and phosphocreatine which act synergistically with ATP to
inhibit muscle PFK but have little effect on the liver enzyme (Tsai & Kemp,
1974; Tejwani, 1978). Muscle PFK is inhibited more by glycerate 3-P than
by glycerate 2-P but the reverse is true for the liver enzyme. Glycerate 2,3-
BP is a more potent inhibitor of the liver enzyme than glycerate 2-P or
glycerate 3-P and may be more important than ATP in erythrocytes where it
reaches levels high enough to be an inhibitor (Tsai & Kemp, 1973). The
erythrocytes contain a heterogenous mixture of five tetrameric isoenzymes
resulting from the random association of M and L subunits to form all the
possible tetramers ie., M4, M3L, M2L2, ML3 and L4 . The subunits seem to
be present at a ratio of 1:1 as is expected from the 50% activity of PFK in
erythrocytes in individuals with Tarui's disease who lack the muscle subunit
(Vora, 1982).
Glycerate 2,3-BP plays a major role in the regulation of oxygen affinity
of haemoglobin in man (Brewer 1974). Binding of glycerate 2,3-BP or ATP
decreases the oxygen affinity. The level of glycerate 2,3-BP is governed
primarily by its synthesis which depends on the level of its precursor
glycerate 1,3-BP (Rose & Warms, 1971; Jacobasch et al., 1974). The
synthesis of glycerate 1,3-BP depends in part on overall glycolytic flux and
therefore on the key glycolytic enzymes HK, PFK, PK, and BPGM. Major
control is exerted by the ratio of PFK/ PK activities; the higher the
PFK/PK ratio, the more 23BPG is formed (Jacobasch, et al., 1974;
1980; Gilman, 1981). Patients with inherited PFK deficiency such as
in Tarui's disease show the expected decrease in 2,3BPG and ATP levels in
the RBC (Lutcher & Bigley, 1974; Oda etal., 1977; Tarui et al., 1978; Vora et
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al., 1980; 1982; Waterbury & Frenkel, 1972; Miwa, etal., 1972).
Simulations (Connett, 1989) suggest that energy dependent control is
linked to the energy charge of the cell as indicated by creatine charge and
not on the absolute concentrations of adenine nucleotides. In heart and
skeletal muscle, ATP levels are very steady because of the buffering action
of creatine kinase (Connett, 1989). A number of studies have suggested that
concerted action by several effectors is required to account for the observed
glycolytic activity in heart and muscle. The discovery in 1980 that F26BP is a
potent regulator of liver PFK (Van Schaftingen et al., 1980b, c) provided a
mechanism by which PFK could be controlled, since at physiological F6P
concentrations, rat liver PFK is inactive unless activators such as F26BP plus
AMP are present (Pilkis et al., 1981b).
1.4.3 THE ROLE OF F26BP
The synergistic action of the effectors F16BP, AMP and Pj was
presumed in the early 1980's to be the way in which liver PFK was activated
in vivo since near saturating concentrations of these individual effectors
would fail to activate the enzyme sufficiently to permit it to function at
physiological F6P levels (Reinhart & Lardy 1980a). The discovery in 1980
that F26BP is a potent regulator of liver PFK provided direct evidence that
notwithstanding in vitro evidence, liver PFK could actually function in vivo.
F26BP is an extremely effective, positive effector of liver and muscle PFK. Its
concentration is greatly increased in the liver when glycolysis is active and is
decreased by glucagon (Van Schaftingen & Hers, 1980b; Claus etal., 1981).
It also inhibits F16BP'ase at micromolar concentrations in liver and muscle
(Pilkis et al., 1981b) and appears to be a major regulator of glycolysis and
gluconeogensis in the liver (Hue & Rider, 1987).
The presence of F2,6BP has been detected in a variety of human
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tissues but not in erythrocytes (Heylin etal., 1982; El-Maghrabi etal., 1986).
It has been found in bacteria, fungi, yeast and in higher plants such as mung
beans (Sabularse & Anderson, 1981). Nanomolar concentrations of F26BP
have been found to stimulate all animal PFK's which have been tested but
no effects have been demonstrated on PFK's from these other sources
(Sabularse & Anderson, 1981; Cseke etal., 1982; Van Schaftingen & Hers,
1983b).
F26BP is formed by PFK2 from F6P and ATP (Furuya & Uyeda, 1981;
El-Maghrabi et al., 1981; Van Schaftingen & Hers, '\98'\&,h). F26BP is
hydrolysed to F6P and Pi by a specific F26BP'ase - FBP'ase 2 (El Maghrabi
etal., 1982b). The bisphosphatase and kinase activities are present on a
single (Pilkis etal., 1983b, c; El-Maghrabi etal., 1982a,b).
1.4.3.1 Response of PFK to F26BP
In the absence of activators or in the presence of 1 mM ATP, very little
PFK activity could be demonstrated for human PFK isoenzyme pools at F6P
concentrations less than 1nM or at ATP concentrations greater than 0.5mM
(Dunaway etal., 1988). The addition of F26BP gives significant activity when
the F6P concentration is less than 1mM and the ATP concentration is greater
than 0.5mM. The muscle type homotetramer has the highest affinity for F6P
in the absence of F26BP with an apparent Km = 2.0mM, while the liver rich
isoenzymes from placenta had apparent Km = 5mM for F6P. The isoenzymes
from platelet and fibroblasts with P type isozyme form contents of 40% and
63% respectively, have lower affinities for F6P with apparent Km = 3.5mM for
the platelet forms and Km = 4.0mM for the fibroblast forms. The presence of
F26BP strongly increases affinities for F6P. The muscle and liver rich
isoenzymes from placenta exhibit very similar F6P saturation curves with
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apparent Km values of 0.07mM whereas the platelet and fibroblast isozyme
pools gave apparent Km values of 0.35 mM and 0.55 mM respectively
(Dunaway eta!., 1988).
Some mammalian tissues, especially the heart, contain a
PFK2/F26BP'ase that acts principally as a kinase (Crepirf^4989b), and
separate F26BP'ases have not been detected. (F26BP is 50-100 times more
effective than F16BP in activating PFK (Pilkis etal., 1981a). The apparent
affinity of PFK for F26BP was measured by its ability to promote
reassociation, and compared with F16BP. The apparent Kd for F26BP under
these conditions was 36pM which is 40-fold lower than the Kd of 1.4mM
measured for F16BP (Reinhart, 1983). The concentration of F6P has a
positive influence on F26BP concentration. (Flue etal., 1981). F26BP'ase is
strongly inhibited by F6P, which decreases Vmax and increases Km. This
inhibition is counteracted by several phosphoric esters, including glycerol-3-
P at concentrations normally present in the liver (Van Schaftingen et at.,
1982 >; Claus etal., 1982). This might explain the low levels of F26BP seen
when glycerol or ethanol is present (Flue etal., 1982).
The apparent affinities of PFK and F26BP'ase for F26BP depend on
the concentration of substrates or effectors such as F16BP and AMP. F26BP
increases the affinity of PFK for F6P, but has no effect on the maximum
activity of the enzyme (Pilkis etal., 1981a; Van Schaftingen1981b;
Uyeda et at., 1981). F26BP strongly counteracts inhibition of rat liver PFK by
high concentrations of ATP and citrate (Soling et at., 1981). The human
isoenzymes have the same response. In the absence of F26BP, M4 showed
the least susceptibility to ATP. L-rich enzymes were less sensitive to ATP
than were the isoenzyme pools from platelets and fibroblasts. The apparent
Km values for ATP of muscle, placenta, platelet and fibroblast forms in the
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presence of 1 pM F26BP were 3.3mM, 2.8mM, 0.5mM and ~50nM
respectively (Dunaway etal., 1988).
6-Phosphogluconate is an activator of PFK from liver, adipose tissue,
kidney and skeletal muscle and acts synergistically with F26BP under most
conditions (Sommercorn et al. 1984). F26BP will also stabilise liver PFK
against the rapid, spontaneous inactivation which occurs in its absence at
37°C (Soling etal., 1981) and 50°C (Uyeda, etal., 1981) and also prevents
inactivation by PFK phosphatase and low pH.
F2,6BP will prevent dissociation of PFK even when the enzyme is
diluted to concentrations as low as 4 x 10"8M and also promotes
reassociation to the tetramer and larger forms from the inactive dimer. It will
also inhibit dissociation by MgATP (Reinhart, 1983). The promotion of
aggregation of PFK by F26BP may be one of the ways in which F26BP
achieves its activating effects in vivo, as aggregation increases the activity of
the enzyme under physiological conditions.
The efficiency of F26BP in activating PFK is 2 to 3.5 orders of
magnitude greater than that of its isomers F16BP and G16BP (Hers & Hue,
1983; Pilkis et al., 1981a). The concentrations of F16BP and F26BP are very
similar in the liver and usually change in parallel. It is likely that at least in
the liver and probably in other cells, F16BP is not a physiological stimulator
of PFK. At high concentrations, F16BP counteracts the positive effect of
F26BP on erthrocyte PFK (Heylin et al., 1982) and yeast PFK (Bartrons et
al., 1982) and could be considered to be an inhibitor.
Trypanosoma brucei pyruvate kinase, together with PK from the
glycosome-containing members of the Kinetoplastida family, i.e. the insect
trypanosomatid Crithidia luciliae, the human trypanosomatid Leishmania
major (Van Schaftingen etal., 1985), the parasitic Bodonid Trypanoplasma
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borelli (Opperdoes et al., 1988), and Trypanosoma cruzi (Cazzulo et al.,
1989) all differ from their homologous eukaryotic counterparts in that their
PFK is not activated by F26BP. However, they contain the only class of PK
that is activated by F26BP (van Schaftingen et al., 1987). PFK is
sequestered in the glycosome of these organisms and is probably
inaccessible to F26BP (Callens etal., 1991).
1.4.3.2. Factors controlling the concentration of F26BP
The major factors that determine the concentration of liver F26BP in
vivo are the concentrations of F6P and the phosphorylation state of
PFK2/F26B'ase. The concentration of F26BP in rat liver is less than 1pM
during starvation or diabetes and up to 20|iM in the fed state (Pilkis et al.,
1986; Claus et al., 1981). In starvation or diabetes, the enzyme is
phosphorylated with a 2 to 3 fold increase in Km for F6P (Murray etal., 1984)
while there is a decrease in F6P concentration to ~50jiM (Hems & Brosnan,
1970; Start & Newsholme, 1986). At this level, the kinase is operating below
its Km for F6P and F26BP synthesis is minimal. The enzyme is
dephosphorylated in the fed state and has a Km of 50jiM for F6P in the
presence of Pj (Murray et al., 1984). The enzyme is operating above its Km
for F6P as F6P concentrations are 0.1-0.2mM (Start & Newsholme, 1986)
giving a high rate of synthesis of F26BP.
1.4.3.3. The effect of F26BP on bisphosphatase activity
The Km of the bisphosphatase (of PFK-2/F26BP'ase) for F26BP is
100nM in the presence of Pi and a-glycerol-P (Stewart et al., 1985) and the
concentration of F26BP never falls to below an order of magnitude larger
than this and so changes in F26BP concentration will not affect the
bisphosphatase activity. There is a strong inhibition of the bisphosphatase
activity by F26BP and F6P (El-Maghrabi etal., 1982b; Sakakibara etal.,
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1984a; Murray et al., 1984; Kitajima et at., 1984; Van Schaftingen et al.,
1982b) but this is relieved by phosphorylation of the enzyme (Van
Schaftingen etal., 1982b; El Maghrabi etal., 1982a, c; Stewart etal, 1986).
Hormone-induced changes in the level of F26BP and F6BP are
achieved by altering the phosphorylation state of the enzyme via cAMP-
dependent protein kinase (Pilkis et al., 1983a) or via protein kinase C
(Crepin etal., 1989c).
F26BP is an activator of PFK-1 and an inhibitor of F16BP'ase (Van
Schaftingen etal., 1981a; Pilkis etal., 1981b). The inhibition is synergistic
with AMP for the liver (but not the muscle) enzyme. Liver PFK-1 does not
appear to be affected by phosphorylation and these two differences may be
a reflection of tissue specificity. The binding sites for F26BP and F16BP may
be different or they may overlap (Van Schaftingen, 1987). The hexose
bisphosphate binding site has not been ascertained with certainty.
In livers of fed rats producing lactate, the tissue concentrations of AMP
(0.1-0.2mM) and F26BP (10jiM), should be sufficient to completely inhibit
F16BP'ase even at saturating concentrations of substrate. Cycling of
metabolites between glucose and triose phosphates does occur however
(Clarkeet al., 1983; Hue, 1987) indicating that PFK-1 and F16BP'ase are
active under these conditions. No reports have demonstrated complete
inhibition of F16BP'ase in vivo, while in contrast, PFK-1 is completely
inactive during gluconeogenesis (Gottschalk etal., 1983). This suggests that
F16BP'ase is less inhibited in vivo than would be expected from in vitro
measurements. Kinetic and binding studies indicate that the affinity of
F16BP'ase for F26BP is about ten fold less than that for PFK-1 (Kitajima et
al., 1983). It may be that control over F16BP'ase is exerted by the level of
phosphorylation, although phosphorylation of F16BP'ase by cyclic AMP-
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dependent kinase has only been demonstrated for the rat liver enzyme
(Ekdahl & Ekman, 1985).
1.4.3.4. Control of glycolytic flux by F26BP
The most obvious role for F26BP is to control glycolysis and
gluconeogenesis. This would be of particular importance in the liver where
both pathways operate. Gluconeogenesis is stimulated by glucagon and
predominates in fasting and diabetes. Upon administration of glucagon or
cAMP to isolated hepatocytes, the levels of F26BP decrease rapidly.
(Bartrons et al., 1983). This is due to the cAMP-dependent protein kinase
mediated phosphorylation of the PFK2/F26BP'ase enzyme which leads to
inactivation of the PFK-2 moiety (Garrison & Wagner, 1982; Pilkis et al.,
1982b).
Insulin, which acts to counter the effects of glucagon by elevating
cAMP levels, opposes the action of glucagon to lower F26BP levels
(Terrettaz et al., 1986). The rate of gluconeogenesis is thus accelerated by
glucagon and decelerated by insulin, with F26BP as the switching signal.
When F26BP levels are high, the activity and flux through PFK-jis high,
F26BP'ase is inhibited and glycolytic flux predominates. When F26BP levels
are low, PFK-i is inhibited, F16BP'ase and flux are enhanced and
gluconeogenic flux increases (Pilkis etal., 1988).
The increase in the levels of F16BP increases the activity of pyruvate
kinase by acting as a positive effector, and also inhibits phosphorylation of
PK . .by cAMP-dependent protein kinase so decreasing its Km for PEP (El-
Maghrabi & Pilkis, 19851 Claus etal., 1979).
Insulin administration increases the synthesis of PFK (Dunaway et
al., 1978) and also increases the concentration of a PFK stabilising factor
which may be F26BP (Van Schaftingen et al., 1983a). F16Pase activity is
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reported to be decreased by insulin administration (Weber etal., 1966).
Increases in glycolysis can occur in the liver and other tissues with no
increases in F26BP levels (Hue et al., 1982). This was observed in
hepatocytes during anoxia, in muscle during electrical stimulation and in
hearts treated with epinephrine. Under these conditions some other factor
must be involved in the control of glycolysis.
In long-term starvation or diabetes, the activities of PFK-2/F2,6BP'ase
decreased and could be restored by re-feeding or insulin administration and
reflected alterations in the level of enzyme protein (Pilkis et al., 1983a;
Richards & Uyeda, 1982; Gil etal., 1986). Thyroxine and glucocorticoids
increased the total activities and did not involve changes in the
phosphorylation state of PFK-2/F26BP'ase. If the steady state concentration
of F26BP is determined by the two opposing reactions of the enzyme then
an increase in the total amount of enzyme should not change the steady
state concentrations of F26BP assuming the phosphorylation state and
concentrations of effectors of the enzymic activities do not change. In the
starvation/refeeding cycle there appears to be a need for additional enzyme
molecules reflecting the need for a lipogenic rather than a gluconeogenic
enzyme (Pilkis & El-Maghrabi, 1988).
In the well fed animal, circulating levels of glucose and insulin are
elevated and glucose homeostasis is maintained primarily by dietary intake,
and when needed, by the breakdown of liver glycogen. The rate of
gluconeogenesis is low due to a high rate of substrate cycling at both the
F6F/F16BP and the pyruvate/PEP substrate cycles which in turn is due to the
high activity of PFK and PK (Hue, 1987). The bifunctional enzyme is
dephosphorylated which leads to high levels of F26BP via activation of the
kinase and inhibition of the bisphosphatase. PFK is activated by the high
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levels of F26BP while F16BP'ase is inhibited. This leads to elevated levels
of F16BP which is a strong allosteric activator of PK. The increased allosteric
activation and dephosphorylation of PK increases flux through the enzyme
and depresses gluconeogenesis (Rognstad & Katz, 1977).
In fasting and longer term starvation the rate of gluconeogenesis is
elevated. Insulin levels fall and this increases hepatic levels of cAMP (Claus
et al., 1984a). The stimulation of gluconeogenesis is due to inhibition of PFK
and activation of F16BP'ase which is effected by lower F26BP levels caused
by cAMP-dependent phosphorylation of PFK-2/F26BP'ase-2. This
phosphorylation inhibits the kinase and promotes the hydrolysis of F26BP
via the bisphosphatase. Lower levels of F26BP and enzyme
phosphorylation inhibit PK (Engstrom, 1978). The increase in
gluconeogenesis is also caused by an increase in the levels of phosphoenol
pyruvate carboxykinase (Hod et al., 1986). In diabetic and starved rat, liver
PFK-2 content but not its encoding mRNA, is decreased (Crepin etal., 1988).
PFK-2 content can be raised by injection of insulin, and the mRNA content
raised by refeeding (Colosia et al., 1988). Thyroid hormone will also
increase levels of PFK-2 content and mRNA content in hypothyroid rats (Wall
etal., 1989).
F26BP is unlikely to be the only regulator of glycolysis and
gluconeogenesis. After refeeding of starved rats, F26BP levels remained low
for several hours, rising toward high fed values only when glycogen levels
had returned to those of the fed state. This is consistent with an elevated rate
of gluconeogenesis during the initial stages of glycogen formation but does
not explain the enhanced rate of glycolysis (Claus et al., 1984c). When
starved rats are fed a diet high in sucrose the bulk of the hepatic glycogen
was gluconoegenic in origin despite the fact that F26BP rose rapidly to high
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levels (Kuwajima etal..; 1986). Castel ijn et al. (1986) reported an unknown
low molecular weight activator of F1,6BP'ase that overcame the inhibition by
F26BP. A F26BP dependent cytosolic protein from liver was identified by
Niemeyer et al. (1987) that inhibited hexokinase, and this might also play a
role in the regulation of glycogen production.
1.4.4 COVALENT MODIFICATION OF PFK BY
PHOSPHORYLATION
Several laboratories tried to phosphorylate PFK without success after
it was shown in 1965 that PFK was made more stable during purification by
the addition of fluoride or ATP (Ling etal., 1966"). Subsequently, Brand and
Soling (1975) phosphorylated a low pH precipitate fraction of liver PFK, and
Hofer & Furst (1976) isolated [32P]PFK from muscle tissue of mice previously
injected with [32P] phosphate.
1.4.4.1. Phosphorylation of PFK
PFK from a variety of sources has been phosphorylated in vitro and
in vivo. Yeast PFK (Huse etal., 1988), mouse muscle PFK (Hofer and Furst,
1976; Riquelme etal., 1978a), rabbit skeletal muscle PFK (Hussey etal.,
1977; Uyeda, etal., 1978), rat skeletal muscle PFK (Uyeda et al., 1978) and
rat liver PFK (Kagimoto & Uyeda, 1979) are all partially phosphorylated in
vivo. They can all be phosphorylated in vitro by cAMP-dependent protein
kinase (Riquelme etal., 1978b; Sorenson-Ziganke & Hofer, 1979; Riquelme
& Kemp, 1980; Claus etal., 1982, 1985; Pilkis etal., 1982b; Mieskes etal.,
1987). The Ca2+-calmodulin dependent protein kinase phosphorylates
rabbit liver, but not rabbit muscle PFK, at a slightly lower rate than cAMP-
dependent protein kinase (Mieskes et al., 1987), and protein kinase C
phosphorylates skeletal muscle PFK in vitro (Hofer et al., 1985; Mieskes et
al., 1987). All three isoenzymes from mammals are reported to be capable of
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being phosphorylated (Kemp & Foe, 1983), and possible phosphorylation
sites on the three rabbit enzymes have been described (Valiatis etal., 1989),
(see section 1.4.4.3).
The extent of phosphorylation of PFK in vivo is dependent on the
tissue and on its metabolic state (Sorensen-Ziganke & Hofer, 1979; Hofer,
1983). The extent of phosphorylation of PFK is higher in contracting muscle
than resting muscle (Hofer & Sorenson-Ziganke, 1979). Hofer and Furst
(1976) calculated a phosphate content of -0.7 moles of phospho group per
mole of protomer. Several groups (Hussey et ai.\ 1977; Uyeda et al., 1978;
Riquelme et al., 1978b; Kemp & Foe, 1983) all found levels of covalently
bound phospho group in rabbit muscle at levels closer to 0.2 moles phospho
group per mole of protomer. Rabbit muscle PFK isolated under three
different conditions had very different covalent phosphate contents. This
was higher than the levels reported by other groups (Hussey et al., 1977;
Uyeda et at., 1978; Riquelme et al., 1978a; Riquelme et al., 1978b). The data
suggest more than one site of phosphorylation and this has also been
observed for rat liver PFK (Pilkis et al., 1982a) and muscle PFK (Starling et
al., 1982).
Other studies indicate that no more than two moles phospho group
per tetramer could be incorporated into PFK by Ca2+/Calmodulin protein
kinase (Mieskes etal., 1987). Domenech etal. (1988) also found no more
than two moles phospho group per tetramer in rat liver PFK confirming the
results of Brand & Soling (1982). There may be a secondary site of
phosphorylation at the high affinity calmodulin binding site (see section
1.4.6).
1.4.4.2 Effects of Phosphorylation
The evidence for a physiologically relevant regulation of the activity of
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PFK by phosphorylation is contradictory and controversial, and regulation is
thought to be mediated primarily by the concentration of F26BP. Isoenzymes
of PFK may vary in their response to phosphorylation. Phosphorylation may
favour gluconeogenesis in liver but favour glycolysis in muscle.
Phosphorylation does not change the maximum catalytic activity of muscle
and liver PFK or their relative mobilities on SDS-PAGE (Sakakibara &
Uyeda, 1983). Differences have been observed in the response of PFK
phosphorylated by cAMP-dependent protein kinase. Phosphorylated muscle
and liver PFK exhibit an increased affinity for ATP at the inhibitory site and
decreased affinity for F6P at the active site (Foe & Kemp, 1982; Kitajima et
al., 1983; Sakakibara & Uyeda, 1983). These enzymes are also less
sensitive to activation by AMP, G16BP and inorganic phosphate (Foe &
Kemp, 1982) and so are more sensitive to inhibition by ATP and citrate than
less phosphorylated forms.
The high-phosphate form of liver PFK also shows a 1.6 fold greater
Kq.5 for F6P than the low-phosphate form and these differences become
greater at lower pH (Sakakibara & Uyeda, 1983).
Rabbit muscle PFK phosphorylated with protein kinase C gives a
slight decrease in activity but an increase in activity when phosphorylated
with protein kinase A (Flofer et al., 1985).
Contradictory findings have been reported for the interaction of
F26BP with phosphorylated or dephosphorylated PFK. Some results
suggest that the phosphorylated forms of muscle and liver PFK are less
sensitive to activation by F26BP (Furuya & Uyeda, 1980; Foe & Kemp, 1982;
Sakakibara & Uyeda, 1983) while no change in sensitivity has been
reported by others (Pilkis et al., 1982a; Kitajima et al. (1983). If
phosphorylation does exert a physiological effect, it may not be a direct
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effect on enzyme activity but via some indirect action such as an interaction
with cellular organelles or some other cell structural component (see section
1.4.5.) It may be that phosphorylation has a more direct effect on PFK-
2/F26BP'ase and PK. Glucagon causes levels of cAMP to rise and the
activation of cAMP-dependent protein kinase. This kinase will then catalyse
the addition of 1 mol of phosphate per mol of liver PFK-2/F26BP'ase subunit
(Murray et al., 1984) inactivating PFK-2. Phosphorylation by cAMP
dependent protein kinase C can also inactivate PK. Liver PK can also be
phosphorylated, and so inhibited, by Ca2+"CaM dependent protein kinase
(Schworer etal., 1985). F16BP is a potent inhibitor of both phosphorylations
(Claus & Pilkis, 1981).
Sale & Denton (1985a, b) describe the activation of rat adipose tissue
PFK by phosphorylation in vitro and by exposure to insulin and adrenalin/'n
vivo. They put forward the view that an increase in cAMP levels in adipose
tissue may result in an increase in glycolysis mediated by the
phosphorylation of PFK by cAMP-dependent protein kinase.
1.4.4.3 The phosphorylation site
The site of phosphorylation in rabbit muscle PFK is a serine residue,
the sixth amino acid from the carboxyl terminus (Riquelme & Kemp, 1980;
Kemp et al., 1981). The serine is preceded by the sequence Arg-Lys-Arg
which is similar to other known substrates for cAMP-dependent protein
kinase (Kemp & Foe, 1983) where basic residues precede the serine
undergoing phosphorylation. The same sequence is present in HMPFK.
HLPFK and MLPFK have the sequence Arg-Arg-Thr-Leu-Ser. The
phosphorylation sites of liver and muscle PFK are susceptible to limited
proteolysis which leaves the catalytic properties intact but reduces the Mr by
-2000 (Riquelme & Kemp, 1980; Krystek & Hofer, 1981). This is seen with
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trypsin and subtilisin (Sakakibara & Uyeda, 1983; Riquelme & Kemp, 1980;
Kemp et al., 1981j Kitajima etal., 1983).
Reports of a second phosphorylation site in the muscle enzyme
(Hofer & Sorenson-Ziganke, 1979; Sorenson-Ziganke & Hofer, 1979) have
been confirmed by Zhao et at. (1991). They note that the site may be in the
connecting peptide region and that phosphorylation inhibits RMPFK but not
RLPFK or yeast PFK. Protein kinase C phosphorylates one or more separate
sites of Ascaris suum PFK (Flofer et al., 1985). Protein kinase C and the
Ca2+/calmodulin-dependent protein kinase phosphoryate PFK at the same
site as cAMP-dependent protein kinase (Flofer et al., 1985; Mieskes etal.,
1987; Domenech etal., 1988).
Phosphorylation sites have been reported for the three rabbit
isoenzymes (Valiatis et al., 1989). Rabbit muscle and liver forms are
composed of the homotetramers M4 and L4 respectively (Tsai & Kemp,
1972,1973; Gonzalez etal., 1975). P type subunit is the predominant form in
rabbit brain with slightly less M type and a small amount of L type (Foe &
Kemp, 1984,1985).
Valiatis et al. describe the same phosphorylation site as in previous
reports (Riquelme & Kemp, 1980; Kemp et al., 1981). The site of
phosphorylation for liver PFK is identical to that proposed by Gehnrich et al.
(1988) for mouse liver PFK and for human liver PFK by Levanon et al.
(1989). The sequence of the labelled peptide from rabbit liver is 80%
identical to the human and mouse liver sequences.
The rabbit platelet type sequence is dissimilar to the sequence of the
human platelet sequence presented in this thesis (see Chapter 5) but only
thirteen residues were reported. The rabbit platelet sequence shows no
similarity to PFK from any organism but sequence conservation may not be
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strong at the carboxyl terminal tail.
The in vitro site of phosphorylation for the rabbit muscle enzyme is
identical to the in vivo site (Kemp et at., 1981) but it is unknown if this holds
true for the liver and platelet sequences.
1.4.4.4 Control of phosphorylation
The elevation of pH or the addition of AMP increases the extent of
phosphorylation of the rabbit muscle and rat liver enzymes (Kemp et al.,
1981; Pilkis et al., 1982a; Foe & Kemp, 1984; Domenech etal., 1988) while
the addition of ATP or citrate inhibits the phosphorylation of both enzymes.
F16BP had no effect on the rat liver enzyme but increased the
phosphorylation rate of the rabbit muscle enzyme (Kemp etal., 1981).
F26BP enhanced the rate of phosphorylation of the rat liver enzyme (Pilkis
et al., 1982a; Foe & Kemp, 1984; Domenech etal., 1988).
Phosphorylation appears to inhibit the activity of the liver and muscle
enzymes. The active form of the enzyme is a better substrate for the cAMP-
dependent protein kinase than the inactive form, and so increased levels of
cAMP may inhibit active enzymes in this way.
Glucagon changes the concentration of F26BP thereby changing the
activity of PFK (see section 1.4.3.1). It also increases the incorporation of 32P
into rat liver PFK in vivo (Kagimoto & Uyeda, 1979), isolated hepatocytes
(Claus etal., 1980) and isolated perfused liver (Kagimoto & Uyeda, 1980).
The phosphorylated enzyme shows a large decrease in activity (Kagimoto &
Uyeda, 1979).
Glucose increases the phosphorylation rate of PFK from rat liver
(Brand & Soling, 1982; Brand et al., 1983; Claus et al., 1982) but this is
dependent on the fed state of the animal (Brand et al., 1983). In starved
animals, glucose or glucagon can separately increase the rate of
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incorporation of 32P, and together they increase phosphorylation to a
maximal rate. In the fed animal, both glucose and glucagon are necessary to
achieve incorporation of 32P into liver PFK (Brand & Soling, 1982; Claus et
al., 1982).
1.4.4.5 Phosphorylation of Ascaris suum and Fasciola
hepatica PFK.
This project was not only concerned with characterising human PFK.
We were also interested in characterising PFK from the human parasitic
filarial nematode Onchocerca voh/ulus, and examining any differences in
structure and control of PFK between the two species (see section 1.10).
Phosphorylation of mammalian PFK by cAMP-dependent protein
kinase does not appear to result in any significant change of the catalytic
and regulatory properties. Hofer et al. (1982) and Daum et al. (1986) noted
that purified PFK from the pig intestinal parasitic nematodeAscaris suum
was effectively phosphorylated and activated by a protein kinase purified
from Ascaris suum muscle, and that the activation could be reversed by the
action of a phosphatase purified from the same tissue. This protein kinase,
and the cAMP dependent protein kinase both catalyse the incorporation of 1
mol of phosphate per subunit of tetramer, but cAMP-dependent protein
kinase does not activate Ascaris suum PFK. This suggests that the muscle
protein kinase is phosphorylating a residue distinct from that phosphorylated
by cAMP-dependent protein kinase. PFK from the liver fluke flatworm
Fasciola hepatica is also activated by phosphorylation (Kamemoto &
Mansour, 1986). The Mr of PFK from F. hepatica is -83,000 which is
comparable to the mammalian isoenzymes. It would be interesting to know
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if there is any structural diversity between the enzymes to account for this
difference in response to phosphorylation. The Ascaris suum
phosphorylation site has been sequenced (Kulkarni etal., 1987) and it bears
no relationship to the proposed phosphorylation sites of the mammalian
enzymes. It may have a relationship to the effector site of E. coli PFK
however (see Section 6.4).
It would be interesting to know if this situation occurs in O.volvulus
as it might then be possible to target phosphorylation in the parasite as a
possible site for drug therapy. This assumes of course that the Ascaris
muscle protein kinase does not have a counterpart in the mammalian host
which is responsible for activating PFK by phosphorylation. The significance
of this activation by phosphorylation is discussed in section 6.4
1.4.5 Interaction of PFK with Actin
Evidence has accumulated which suggests that some of the glycolytic
enzymes are actin binding proteins (Masters, 1984; Clarke etal., 1983).
PFK, aldolase, glyceraldehyde 3-P-dehydrogenase and PK bind to
paracrystalline actin bundles (Clarke et al., 1983; Roberts & Somero, 1987).
High concentrations of PFK form a precipitate with actin A. The addition of F-
actin to a solution of rabbit muscle PFK partially reverses the inhibition seen
at high ATP concentrations, and increases the affinity of the enzyme for F6P
with a slight effect on Vmax(Liou and Anderson 1980). F-actin also augments
activation by AMP and partially counters inhibition by citrate. Luther and Lee
(1986b), proposed that in contracting muscle, the need for energy is high
and that localising the glycolytic enzymes at the point where energy is
needed would increase the efficiency of the system. If the glycolytic enzymes
are in the muscle matrix where ATP is utilised, then the ATP produced can
be more efficiently delivered and used. If PFK is considered to be the key
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regulatory enzyme in glycolysis then its location needs to be controlled and
this could be determined by phosphorylation status. There may be a time lag
between phosphorylation and the formation of a PFK-actin complex. The
kinetic behaviour of phosphorylated PFK not complexed with actin is more
sigmoidal than the dephosphorylated form, and so its activity at the same
F6P concentration is lower than the dephosphorylated form. In resting
muscle, energy is still needed and a dephosphorylated PFK not complexed
with actin will give higher activity at the same concentration of substrate.
Phosphorylated PFK has a higher affinity for F-actin than the
dephosphorylated enzyme. F-actin acts as a positive effector of the
phosphorylated form but does not significantly affect the kinetic properties of
the dephosphorylated form (Luther & Lee, 1986b). Once the complex is
formed, the enzymic activity is increased so that glycolytic flux increases to
meet the needs of the contracting muscle.
Actin stabilises the active tetrameric form of PFK and it is possible that
this is the cause of the kinetic activation (Roberts & Somero, 1987).
Polyethylene glycols have been found to prevent or decrease the rate of
spontaneous deactivation of rat liver PFK which is due to subunit
dissociation. The Km for F6P at pH 7 in the presence of 3mM MgATP was
dramatically lowered by increasing PEG concentration (Reinhart, 1980).
Tropomyosin and troponin are thin filament proteins associated with
actin, and they reduce the binding of PFK to actin. ATP and ADP also inhibit
binding but not F6P or F26BP. It is possible that actin binds to PFK at the
adenosine activating site (Roberts & Somero, 1989) and that the
phosphorylation of PFK could lead to a change in conformation which is too
minor or distant to affect access of ATP or ADP but modifies the ability of the
enzyme to interact with actin.
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Binding sites for GAPDH, aldolase and PFK were localised on the
actin monomer in microfilaments (Mejean eta!., 1989). The locations were
investigated by measuring the competition between each enzyme and anti-
actin antibodies directed against known, limited portions of the actin
sequence. GAPDH and aldolase gave specific reactivity to certain parts of
the actin microfilament, but PFK modified the reactivity of all antibodies
tested suggesting that the interface between PFK and actin is large with ill-
defined boundaries.
1.4.6 Interaction of PFK with Calmodulin
Calmodulin (CaM) is a ubiquitous intracellular Ca2+ receptor, which
plays a part in the majority of the Ca2+-regulated processes that have been
studied in eukaryotic cells. Phosphofructokinase has been shown to be a
calmodulin binding protein (Mayr & Heilmeyer, 1983). The high affinity
interaction of CaM with PFK could be attributed to binding of CaM to the
inactive dimeric form of the enzyme (Buschmeier etal., 1987).
There are two CaM binding sites per subunit of rabbit skeletal muscle
PFK each with different affinities for CaM. The high and low affinity sites
have Kd values of 1pM and 3mM, respectively. The high affinity site can bind
CaM when PFK is a dimer or a monomer but not a tetramer (Mayr, 1984b).
The weaker binding site is in the C-terminal part of the enzyme and contains
the site which is phosphorylated by the cAMP-dependent protein kinase
(Kemp etal., 1981). The high affinity site is in the 'connecting peptide
region' (Poorman etal., 1984). This region is also proposed to make contact
between dimers in the tetrameric state, a view supported by the inability of
CaM to bind to the high affinity site in the tetramer. Its resistance to digestion
with sub tilisin in the tetramer also supports this conclusion (Buschmeier et
a!., 1987)).
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Under certain conditions, Ca2+-calmodulin (Ca2+-CaM) will accelerate
the rate of dissociation of PFK from the active tetramer to inactive dimeric
and monomeric forms, and will oppose the effect of regulatory activators
(Mayr, 1984a, 1984b). On the one hand, CaM acts as a Ca2+-dependent
hysteretic inhibitor of the active tetramer inducing the shift to the inactive
dimeric state which is stabilised by CaM so shifting the equilibrium state to
dissociated inactive forms. On the other hand, CaM can also allosterically
activate tetrameric PFK under certain conditions. The hysteretic inactivation
implies that the dimer can no longer be reconstituted to the active tetramer if
CaM dissociates when the concentration of calcium falls and that the dimers
have undergone a conformational change. Large inactive polymers are
formed under these conditions (Mayr & Heilmeyer, 1983; Mayr, 1984a). If
Ca2+CaM is present in high concentrations then the oligomerisation of
dimers is suppressed and a slow depolymerisation to inactive oligomers can
occur. The Ca2+ CaM deactivated enzyme isomer can be back isomerised by
Mg2+ ATP and dimers can be best reassociated to the active tetramer by
F26BP, although CaM is still required for this process (Mayr, 1984a). High
concentrations of Ca2+CaM modulate the association state of PFK in a way
resembling that of allosteric effectors such as F26BP. The apparent allosteric
activation of dilute PFK by CaM is in fact a slowdown of tetramer
dissociation.
The binding of CaM can prevent phosphorylation, and vice versa.
The unknown secondary phosphorylation site for PFK may be present at the
CaM high affinity site (see Section 1.4.4.1) or may be involved at the ATP
inhibition site (see section 6.4). The serine residue at position 377 in RMPFK
at the amino end of the high affinity CaM site,is preceded by Lys-Leu-Arg-
Gly-Arg has three basic residues and is partially consistent with the
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sequence of other cAMP-dependent phosphorylation sites (Kemp & Foe,
1983). This is not the case with the liver enzymes. It has been suggested
that CaM and cAMP-dependent protein kinase act on common sequences in
proteins, subject to dual control by Ca2+ and cAMP, and that modification of
certain CaM binding sites is one of the functions of the cAMP-dependent
protein kinases (Malencik & Anderson, 1982, 1983; Anderson & Malencik,
1986).
Another activity of Ca2+-CaM dependent protein kinase is the
phosphorylation of liver (but not muscle) PK at two sites (Schworer etal.,
1985). One site is the same serine residue phosphorylated by cAMP
dependent protein kinase while the second site is an unique threonyl
residue close to this serine. Phosphorylation inhibits PK and enhances flux
towards gluconeogenesis. It is possible that Ca2+-CaM dependent
phosphorylation of PFK is modulated by Ca2+ linked hormones such as
vasopressin and angiotensin in a manner similar to PK.
Sheep heart PFK is reputed to be phosphorylated by Ca2+-CaM
protein kinase at two sites distinct from those which are phosphorylated by
cyclic AMP dependent protein kinase (Mahrenholz et al., 1991). Inactivation
of RMPFK by other proteins has been noted by Zhao et al. (1991). In
decreasing order of effectiveness these proteins are, skeletal muscle
troponin, >troponin, the two smooth muscle myosin light chains, a-actin and
(the calcium binding protein) bovine brain S-100»parvalbumin and
soybean trypsin inhibitor. Troponin and Ca2+-CaM-induced phosphorylation
is strongly inhibited by F26BP and/or F16BP. Binding to or phosphorylation
of a site in the connecting peptide of PFK may result in the formation of
inactive dimers. Rabbit liver and yeast PFK do not show any appreciable
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loss of activity in the presence of Ca2+-CaM or troponin
The connecting peptide serine residue which is thought to be
phosphorylated is also found in HMPFK, SHPFK, SLPFK and FILPFK. In
resting muscle, PFK may be inactivated in a dimeric form. This could be
mediated by Ca2+ concentration for example, via troponin or myosin or
perhaps by phosphorylation. Activation of PFK in active muscle could
perhaps be achieved by rising levels of F16BP and F26BP induced by
dephosphorylation of F16BP'ase and F26BP'ase.
1.5.1 Regulation of PFK In Vivo
The isoenzymes of PFK are found in differing amounts depending on
the tissue being examined (see Section 1.3.1). The isoenzymes are
kinetically distinct and do not simply exist in homotetrameric forms but can
combine to form heterotetramers. The kinetic and regulatory properties of
various isoenzyme pools are dependent on subunit composition, and
contribute significantly to the diversities of glycolytic and gluconeogenic
rates which have been observed for different tissues (Dunaway, 1983).
1.5.1.1 Regulation of Muscle PFK In Vivo
Adult muscle is the only tissue so far to show a homotetrameric
enzyme composed of four identical muscle PFK subunits. When muscle
contracts, it has an immediate requirement for ATP and this is met by
glycolysis which utilises blood glucose, creatine phosphate and muscle
glycogen. Creatine phosphate is the first metabolite to be exhausted in
stressed muscle (Hearse & Chain, 1972). Under most conditions, there is an
excess of creatine phosphate which ensures that a high ratio of ATP to ADP
and AMP exists. Helmreich and Cori (1965) have shown that ATP levels do
not vary greatly when muscle is stimulated electrically or when glycolytic flux
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is increased greatly. The decrease in creatine phosphate concentrations
would relieve the inhibition of PFK, PK (Kemp, 1973) and GAPDH (Oguchi
et al., 1973). Regulation of muscle PFK in vivo by changing levels of ATP,
ADP and AMP may only be significant therefore when energy reserves are
severely depleted.
When muscle is metabolising fatty acids, the resulting high
concentrations of citrate will cause inhibition of muscle PFK and reduce
glycolytic flux. During anaerobosis, decreasing pH inhibits muscle PFK. This
effect can be partially countered by positive modulators such as F26BP,
G16BP and AMP (Section 1.4.2.3). It is important to note that synthesis of
F26BP by PFK-2 is stimulated by cAMP induced phosphorylation, and so
adrenalin will stimulate glycolysis in muscle. The reverse is true for the liver
enzyme (see Section 1.4.3).
Alternative splicing has been reported for HMPFK mRNA (Nakajima
etal., 1990a;1990c). Two RNA's for HMPFK have 5' non coding sequences
differing in length due to alternative splicing, while another contained an
additional sequence at the 5' end of a non-coding 5' sequence. This
suggests that the third type was under the control of another promoter.
1.5.1.2 Regulation of Liver PFK In Vivo
Gluconeogenesis is more important than glycolysis in the liver. The
reactions catalysed by PFK and F16PBP'ase are important to the regulation
of glucose metabolism (Hers, 1976; Weber et at., 1967) If both enzymes are
active then the homeostatic regulation of ATP is lessened and glycolytic flux
is decreased (Hers & Hue, 1983). A high ratio of F1,6B'ase to PFK activity is
needed for gluconeogeri&is while F16BP'ase activity must be reduced for
the promotion of glycolysis. In the livers of fed rats (Van Schaftingen et al.,
1980a) and in isolated hepatocytes (Van Schaftingen etal., 1980b), there is
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evidence that PFK and F16BP'ase are both active, as there is a recycling of
metabolites between F6P and F16BP. Recycling is highest when the switch
is taking place between glycolysis and gluconeogenesis (Clark etal., 1974).
F26BP is an inhibitor of F16BP'ase but it seems that the inhibition is
incomplete allowing PFK and F16BP'ase to be active simultaneously.
A major source of the raw material for gluconeogenesis in the liver is
lactate. The Cori cycle allows contracting skeletal muscle to reduce pyruvate
to lactate in anaerobic conditions and so regenerate NAD+. The NAD+
allows glycolysis to proceed and so the muscle can shift some of the
metabolic burden to the liver. The glucose produced during
gluconeogenesis can then be carried to the muscle allowing contraction to
proceed.
1.5.1.3 Regulation of Platelet Type PFK In Vivo
Platelet PFK is found in association with other PFK isoenzymes. ATP
inhibition of platelet-rich isoenzyme pools in vitro increases as the
proportion of the platelet subunit increases. The effect is the same when
F26BP is present (Dunaway etal., 1988). Platelet-rich isoenzymes also
show the lowest affinity for F6P in vitro, and this is also true when F26BP is
present (Dunaway etal., 1988).
The physiological implications of these in vitro results may be that the
platelet type isoenzyme subunit is present in those tissues which are less
important for an organism's survival when glucose is scarce. An important
tissue for survival in this regard is muscle, which shows the least sensitivity
to ATP, although it is undeniable that brain is an important tissue.
Isoenzymes rich in platelet type subunits would also slow down glycolysis
more quickly than other types when excess lactate production occurred, so
protecting the cell from a dangerous drop in pH.
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It is interesting to note that cancerous cells show altered isoenzyme
profiles (Vora etal., 1985<y>:Gekakis et al., 1989). Cancerous cells show an
increased rate of glycolysis and a decrease in the rate of gluconeogenesis.
Several cancerous cell lines have platelet type species as the predominant
subunit in the PFK isozymes when compared to their pre-cancerous
counterparts. The L-subunit also increases in certain cancerous cell lines
and it may be that the L and P isoenzymes are essential to the survival of
cancer cells and may provide sensitive targets for the design of selective
cancer chemotherapy (Vora etal., 1985b).
Several reports have characterised the platelet enzyme. Meinhofer
et at. (1980) purified human homotetramers and investigated their kinetics.
Maximum cooperativity to F6P was shown by M4 (Hill coefficient ~3-4) and
L4 (Hill coefficient 1.4-3.4) while positive homotropic interactions were much
less pronounced for the platelet homotetramer P4 (Hill coefficient <1.5). .
The main kinetic features were: hyperbolic kinetics for F6P (except at high
ATP concentration); absence of activation by AMP and glucose 16BP; slight
activation by NH4+ and slight inhibition by ATP and citrate. Meinhofer et at.
(1980) found the same kinetic properties for the enzyme from human
fibroblasts, which contain up to 63% platelet type monomers (Dunaway et
al., 1988; Kahn et al., 1979, 1980) and from some malignant tissues which
can contain up to 85% of platelet type subunits (Vora , 1982).
Meinhofer et al. (1980) have described HPPFK as being a virtually
non-allosteric enzyme and that it is a poor regulatory enzyme as compared
to the other PFK forms.
Foe & Kemp (1985) found rather different kinetic properties for rabbit
platelet type enzyme (RPPFK) isolated from rabbit brain. Whereas (at 1 mM
F6P), the RLPFK was completely inhibited by 0.1 mM ATP, RLPFK required
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2mM ATP for complete inhibition. RMPFK and RPPFK were completely
inhibited at 1mM ATP wherease HMPFK and HPPFK still showed activity at
3mM ATP. Another difference is shown in citrate inhibition. The rabbit muscle
homotetramers are inhibited most easily by citrate, with RPPFK being less
sensitive while RLPFK requires the most citrate for inhibition giving the order
RL>RP>RM. For the human tetramers this order is HP>HL>HM. AMP
activation was qualitatively but not quantitatively similar between
homotetramers, with L and M PFK requiring the same amount (but less than
required for the platelet type) of AMP to achieve activation. The different
findings for the kinetic activities of the human and rabbit homotetramers are
difficult to explain. First, differences in the methods of purification might have
caused one or more preparations to be 'purer' or more denatured than
another. Foe and Kemp (1985) noted that either HPPFK may not have fully
reassociated during the final stage of purification or that some other intrinsic
property of the enzyme would explain that the specific activity of HPPFK was
only 70% that of HMPFK with their assay at pH 8.0. Secondly, enzyme
assays were done using aldolase, glycerophosphate dehydrogenase, triose
phosphate isomerase and NADH but assay conditions were not identical.
Thirdly, there may be some real differences between isoenzymes of the two
species. Cross species identity and similarity between isoenzymes is -98%.
Similarity and 96% identity between HMPFK and RMPFK and 96% similarly
and 93% identity between HLPFK and MLPFK. These small differences may
be enough to account for the different observations of the two groups. Vora
et al. (1985b) reported different inhibition and activation characteristics of rat
PFK homo and heterotetramers compared to the other two groups. A better
comparison between homotetramers of different species might be made
using cloned genes with the same expression system and the same enzyme
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assay conditions.
1.5.1.4 Developmental changes of isoenzymes
Dunaway & Kasten (1989) have examined the subunit
compositions of PFK isoenzyme pools in foetal, neonatal and postnatal rat
heart and skeletal muscle. Whereas adult rat muscle contains only muscle
type PFK subunits, foetal muscle isoenzyme pools comprise 60% L type,
36% M type and 4% P type. Adult heart contains 75% M type but foetal heart
contains a roughly equal proportion of all three types of subunit. Presumably,
heart in this study refers to heart atria. Adult human heart ventricle PFK is
about 92% M type whereas adult human atria contains about 77% M type
(Dunaway etal., 1988).
The total activity of PFK in foetal muscle is only 4% of that in adult
muscle. Foetal heart has about 33% of adult heart PFK activity. The
presence of P type subunit imposes a decreased ability for F26BP to
promote PFK activity at low levels of F6P and this effect appears to be
directly related to the proportion of P type subunit present in an isoenzyme
pool.
The low levels of PFK activity in prenatal heart and muscle may
increase chances of survival by keeping glycolytic flux low and preventing a
build up of lactate. In adult heart and muscle, the increased levels of M type
subunit will allow for effective utilisation of glucose due to the higher affinity
for F6P and tolerance of high levels of ATP shown by this subunit. As the
levels of M type subunit rise, isoenzymes require less F26BP to increase
enzyme activity. This may provide an explanation for the low levels of F26BP
seen in adult muscle (Uyeda etal., 1981; Hue etal., 1982)
1.5.1.5 Overview of regulation of PFK in vivo
Glycolysis is a virtually ubiquitous pathway which usually
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consists of ten main enzymes and also has a regulatory enzyme, PFK-
2/F26BP'ase. In addition to its catabolic role, it serves an anabolic function
by providing C3 precursors for the synthesis of fatty acids, cholesterol and
amino acids and is therefore an amphibolic pathway. In mammalian tissues,
the orientation of glycolytic flux (glycolysis or gluconeogenesis) is
determined by tissue type and the hormonal and nutritional state of the
tissue (Dunaway & Weber, 1974b). It has been an assumption that control of
a pathway is located at those enzymes (preferably allosteric) which catalyse
reactions far from equilibrium (Newsholme & Start, 1973). Evidence
supporting the key role of PFK is based on changes in the concentration of
allosteric effectors of PFK when glycolysis is stimulated (Ramaiah, 1974).
More quantitative analysis of control of enzyme flux has been developed by
Kacser & Burns (1973) and by Heinrich & Rapoport (1974) which allow
control coefficients to be distibruted to each step in a pathway.
Application of control analysis to glycolysis in erythrocytes (Rapoport
et al., 1976), yeast (Fell, 1984) and a rat liver extract (Torres et al., 1986),
indicate that control is mostly distributed between HK and PFK. The most
potent activator of PFK is F26BP which is also a strong inhibitor of
F16BP'ase. F26BP is present in all mammalian tissues examined (Van
Schaftingen, 1987) and it is likely that it plays a pivotal role in the control of
glycolytic flux in a variety of these tissues.
F26BP cannot be regarded as the only regulator of flux in all tissues,
but it is likely to be the major control element for switching between
glycolysis and gluconeogenesis in the liver and so for the control of
provision of lipogenesis. The affinity of liver PFK for F26BP is at least one
hundred fold greater than for F16BP but only tenfold greater in muscle.
F16BP is likely to have a greater stimulatory effect than F26BP when it
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exceeds F26BP concentrations e.g. in contracting muscle (Uyeda et al.,
1981). Muscle rich isoenzymes are activated by lower levels of F26BP
however and also are less inhibited by ATP than liver or platelet rich forms
(Dunaway & Kasten, 1989). (See section 1.5.1.4).
Phosphorylation of PFK-1, PFK-2/F26BP'ase, F16BP'ase and PK by
cAMP-dependant protein kinase is under the control of short and long term
hormonal changes and these changes can be tissue specific. Hormones can
also exert tissue specific control over glycolytic flux by affecting the synthesis
and degradation of specific glycolytic enzymes.
The regulated import and degradation of F16BP'ase into the yeast
vacuole has recently been described (Chiang & Schekman,1991). The loss
of F16BP'ase to the vacuole is dependent on glucose. Cells transformed
with a multicopy plasmid containing the F16BP'ase gene (expression
elevated twenty fold) were transferred during logarithmic growth from a
medium containing ethanol as a carbon source, in which F16BP'ase has a
half life of ninety hours, to glucose medium, in which F16BP'ase has a half
life of thirty minutes. After three hours in glucose medium, F16BP'ase activity
was reduced by ninety percent.
Cell fractionation and immunofluorescence studies indicate that
F16BP'ase becomes localised to the vacuole fraction after growth on
glucose. This may be a way in which the yeast cell prevents the futile cycle
of glucose anabolism and catabolism when glucose is available as a carbon
source (Chiang & Schekman, 1991).
Apparently direct import of cytosolic proteins into the lysosome have
been reported. A large family of cytosolic proteins that bear a Lys-Phe-Glu-
Arg-Gin (KFERQ) localising signal are degraded in the lysosome when
mammalian cells are deprived of serum (Lamponi et al., 1987; Chiang &
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Dice, 1988). The yeast F16BP'ase has two KFERQ like motifs, EKVKQ and
QKKLQ (Dice, 1990).
Yeast PFK1 contains two KFERQ like sequences; KFPKQ at position
132 with 80% similarity and 60% identity; KFDTH at position 910 with 80%
similarity and 40% identity. Yeast PFK2 contains QLERA at position 700 with
60% similarity and 40% identity.A definition of similarity based on the
programs of the GCG computing package is found in section 2.2.15. It seems
reasonable to speculate that two different degradatory pathways could
function to prevent futile cycles in glycolysis or other systems with one
signal, e.g. glucose. This signal could cause degradation or
compartmentalisation of an anabolic glycolytic enzyme while its absence
could have the same effect on a catabolic enzyme.
A search of the sequences for PFK to find a KFERQ like sequence
shows that all sequences have a sequence with 40% identity and 60%
similarity to KFERQ. It could be argued however that this is not sufficiently
similar to justify the argument for PFK sequences to be involved in the
"KFERQ" transport system. RMPFK and SHPFK have sequences which
show 80% similarity but only 40% identity. It would be necessary to examine
the localisation of PFK during gluconeogenesis to see if such a situation
exists in reality.
Another possible control over PFK could result from anomeric
specificity. PFK and F16BP'ase act on the p anomer of F6P and the a
anomer of F16BP, and are activated by the a anomer of F16BP and the p
anomer of F6P respectively. Koerner et al. (1977), suggest that PFK and
F16BP'ase are allosterically activated by the substrate, and competitively
inhibited by the product of the other, and that this could suppress futile
cycling between the two enzymes.
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1.6 SPECIFIC RESIDUES CONTRIBUTING TO ACTIVITY
The crystal structures of the PFK's from B. stearothermophilus (T + R
states; Schirmer & Evans, 1990) and E. coli (Rypniewski & Evans, 1989)
have been determined. Site-directed mutagenesis can be used to examine
the role of specific residues necessary for the observed actions of the
enzyme. The eukaryotic enzymes arose from a duplication of the prokaryotic
gene and are regulated by a wider number of effectors. Some catalytic and
allosteric sites in the eukaryotic enzyme are thought to have changed to
provide for new functions for the enzyme (Poorman etal., 1984).
1.6.1 Crvstalloaraphic studies of bacterial PFK
ECPFK and BSPFK have been crystallised in their high (R) and
low (T) affinity states and their structures have been determined by X-ray
crystallography to resolutions from 2.4A to 7A. (Evans et al., 1986;
Rypniewski & Evans, 1989; Evans & Hudson, 1979; Evans etal., 1981;
Shirakihara & Evans, 1988; Schirmer & Evans, 1990). Site directed
mutagenesis has also been used to investigate key residues in the active
site of the E. coli enzyme (Hellinga & Evans, 1987; Lau & Fersht, 1989;
Berger & Evans, 1990; Lau etal., 1987; Kundrot & Evans, 1991). The subunit
of bacterial PFK is divided into two domains. Each domain contains a core of
(3 strands surrounded by a helices.
The active BSPFK is a tetramer of identical subunits of 319 amino
acids each. Dimers are formed by two subunits packing together at a large
interface and dimers pack together at a small interface to form the tetramer.
The large interface within the dimer contains residues which define the
allosteric site, which binds the activator and the inhibitor. In the R state the
small interface between the dimers contributes residues which bind the 6-
phosphate group of a F6P bound in the other dimer. The dimer-dimer
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Figure 3.
The catalytic site in a) the T state
and b) the R state of B. stearothermophilus
Taken from Schirmer & Evans (1990)
a
Figure 4.
Stereo view of the effector site of B. stearothermophilus.
a) the T state with the PEP analogue 2-phosphoglycolate bound
b) the R state with ADP bound
interface is altered in the transition to the T state by a rotation of about 7
degrees. The significant structural change associated with this rotation is a
rearrangement of loops 6-F and 8-H, and of helices 8 and 9.
Figure 3 shows the active site of B. stearothermophilus PFK in the R
and T states, with FbP and ADP bound at the catalytic site
Figure 4a shows a stereo view of the effector site.The PEP analogue
phosphoglycolate is bound. Figure 4b shows the same stereo view of the
effector site with ADP bound.In the eukaryotic enzyme these sites are
presumed to have mutated to form novel effector sites.The reorganisation of
arginines 72 and 162 appears to be theunderlying mechanism for the low
F6P affinity seen in the T state
1.6.2 The Active Site.
The binding site for the cooperative substrate F6P consists of residues from
both subunits of one dimer and also from the other dimer. The binding site
from the other dimer is altered by the change in the 6-F loop. Arg-162 and
Arg-243 give a major part of the binding energy for F6P across the subunit
interface. This has been demonstrated by mutation of these sites; R162S
and R243S (Berger & Evans, 1990). The Km for the binding of F6P for the
mutants R162S and R243S were increased by 165 fold and 53 fold,
respectively. On reorganisation of the 6-F loop during the R to T state
conversion, Arg 162 swings around to bring its guanidinium group close to
the main chain end of helix 8. Glu-161 adopts the R state position of Arg-162
and forms a salt bridge with Arg-243 while its carboxylate group overlaps
with the old guanidinium position. In this way, the positive charges of Arg-
162 and Arg-243 cannot bind the doubly negative charged 6-phosphate of
F6P. E.coli and the mammalian amino half domains have Gin at position
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161 and the charge change is smaller. The sequence of the mammalian
carboxyl halves have an Arg at positions 161 and 162 except for the sheep
liver sequence which has a Gin at position 161.
The catalytic binding site is composed almost entirely of residues from
the large domain. In the change from the R to the T state, Arg 72 forms a salt
bridge with Glu 241 and cannot interact with ATP or F6P. In the R state, Arg
72 contacts the beta and gamma phosphates of ATP and also forms a bond
via a water molecule to the 6-phosphate of F6P. After transfer of the gamma
phosphate of ATP to F6P to form F1.6BP, Arg 72 interacts with the 1-
phosphate of F1.6BP. The mutation R72S reduces the catalytic activity 33
fold and also reduces the cooperativity and binding of F6P and F1,6BP
(Berger & Evans, 1990). These observations suggest that Arg 72, Arg 243
and Arg 162 perform a critical role in the communication of cooperative and
allosteric signals between subunits, particularly Arg-162 and Glu-161 which
show the largest movement in the interconversion between the R and the T
states.
Asp 127 appears to be the key catalytic residue for the active
site (Hellinga & Evans, 1987) and forms hydrogen bonds to the 1-OH group
of F6P thus increasing its nucleophilicity for the gamma phosphate of ATP.
Asp 127 is conserved in the amino halves of all the eukaryotic enzymes and
in all four known prokaryotic PFK sequences. In eukaryotic carboxyl halves
however, residue 127 is a serine which may be part of the sugar
bisphosphate effector site. Asp-127 is likely to cause electrostatic repulsion
of F1,6BP after its formation in the active site, and the removal of the
negative charge by replacement with serine makes the the binding of a
sugar bisphosphate more favourable.
1.6.2 The Effector Site.
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The effector site lies in a deep cleft formed by the residues
between the large interface of the dimers and binds both activator ADP and
inhibitor PEP. The binding of an effector molecule seems to change the
packing of the site itself and the position of the 8H-loop (residues 213-215).
The positioning of the 8H-loop is dependent on the bound effector molecule
and this movement is somehow coupled to the arrangement of the 6F-loop
(residues 155-162) which is responsible for the replacement of Arg 162 with
Glu 161 at the active site. The difference in the movement of the 8H-loop and
the 6F-loop is presumably a function of the difference in size between ADP
and PEP. ADP is larger than PEP and is not totally buried in the effector cleft,
as is PEP. It is presumable that the low affinity site can only be formed when
the "lips" of the effector site are closed over PEP which does not occur with
ADP. The movement of the dimers in the transition from the R to the T state is
accommodated by the removal of a layer of water molecules that lie between
the dimers and by the rearrangement of the 6F-loop. Lau & Fersht (1989)
have also examined the effector binding site of E.coli by site directed
mutagenesis. They found essentially the same as Schirmer & Evans (1990)
with positively charged arginines contacting the activator Mg2+ADP/GDP
and the inhibitor PEP. The interesting mutation E187A caused PEP to act as
an activator and GDP to act as an inhibitor. E187Q made both regulators into
inhibitors. Glu 187 is known from the crystal structure to bind the coordinated
Mg2+ ion of ADP/GDP and seems to play an essential role in the allosteric
transition. Glu 187 may provide a crucial stabilisation of the R state by
binding Mg2+. This residue is conserved as an aspartate in the amino and
carboxyl halves of all the mammalian enzymes and may fulfil the same
function in the amino half and may possibly bind Mg2+ATP in a carboxyl half
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inhibitory site. This remains speculative however, until the crystal structure of
a mammalian PFK can be examined.
The DNA for PFK from the thermophilic bacterium T. thermophilus
has been cloned and sequenced (Xu et al., 1991). While almost all the
residues contributing to ligand binding sites have been conserved, some
differences at the effector site are seen which cause PEP to effect tetramer-
dimer interconversion and so inactivate the enzyme.
1.7. Metabolite binding studies
Metabolite binding studies do not give a precise figure for the number
of substrate and effector binding sites. The mammalian PFK enzyme, by
virtue of its tetrameric association and its larger size when compared to the
prokaryotic enzyme is reported to have a variety of binding sites. Three ATP
binding sites, one adenine binding site, one or two F6P binding sites, one
citrate binding site and one FBP binding site appears to be the general
concensus.
Of the three ATP binding sites, one is the catalytic site, one is the
inhbitory site and the other is the same as the AMP binding site (Kemp &
Krebs, 1967). They differ in their biological actions and ligand specificities.
The inhibitory site has a low affinity for ATP (Kd= 100pM), while the catalytic
site has a much higher affinity for ATP (Kd = 1pM) (Wolfman et al., 1978;
Pettigrew and Frieden, 1979a).
The adenine binding site from sheep heart PFK was compared to the
homologous sequences B. stearothermophilus (Weng et al., 1980). The B.
stearothermophilus sequence contained two arginine residues at position
21 and 25 which bound to the phosphates of allosteric effectors (Evans and
Fludson, 1979; Hellinga and Evans, 1985). However, when this tryptic
fragment is compared to the RM sequence (Lee et al., 1987) and then
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compared to the B. stearothermophilus sequence it can be seen that the
original comparison of the SH fragment to B. stearothermophilus was
wrong. The comparable part of the B. stearothermophilus and E. coli
enzyme has not been proposed to make any contact to effectors (Hellinga
and Evans, 1985).
Riquelme and Kemp (1980) treated muscle PFK with subtilisn and
produced a tetrameric enzyme of Mr 74,000 which was inactive. Binding
studies showed that only one of the three adenine binding sites was present
and that the ATP and F6P binding sites and the ATP inhibitory sites were
lost. The enzyme retained the same affinity for cAMP, and binding sites for
F16BP and AMP were also present (Gottschalk et al., 1983). It is likely that a
separate catalytic site is present as a discrete domain and that several
allosteric regulatory sites are present.
There appear to be low and high affinity sites for F6P in SHPFK with
Kd's of 11 jiM and 0.2(iM respectively, which are influenced by effectors.
F26BP shows the highest affinity while F16BP has a higher affinity than
G16BP (Foe et al., 1983). It has been suggested that the fructose/glucose
bisphosphate binding site has evolved from a matched F6P binding site in
the carboxyl domain (Poorman et al., 1984). Foe et al. (1983) also
suggested that the binding of F26BP produces a conformational change in
PFK which makes it less inhibitable than the conformation produced by
F16BP and G16BP.
The citrate binding site can be modified by using pyridoxal phosphate
and sodium borohydrbe (Colombo 197£). The citrate binding
site of rabbit skeletal muscle was sequenced by Kemp and co-workers
(1987) and found to match the E. coli and Bacillus PFK allosteric effector
site.
59
1.8 Syndromes Associated with Inherited Deficiencies of
PFK Isoenzymes
Vora (1982) describes 25 cases of inherited PFK deficiency occurring
in 20 unrelated families. She classed the reported cases into five major
groups. Group I - patients with the classic syndrome as described by Tarui
et al. (1965) and Layzer et al. (1967) with both myopathy and haemolysis.
Group II - patients with myopathy. Group III - patients with hemolysis. Group
IV - asymptomatic patients with partial deficiency of RBC PFK and Group V -
patients with progressive fatal myopathy associated with other atypical
features.Some Group III cases may belong to Group I but other Group III
cases may be genuine (Etiembie etal., 1976; Miwa etai, 1972).
1.8.1 Deficiency of the Muscle Isoenzyme
Group I patients display the classical syndrome resulting from almost
a complete lack of muscle PFK corresponding to only 0.5% of normal activity.
Erythrocytes have 29-64% of normal activity. When undergoing an
ischaemic exercise test, venous lactate and pyruvate fail to increase which
implies a block in glycolysis. An increase in the glycolytic intermediates -
hexose monophosphates - and a decrease in F16BP and those phosphates
indicate that this block appears to be at the level of PFK (Tarui, 1967; Layzer
etal., 1967).
The accumulation of hexose monophosphates can lead to activation
of glycogen synthetase resulting in a moderate deposition of glycogen
(Agamonolis etal., 1980). The increased F6P concentrations increase the
flux through the pentose phosphate pathway. The increased levels of
purines and pyrimidines from 5-phosphoribosyl-pyrophosphate (PRPP) in
the pentose phosphate shunt may explain the hyperuricemia seen in these
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patients (Howell, 1965; 1968). Patients often lose the ability to generate heat
by increasing glycolytic flux to maintain body temperature in the cold
(Newsholme, 1976).
The possibility that unstable forms of muscle PFK may exist has been
investigated but not proven (Vora, 1982). Alternative splicing has been seen
for two transcripts encoding HMPFK. One cDNA was lacking sequence
encoding exon IX (Sharma et ai, 1990). This would result in a HMPFK
lacking 31 amino acid residues. Two of these residues have been predicted
to be involved in the binding of F6P at positions Arg 243 and Arg 252. On the
basis of the bacterial crystal structures the 31 residues are located between
the second half of a-helix 9 and all of a-helix 10 and includes (3-sheet I. This
would presumably lead to a different conformation of the monomer. A
homotetramer of this type of subunit would presumably be non-catalytic but it
is possible that this subunit could influence the allosteric properties of
heterotetramers. An appropriate mammalian expression system would allow
investigation of this possiblity. The deletion removes Arg 252 which is
implicated as being central to subunit interfaces (Hellinga & Evans, 1985).
The deletion of this residue may mean that a subunit containing this deletion
may not be able to associate with other subunits.
Nakajima and co-workers (1990b) reported on the nature of the
genetic defect associated with group I glycogenosis/ Tarui's disease in a
patient. A point mutation at the 5' end of intron 13 changed the normal splice
site of CAG:GTATGG to CAG:TTATGG. This caused a cryptic splice site of
ACT:GTGAGG to be recognised and spliced in the patient. A silent base
transition at position 516 was also seen, ACT-Thrto ACC-Thr. The 75bp in-
frame deletion of the mRNA corresponds to a deletion of 25 amino acid
residues in the C-terminal half of the peptide just down from the connecting
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peptide. This area is considered to contribute in part to the allosteric sites of
ADP/AMP activation and sugar bisphosphate activation (Poorman et al.,
1984). This deletion would remove residues from the second half of a-helix
1 and all of (3-sheet B and a-helix 2 of the C terminal half. This would
presumably result in a disadvantageous conformational change but may not
completely inactivate the subunit. There may be other mutations of PFK with
Tarui disease as several heterogeneous symptoms are shown with this
disease (Nakajima et al., 1990b). As with the alternative splicing noted by
Sharma et at. (1990), site directed mutagenesis of PFK and an appropriate
mammalian expression system would allow the investigation of the nature of
the physical defects associated with PFK in Tarui's disease and glycogen
storage diseases.
1.8.2 Deficiency of the Liver Isoenzyme
Vora et al. (1980) speculated that the heterogeneous group of
haemolytic syndromes discussed in 1.8.1 may represent a total absence of L
subunits or defects in L subunits. No such evidence has been found.
The locus for HLPFK on chromosome 21 has been mapped to band
21q22.3 (Cox et al., 1984; Van Keuren etal., 1986) in the region known to be
involved of the phenotype of Down's syndrome (DS). Analysis of the subunit
types in erythrocytes of DS patients shows an increase of up to 40% of the L
isoenzyme and an absence of M4 (Vora, 1981). Levanon et al. (1989)
suggested that if a similar alteration occurs in the brain of DS fetuses, it
might affect glycolytic flux and the availability of glucose and ATP. Because
brain is heavily dependent upon glucose it had been suggested that such an
alteration might be linked to the neuropathological changes and their
physiological consequences observed in DS.
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Levanon et al. (1989) observed that LPFK mRNA was present at a
relatively high level in normal foetal brain which diminished in adult brain.
DS fetal brain showed even higher levels of LPFK mRNA
1.8.3 Deficiency of the Platelet Isoenzyme
No work has apparently been done on the possible results of a
deficiency of the platelet isoenzyme. Dunaway et al. (1988) examined the
distribution of human isoenzymes. Platelet subunits are most common in
fibroblast, platelet and cerebral cortex having 61.2%, 31.7% and 27.4%
respectively as determined by Western blotting. They suggest that enhanced
sensitivity to inhibitory concentrations of ATP is intrinsic to the platelet
subunit. Platelet-type subunit may exert a dampening effect on glycolysis
and may also allow other tissues which are relatively more important for
immediate survival to compete more effectively for glucose (Dunaway eta!.,
1988).
HPPFK has previously been assigned to chromosome 10pter-p11.1
(Vora et al., 1983). About 40 cases of 10p duplication on chromosome 10
have been reported. The phenotype represents a relatively specific
syndrome (Gonzalez etal., 1983), with severe mental, developmental and
growth retardation; characteristic facies; congenital heart disease; CNS,
ocular, renal, genital and skeletal abnormalities; congenital hip dysplasia,
flexion deformity of hands and fingers and clubfoot.
1.9 Enzymic Evolution
The observation of Poorman et al. (1984) that rabbit muscle PFK
appeared to be a duplication of the bacterial enzyme raises two problems. It
is necessary to understand the molecular basis of this process and also how
mutation can affect the duplicated gene.
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Most amino acid replacements are the result of single base
substitutions. If the mutation is 'conservative' then it is likely not to affect the
protein to any great degree. Amino acids can be grouped into such
'conservative' changes. A change such as isoleucine --> valine which could
be caused by ATT~>GTT, ATC-->GTC or ATA-->GTA only replaces an
aliphatic-hydrophobic amino acid with another. A change in the charge of a
residue would be caused by about one third of all point mutations which
would be less likely to be tolerated by the protein.
Changes in the amino acid sequence between homologous enzymes
or isoenzymes may be tolerated more or less depending on their position in
the structure. Catalytic residue changes are much less likely to be tolerated
than those on the outside of a protein. Dickerson (1971) and Kimura and
Ohta (1973) have shown that these surface residues of mammalian
haemoglobin are experiencing ten times more evolutionary change than
those in the haem pocket.
If an enzyme is only present as a single copy gene, then such
replacements would tend to be conservative at the least, as the scope for
change would be severely limited by the need to conserve the structural and
catalytic properties of the enzyme. If the gene exists at more than one locus
however, or if as seems to be the case with eukaryotic PFK, it has doubled in
size then this selective pressure is relaxed. One of the loci or one domain of
the duplication event, should be available to allow a much more rapid
evolution of the enzyme in a variety of ways. This seems to be the case with
mammalian PFK where the amino terminal domain retains much of the
original activity of the ancestral protein while the carboxyl domain has
evolved to create new effector sites and inter-domain binding sites. The
existence of isoenzymic PFK has allowed different tissues to express those
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isoenzymes which fulfill the characteristics best suited to the tissue
concerned.
1.9.1 Evolution of Glycolysis
The 10 glycolytic enzymes are of central metabolic importance and
are virtually ubiquitous. A large number of them have been sequenced and
all have known crystal structures (reviewed by Fothergill-Gilmore 1986).
Glycolysis is therefore a suitable enzyme system to study in order to
understand the evolution of enzymes and pathways.
There are three main theories put forward to describe the evolution of
proteins, by divergence.
(1) Those enzymes with a requirement for binding similar ligands such as
nucleotides have evolved from a common ancestor. They might also of
course have incorporated a domain from such an ancestral enzyme such as
the typical NAD+ binding domain present in dehydrogenases (Rao &
Rossmann 1973; Rossmann etal., 1975).
(2) Enzymes catalysing similar reactions eg. kinases, mutases arose as
independent groups which have gradually specialised by divergence.
(3) Enzymes which bind the substrates and products have evolved by
gene duplication and subsequently diverged to form a pathway of related
enzymes.
One of the most striking and elegant domain structures is the a(3
barrel found in TIM and PK. It is also seen in at least 14 other enzymes. A
comparison of the amino acid sequences shows no obvious similarity and it
appears that ap barrels have occurred by convergent evolution. Similarly
the mononucleotide binding fold (mnbf) is not proposed to have appeared
by divergent evolution on account of the lack of amino acid sequence
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similarity. A good example of divergence is that of diphosphoglycerate
mutase from phosphoglycerate mutase. They can be considered as
isoenzymes although the three reactions they catalyse are at very different
rates. They catalyse reactions involving the phospho groups among the
carbon atoms of phosphoglycerate (Rose, 1980; Leadlay eta!., 1977). The
mutase reaction, in which glycerate 3-phosphate goes to glycerate 2-
phosphate (reaction 1) is the major reaction catalysed by phosphoglycerate
mutase. The cofactor dependant phosphoglycerate mutase can also act as a
synthase transferring a phospho group from 1,3BPG to form 2,3BPG
(reaction 2), and as a phosphatase, catalysing the removal of a phospho
group from 2,3BPG to form 2PG or 3PG (reaction 3). These reactions are at
lower rate than the mutase reaction however.
BPGM catalyses reaction 2 at the highest rate and is relatively
efficient at catalysing reactions 1 and 3. The BPGM and PGM are about 50%
identical in primary structure (Fothergill-Gilmore & Watson, 1989). The
different mutases can associate to form heterodimers indicating that they are
very similar in tertiary structure and are so an example of divergent
evolution.
Similarities are also found between PGM and PFK-2/FBP-2. Residues
250-471 of human liver PFK-2/FBP-2 (Lange & Pilkis, 1990) show 46%
similarity and 24% identity to human muscle PGM (Shanske et al., 1987;
Tauler et al., 1987). This part of PFK-2/FBP-2 contains the active site
histidine of the phosphatase domain of the enzyme and appears to have
diverged from an ancestral PGM and undergone a gene fusion with a
kinase.
It appears that the glycolytic enzyme pathway has arisen by
convergent evolution and random association of enzymes and subsequently
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evolved by gene duplication. Gene duplication gives rise to isoenzymes
with differing properties and this allows the different metabolic requirments
of a variety of tissues to be met.
A striking property of the glycolytic enzymes is their conservation
throughout evolution. They are amongst the most conserved enzymes
known and are changing at a much slower rate than, for example, the
globins (Dayhoff, 1978). With the exception of ADH, which shows
an increase and aldolase, which shows a decrease in mutation rates, the
glycolytic enzymes are evolving at about the same rate as cytochrome C.
1.9.2 Evolution of PFK
Poorman et al. (1984) noted similarities in the amino acid sequences
between the amino and carboxyl halves of the 85kDa RM enzyme and the
33 kDa BS enzyme. They suggested that the mammalian enzymes could be
considered as two bacterial monomers joined by a connecting peptide.
Since then, sequences have been reported for E. coli, mouse liver, human
muscle, human liver and S. cerevisiae, which support the theory of gene
duplication. The reported sequences of the two yeast PFK subunits
(Heinisch et al., 1989) gives more information on the evolution of PFK. It is
proposed that the duplication of the bacterial enzyme occurred in an ancient
organism before the split between yeast and the rest of the eukaryotes. A
much later duplication event occurred giving rise to the two yeast subunits
(Heinisch etal., 1989) The subunits PFK1 and PFK2 of yeast are present on
two different chromosomes (Heinisch, et al., 1989) and encode two subunits
essential for a functional PFK (Kopperschlager et al., 1977).
Examination of the intron-exon gene structures of HLPFK, HMPFK
and RMPFK does not reveal any internal symmetry between the amino and
carboxyl halves of the individual enzymes. The amino and carboxyl halves
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of the molecule are similar in size but are encoded by different numbers of
exons, twelve for the amino half and ten for the carboxyl half.lntron lengths
vary while exon lengths remain the same The rabbit muscle and human
muscle genes are 40% smaller than the human liver gene but have the
same number of exons and introns. This lack of symmetry does not support
the idea of a gene duplication and subsequent fusion, but may indicate that
the time elapsed since duplicationcccurred has obliterated any evidence of
such an event.
1.10 Aims of the project
Onchocerca volvulus is a filarial nematode which infects humans and
causes the disease onchocerciasis commonly referred to as river blindness.
It is estimated to affect eighteen million people in Africa, and Central and
Southern America (WHO, 1987). The vector of the parasite is the blackfly
Simulium damnosum which transmits infective juvenile forms into the host
during a blood meal. These juvenile forms mature to become adult filarioids
which migrate to subcutaneous or intramuscular tissues. The adults form
nodules in which they mate and the female produces microfilariae which
migrate to the circulatory system to be picked up by a feeding blackfly in
which they develop into infective juvenile forms to complete the cycle. It is
the microfilariae which cause the serious clinical manifestations of
onchocerciasis by causing keratitis of the sclerosa.
The overall aim of this project was to obtain detailed structural
information on phosphofructokinase from humans and O. volvulus.
Glycolysis is required for metabolism by the parasite (Barrett, 1983). The
inhibition of PFK would provide a potentially effective way of shutting down
the glycolytic pathway. If small but important differences existed between the
structures of the enzymes between human and 0. volvulus, then nematode-
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specific PFK inhibitors could be designed. Because of the very limited
amounts of parasite source material, it was decided that the best way of
obtaining the primary sequence of O. volvulus PFK would be by means of
screening cDNA libraries. Ultimately, the quality of available libraries and the
unexpected nature of the parasite's DNA codon bias meant that this was not
achieved. Another aim of the project was to characterise PFK from humans.
During the project, DNA sequences have been reported for the human
muscle and liver isoenzymes. This study has provided a partial sequence of
platelet PFK, the third and probably the only other human isoenzyme.
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CHAPTER TWO
EXPERIMENTAL
2.1 Materials
2.1.1 E. coli strains.
BHB2688. (N205 recA [Iimm434 cits b2 red E am S am/I])
BHB2690 (N205 recA [Iimm434 cits b2 red D am S am/I])
C600hfl (F- thi-1 thrl leuB6 lacY1 tonA21 supE44 hfl)
DF1020 (D15 (rha-pfkA) DpfkB recA56 HfrC IrelAI spol pit-10 tonA22 T2r)
ED8654 (supE supF hsdR metB lacY gal trpR)
HB101 ( supE44 hsdS20 (rB-mB-) recA13 ara-14 proA2 lacY1 galK2 rpsL20
xyl-5 mtl-1
NM531 (supE supF hsdR trpRlacY recA13 metB gal)
TG1 (supE hsdD5 thi D(lac-proAB) F'[traD36 proAB+laclq lacZ D15])
Y1090 ( DlacU169 D(lon, araD)139 strA supF (trpC :: Tn10) (pMC9))
2.1.2.1 ^ Vectors
EMBL3 (sbh I 11 b189 <polyc!oning site int29 ninL44 trpE polycloning site>
KH54 chiC srl I40 nin5 srl I50)
gt10 Isrl 11 Ob527 srl I30 imm434 (sr134+) srl I40 srl I50
gt11 Ilac5 Dshn dill I2-3 sr I30 cits 857 srl I40 nin5 srll50 SamlOO
2.1.2.2 Plasmid vectors
Source
pK19 Dr. A. Boyd, Edinburgh.
pKS+ Stratagene LTD. Cambridge, U.K.
M13mp8 Amersham International, Amersham, U.K.
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M13mp18 and mp19 Bethesda Research, Cambridge, U.K.
2.1.3 Growth media
a) Oxoid LTD, Haverhill, Suffolk. Tryptone, agar No. 1, yeast extract.
b) Difco Laboratories, East Mosely, Suffolk. Bactopeptone.
c) Sigma Chemical Company, Poolem, Dorset. Ampicillin, Gentamycin,
Kanamycin, Tetracycline, X-gal, IPTG.
2.1.4 Radiochemicals
Amersham International, Amersham, Buckinghamshire.
Deoxyadenosine 5'-[a-32P]triphosphate, triethylammonium salt, stabilised
aq'feous solution, 3000Ci/mmol
Deoxyadenosine 5'-[a-35S]thiotriphosphate, triethylammonium salt,
stabilised acfeous solution, >400Ci/mmol
ICN LTD, High Wyckombe, Buckinghamshire.
Deoxyadenosine 5'-[-32P]triphosphate, triethylammonium salt, stabilised
acjeous solution, >5000Ci/mmol
2.1.5 Enzymes
Sigma. Collagenase.
Northumbria Biologicals LTD, Cramlington, Northumberland.
Aval, BamHI, Bglll, Clal, EcoRI, HinDIII, Kpnl, Pstl, Sacl, Sail, Smal, Taql,
Xmal. T4 DNA ligase, T4 DNA polymerase, Klenow enzyme, Taq
polymerase
Boehringer Manheim LTD, Lewes, Sussex. RNA'se A, Proteinase K.
2.1.6 Oligonucleotides
OSWEL DNA service, Chemistry Department, University of Edinburgh.
2.1.7 Miscellaneous
a) Amersham; Hybond filters (discs and rolls), Hyperfilm MP X-rayfilm
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Sigma; Polaroid 665 and 667 film.
c) Pharmacia; Hexadeoxyribonucleotides, dNTP's.
d) Cambridge Bioscience, Cambridge; Sequenase and sequencing kits.
e) BIORAD LTD, Hemel Hempstead, Berkshire; Goat anti-rabbit lgG(H+L)
Alkaline Phosphatase Conjugate
All other chemicals were supplied by Sigma or B.D.H., Poole, Dorset, and
were reagent grade or better.
2.2 METHODS
Good laboratory practice was observed at all times. Where work
involved the growth of micro-organisms or manipulation of parasite tissue,
sterile technique and equipment were used. Plastic ware was incinerated
after use and glass and ceramic ware were autoclaved or soaked in
hypochlorite bleach prior to washing. Guidelines for the use of radioactive
isotopes and other departmental guidelines were strictly adhered to.
Standard experimental techniques were performed as described in
Methods In Enzymology (1988) vol. 152, A Guide to Molecular Cloning
Techniques. Pages
Enzymic manipulation of DNA 91-144
Growth and storage of E. coli 145-151
Extensive use was also made of Maniatis et al., (1982) and Sambrook et
al., (1989), the first and second editions respectively of Molecular Cloning:
A laboratory manual.
2.2.1 DNA Sequencing
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Two methods of DNA sequencing were used. One used Klenow
enzyme. The other used a modified form of T7 DNA Polymerase
(Sequenase').
Transformation of E.coli.
For a 90mm plate.
1 Add up to 100ng of recombinant M13 DNA to 100pl of competent E.coli
containing the F plasmid such as TG1.
2 Incubate on ice for at least 30 minutes, heat shock at 42 C for 3 minutes
and put back on ice.
3 Add 40|il each of X-Gal and IPTG and 300pl of fresh TG1 cells. These
should be grown first thing in the morning by adding 10Opil of an overnight
culture to 10ml of fresh broth. These cells form a lawn on the plate and allow
the plaques to be seen more easily
4 Heat the tube up to 37°C, add 3ml of top agar (for a 90mm plate) and pour
the mixture onto a prewarmed 37°C bottom agar plate.
5 Allow to set and incubate overnight at 37°C.
6 Recombinant plaques will be clear while wild type plaques will be blue.
7 Pick recombinant plaques by spearing with a sterile toothpick. Put the
toothpick into a test tube containing 1.5ml of 2XTY. The TY contains a 1:100
dilution of an overnight culture of TG1.
8 Grow at 37lC for 5 hours shaking hard.
9 Spin down the cells at 12,000 r.p.m. for 5 minutes and remove the
supernatant to a fresh eppendorf being careful not to pick up any cells.
10 Add 200pl of PEG/NaCI and mix. Leave for 15 minutes.
11 Spin at 12,000 r.p.m. for 2 minutes and remove the supernatant. Spin
again and remove the last of the supernatant with a drawn out pasteur
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pipette.
12 Add lOOpI of TE and then 50pJ of phenol.Vortex for 15 seconds and leave
for 15 minutes. Vortex for 15 seconds and then spin at 12,000 r.p.m. for 3
minutes.
13 Remove the top aqueous layer to a fresh eppendorf and add 10(il of 3M
Na«*cetate. Add 250pl of ethanol (kept at -20°C). Incubate at -20°C for at
least 1 hour and spin at 12,000 r.p.m. for 10 minutes. A pellet should be
visible.
14 Redissolve the DNA in 50(il of TE.
Sequencing the DNA
For Klenow enzyme,
single stranded template 5pl
M13 primer @ ipM 1pl
Klenow reaction buffer 1.5p.l
Distilled water 2.5(il
Incubate at 60°C for 1 hour.
Spin the annealed primer/template and add 2pl of [35S]dATPaS
(600Ci/mmol)
3 Add 1pl of Klenow fragment (at 1 unit/pl) and mix by pipetting. This is the
reaction mix
4 To 4 eppendorf tubes marked A,T,G and C add 2.5fil of the
reaction mix.
5 Add 2pl of the relevant dNTP/ddNTP mix to each tube. Place the drop just
inside the tube. When all tubes are ready, start the reaction by spinning the
tubes which mixes the two solutions.
6 Incubate for 20 minutes at 37°C. Before this time is up add 2pl of the chase
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solution just inside the rim of the eppendorf to each tube. After 15 minutes,
spin the tubes to mix and incubate for 15 minutes at 37°C.
7 Add 4pl of stop solution/dye to the rim of the eppendorf and spin to stop the
reaction at 15 minutes. The samples can be left overnight at -20°C.
8 Heat the reaction tubes to 95°C for 5 minutes and use 3jil of each reaction
to load onto the gel.
For Sequenase (Sequenase Protocol Handbook, 1989)
DNA 7pl
Sequencing buffer 2j.il
Primer@1jiM 1jil
Anneal at 65oC for 1 hour
To this mixture add;
DTT0.1M 1pl
diluted labelling mix 2pl
[a-35S]dATP 0.5pl
3 Mix by pipetting and incubate for 5-10 minutes at room
temperature. This is the reaction mix.
4 Put 2.5jil of the relevant termination mix into tubes labelled A,C,G or T.
Prewarm the tubes to 37°C. Add 3.5pl of the reaction mix to each tube and
spin to start the reaction.
5 Incubate for 5 minutes at 37°C or longer.
6 Add 4pl of stop solution to each tube and store at -20°C.
7 When ready to load the gel, heat the reaction tubes to 95°C for 5 minutes.
Double stranded sequencing
Double stranded sequencing was performed essentially
according to the method of Sambrook et al. (1989)
Running the gel
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All sequencing reactions were run on a BRL SO gel system.
1 Mix 100ml of acrylamide stock with 200pl of fresh 10%
ammonium persulphate and 200pl of TEMED.
2 Pour slowly (avoiding bubbles) into the taped-up glass plates and put in
two sharkstooth combs to form a flat surface on the top of the gel. Use two
fold-back spring clips to hold the gel at the top. The gel should set after 30
minutes.
3 Untape the gel plates and put it into the gel apparatus. Turn the combs to
form sample wells and flush urea out of the wells using a syringe and TBE.
Fill the apparatus with TBE. Prerun the gel at 60W for at least 30 minutes.
Incubate the samples for two to three minutes at 75-95°C
4 Load the heated samples into the wells. This should be done
reasonably quickly. If loading a large number of samples, the gel can be run
for 5 minutes to stop any spreading of the samples before loading more.
5 Run the gel at a constant 60W. The bromophenol blue (lower dye) runs at
the same position as the first few bases and comes off in about 90 minutes.
Gel runs can be varied to see areas further up the gel by loading one
sample, running the gel for 2 hours and then loading another 4pl of the
same sample and running for another 90 minutes.
6 Take care when dismantling the gel. The lower buffer contains
unincorporated 35S. Dismantle the plates, fix for fifteen minutes in 10%
acetic acid and drain. The gel is transferred to 3MM paper by inverting the
plate and dried on an ATTO gel drier for 1 hour at 75°C.
7 Put the dried gel on 3MM paper into a film cassete with an
autoradiography film (Amersham Hyperfilm) and expose
overnight at room temperature.
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2.2.2 Maxiprep of plasmid DNA (Sambrook etai, 1989)
1 Infect 10ml of liquid broth, containing antibiotic if necessary, with a single
bacterial colony bearing the required plasmid, and grow overnight.
2 Infect 500ml of broth with antibiotic if necessary with the overnight culture
and grow to saturation overnight.
3 Harvest the cells in a Beckman JA14 rotor (or equivalent) at 4,000 r.p.m. for
5 minutes.
4 Resuspend the cells in 8ml of Solution 1 and leave at room temperature
for 5 minutes.
5 Transfer the cells to tubes for a Beckman JA20 rotor (or equivalent) and
add 16ml of Solution 2. Leave on ice for five minutes with occasional mixing
6 Add 12ml Solution 3 (kept on ice) and mix gently by inversion. Leave on
ice for at least 5 minutes and spin in a Beckman JA20 rotor (or equivalent) at
15,000 r.p.m. for 10 minutes. If any precipitate remains, spin again.
7 Transfer the supernatant to a fn^h JA20 tube and add an equal volume of
propan-2-ol (kept at -20°C). Mix well and store at -20°C for at least ten
minutes.
8 Spin as in 6 for ten minutes.
9 Carefully remove the supernatant and wash the pellet in 80% ethanol
(kept at -20°C). Dry the pellet in a dessicator.
10 Resuspend the pellet in 4ml of TE
11 Dissolve 4g of CsCI in the sample and add to a tube for a Beckman 70Ti
rotor (or equivalent). Add 800pl of ethidium bromide at 10mg/ml and top up
the tube with TE containing 1g of CsCI/ml of TE.
12 Seal the tube with a Beckman heat sealer and mix the sample
thoroughly. Spin at 45,000 r.p.m. in a Beckman 70Ti rotor for 36 hours. The
rotor should be stopped by allowing to coast without the brake after braking
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down to ~1000r.p.m.
13 Carefully remove the tube and examine it. A plasmid band is often visible
in normal light but may have to be visualised with long wave U.V.
transilluminator. The plasmid band is extracted with a 21 gauge needle by
first piercing the top of the tube and then removing the plasmid DNA by side
puncture. The upper chromosomal band is often not present.
14 Transfer the plasmid band (in about 3ml) to a small test tube and add an
equal amount of CsCI saturated propan-2-ol. Mix and remove the upper
layer. Repeat until all the ethidium bromide has gone.
15 Transfer the bottom layer to eppendorfs and flush the sample test tube
with 2 volumes of water. Add to the sample.
16 Add 1 /20th volume of 7.5M NH4 acetate and 1 volume of propan-2-ol
(kept at -20°C). Mix and store at -20°C for 30 minutes.
17 Spin at 12,000 r.p.m. for 10 minutes, wash the pellet in 80% ethanol (kept
at -20°C). Dry the pellet in a dessicator.
17 Resuspend the pellet in 360pl of TE and add 140pl of 7.5M NH4 acetate
and 1ml of propan-2-ol. Leave at room temperature for ten minutes and spin
at12,000 r.p.m. for 10 minutes.
18 Resuspend the pellet in 100jil of TE. Concentration estimation, restriction
and ligation analysis should then be done on agarose gels. For long term
storage, keep at -20°C.
Solution 1 50 mM Glucose, 25 mM Tris.CI (pH 8.0), 10mM EDTA (pH 8.0)
Solution 2 0.2N NaOH, 1% SDS
Solution 3 5M Kacetate 60ml, glacial acetic acid 11.5 ml, H20 28.5 ml
2.2.3 Minipreps of plasmid DNA
Boiling method (Holmes & Quigley, 1981)
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This method was used to prepare small amounts of plasmid DNA for
subsequent analysis by restriction enzyme digestion in analysis of
constructs, for subcloning of fragments and for preparation of replicative form
M13 bacteriophage DNA.
1. Innoculate 10mls. LB. with a single bacterial colony and grow at 37°C
overnight.
2. Spin down 2x 1.5 mis. in a 1.5 ml eppendorf tube.
3. Remove the supernatant carefully and resuspend the bacterial pellet in
300 pi. STET + 200 pg. lysozyme and place the tube on ice for one to ten
minutes.
4. Put in boilng water bath for two minutes.
5. Spin in cold room microfuge for twenty minutes.
6. Pour off supernatant into fresh tube and add an equal amount of
isopropanol. Store in -20°C freeezer for at least twenty minutes, and then
spin in cold room microfuge for five minutes.
7. Remove all of supernatant and add 500pl. of 80% ethanol at -20°C.
Dislodge pellet by flicking eppendorf, spin down and remove supernatant
without dislodging the pellet. Dry under vacuum and resuspend in 50ul. TE.
The plasmid DNA should be clean enough to manipulate with most
enzymes. If not, then a further precipitation with NH4 Ac + isopropanol will
solve most problems.
If the plasmid is to be cut with restriction enzymes to give fragments of
a size less than 500 bp. then treatment with RNase will be useful. Add 1 pi. of
RNase (10 mg/ml.) to each digest.
STET = 0.1 M NaCI
10mM Tris.CI (pH8.0)
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1 mM EDTA (pH8.0)
5% Triton X-100
2.2.4 Radiolabelling of DNA by random priming (Feinberg &
Vogelstein, 1983,1984)
DNA fragments can be recovered by electroelution or directly from a low
melting point (Ima) agarose gel. The reaction can be left overnight at room
temperature or for at least 3 hours at 37°C.
Reagents are added in the following order for DNA in TE.
OLB, 3ul. BSA, 1.2pl. DNA, 20ng. [32P]dATP, 3pl. Klenow fragment, 1.2pl.
H20 to a total of 30|il.
DNA in Ima is excised from the gel with a sterile scalpel and weighed.
Sterile distilled water is added at a ratio of 1.5ml of water to 1g of DNA in
agarose. The DNA is boiled for 7 minutes and equilibrated for 10 minutes
before labelling. If the DNA is not to be labelled immediately, it is frozen at -
20°C in 20fil aliquots
Labelling DNA in Ima agarose
OLB 5ul, BSA 2ul, DNA 20ul, [32P]dATP 3ul, Klenow fragment 2ul
H2 O to 50 pi
It should usually be unnecessary to remove unincorporated [32P]dATP
but the easiest way to do this is to make the reaction 2M NH4Ac and add 2
volumes propan-2-ol. A wash in 80% ice cold ethanol followed by
dessication and resuspension in 20pl TE should remove the vast majority of
unincorporated [32P]dATP.
Reagents.
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OLB; Solutions A,B and C in a ratio of 2:5:3 will remain stable for several
months at -20°C.
Solution A
625|il 2M Tris.CI(pH 8.0), 25|il 5M MgCI2, 350|il SDW, 19pl 2-
mercaptoethanol. 5pl each of 0.1 M; dCTP, dTTP and dGTP, in 3mM Tris
(pH8.0) and 0.2mM EDTA (pH 8.0). Store at -20°C
Solution B 2M Hepes pH 6.6 with NaOH. Store at 4oC.
Solution C Hexadeoxyribonucleotides-pD(N)6. These are random
hexamers of calf thymus DNA. Pharmaciacat.no. 27-2166-01
Suspend in 3mM Tris, 0.2mM EDTA, pH 7 at 90 O.D units/ml and store at -
20°C. BSA 10mg/ml in H20 stored at -20°C
[32P]dATP, Amersham 3000 Ci/mmol, 10pCi/|il
Klenow fragment diluted to 1.5 units/pl
2.2.5 Small scale preparation of lambda. Modified from Sambrook
etal. (1989)
Isolate a single plaque by spearing it with a sterile pipette tip and
blow it into a 50ml. conical flask containg 10ml. of LB. +10mM. MgS04. Add
a drop of plating cells. The cells are best when fresh, but can be used for up
to a week after preparation. Shake hard at 37°C overnight.
The next morning, add a drop of chloroform to each lysate and shake gently
at 37°C for 10 minutes. The lysate should appear stringy. Spin down lysate
for 10 minutes in a Falcon tube and then spin the supernatant at 35,000
r.p.m in a Beckman 45Ti or (equivalent) for at least 1 hour.
Pour off the supernatant and resuspend the glassy pellet in 1 ml. of TM. Take
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up the resuspended pellet in a 1.5 ml. eppendorf tube and spin at room
temperature for 2 minutes at 12,000 r.p.m. Take up 800pl of supernatant in
an eppendorf tube and add DNAse and RNase to a final concentration of
50ug/ml. Incubate at 37°C for about 15 minutes.
Add 200ul of TES, mix well and incubate at 70°C for 15 minutes. Cool to
room temperature add 150pl of 8M potassium acetate and place on ice for
15 minutes. Spin for 10 minutes at 12,000 r.p.m. and remove 800pl to a new
eppendorf. Extract with phenol/chloroform, chloroform and finally with ether.
Add 500|a.l of ice cold propan-2-ol, mix gently and leave at -20°C for at least
15 minutes. A precipitate should form almost immediately. Spin down the
precipitate for 10 minutes at 12,000 r.p.m., wash with 80% ice cold ethanol
and dry in a vacuum dessicator. The pellet is resuspended in 20pl of TE. For
each restriction digest, use 5-1 Opl, depending on yield. The addition of
RNase to a final concentration of 10ug/ml will allow visualisation of small
DNA fragments in a gel.
TM 10mM. Tris pH 8, 2mM. MgCI2
TES 300mM Tris pH 9.0, 150mM. EDTA pH 8.0, 1.5% S.D.S
This miniprep is usually good enough to prepare at least 5pg ofADNA
suitable for restriction analysis. A scaled up miniprep of 50ml of lysate can
produce up to 50pg of DNA. This is easily sufficient to produce enough insert
DNA from a recombinant plaque for subcloning.
2.2.6 Large Scale Preparation of Lambda. Sambrook et at. (1989)
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1 Use 25ml of a miniprep lysate to infect 5ml of the appropriate E.coli host in
MgSCV- Incubate at 37°C with 2mM MgCI2and 2mM. MgCI2 for 15 minutes.
Grow culture with good aeration overnight and treat with chloroform as in
minilysate.
2 Spin in Beckman JA14 or equivalent at 10,000 r.p.m. for 5 minutes at 4°C.
Put the supernatant into fresh 250ml bottles and add equal amounts of PEG
solution. Leave overnight at 4°C.
3 Spin at 3,000 r.p.m. for 5 minutes at 4°C, keep back ~50ml of the
supernatant and discard the rest being careful not to lose any of the white
precipitate. Use the supernatant to wash down the sides of the centrifuge
bottles and pool the supernatant with the white precipitate which contains
the PEG and the phage. Spin this down at 5,000 r.p.m. in a Beckman JA20
rotor or equivalent and discard the supernatant. Add solid KCI slowly to a
final concentration of 1M, mix gently but thoroughly and leave on ice for 15
minutes. Spin down at 10,000 r.p.m. in a JA20 rotor and discard the pellet.
The phage are then concentrated on a CsCI step gradient. This is done in a
Beckman SW27 rotor or equivalent. Pipette the phage suspension into the
tube and carefully underlay it with a 1.4g/cm3 CsCI solution. Then underlay
these two phases with a 1.5g/cm3 solution and finally with a 1.7g/cm3
solution. Spin at 24,000 r.p.m. for at least two hours. The brake should not be
used to slow down the rotor. The phage band should be located between the
1.4g/cm3 and 1.5g/cm3 band interface and will be a blue colour depending
on the concentration of the phage. Other bands will be present but these are
not intact phage. The band is collected with a 26 gauge needle by side
puncture of the tube. Make a hole at the top first to allow for pressure
equilibration. If there is no band visible, it is probably not worth proceeding
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due to the low yield. The DNA is extracted as above with phenoi-chloroform.
Several methods exist for a large scale lysis procedure. Some demand that
the host cells are in mid-log phase when harvested or that a specific ratio of
phage to host cells is used. Phage yield will vary according to the procedure
and phage used. If a low yield is encountered then try threetor four different
ratios of phage to host cells in the above procedure and titre the lysate in the
morning. It may be possible to increase the yield further by varying the ratio
around the best yield.
The step gradient is desired for wild type lambda which has a genome size
of 48.5kbp. A smaller phage will have a lower density and vice versa for a
larger phage. The phage can also be purified on an equilibrium gradient.
This is performed under the same centrifigation conditions, but the phage
suspension is mixed with CsCI to a final concentration of 1.5g/g/cm3. This
method is used when preparing less than 1 litre of lysate. Other methods are
sometimes used such as glycerol gradients, but the CsCI method is
relatively easy to use, quick and gives a reasonably pure preparation.
A large scale liquid lysate is used to produce up to 1mg of DNA from
1000ml of lysate. The lysate is treated with DNase and RNase to release
phage from the mass of bacterial DNA in the lysate and then the phage are
precipitated using polyethylene glycol and KCI. Phage are concentrated on
CsCI step gradients , dialysed and phenol extracted. This method is used
when large quantities of highly purified X DNA is needed such as when
making libraries.
2.2.7 Plating lambda bacteriophage to generate plaques.
Sambrook etal. (1989)
It is often necessary to generate single plaques of lambda such as
84
when determining the titre of a library, to separate nonrecombinant from
recombinant plaques or to isolate a positive clone during a screening
procedure. Although not a complex procedure, it is important to have a good
sterile technique and to pay attention to detail.
To generate lambda plaques.
1 Grow up a suitable strain of E.coli overnight to saturation in a suitable
broth such as NZCYM + 10mM MgS04 + 0.2% maltose
The maltose induces production of the lambda receptor (lamB protein)
which also allows maltose transport. Magnesium is necessary for the
integrity of the phage coat which can therefore be disrupted by divalent
cation chelators such as EDTA. This is sometimes utilised in lambda DNA
isolation.
2 Spin down the E.coli in an MSE benchtop centrifuge (or equivalent) at
3000 r.p.m. and resuspend in 0.4x the original volume of 10mM MgS04. The
cells are best when fresh but are easily usable for a week if kept at 4°C.
3 Make serial dilutions of the lambda suspension into a sterile test tube and
add 10Opil of the plating cells for each 90mm plate.
A lambda library will normally have a titre of between 108-1011 particle
forming units (pfu)/ml of library. A single plague in lambda diluent,SM,will
contain about 2x106 pfu/ml. It is best therefore to titre a phage suspension
giving two scoreable plates. This gives a good estimate of the phage
concentration. When the phage are stored at 4°C in the dark with a few
drops of chloroform, the titre should remain stable for several months.
4 Add 3ml of top agar (at a temperature of 45°C)such as NZCYM to the
bacterial phage suspension and quickly pour onto a prewarmed plate of
bottom agar making sure to cover the plate and avoid bubbles. Let set on
85
a level bench and incubate at the desired temperature.
Many people use many sorts of top and bottom agars. NZCYM
contains magnesium and is a rich food allowing quick growth of the E.coli
and of the lambda plaques. Most phage are grown at 37°C, but temperature
sensitive lysogens are grown as at 32°C while lytic growth is at 42°C. X gt11
has a temperature sensitive repressor and is usually grown at 37-42°C
5 Incubate the plates at the required temperature for 4 hours in the case of
gt11 or overnight if necessary. Count the plaques and estimate the titre of the
A suspension.
Different strains of X grow into different types of plaques. A large
number of plaques with an overcrowded plate gives small plaques and the
reverse is true with undercrowding. Some plaques are 'sick' and grow much
less well than others. This can be a problem if the insert that you want in a
recombinant phage gives a 'sick' plaque. The problem can be further
exaggerated in an expression library where a fusion protein can be toxic to
the host cell. These problems can be got around by using different host
strains and growth conditions for particular phage strains
2.2.8 Heparin Hybridisation Method. Singh & Jones (1984)
1. Prehybridise blot in 4xSSC for at least 15 minutes
2. Heat Hybridisation Solution (HS) to 42°C and prehybridise blot for at
least a further 15 minutes. This may sometimes require several hours for a
plaque lift or colony blot. Southern transfer blots only require 15 minutes.
3. Boil the labelled probe and add to the hybridisation solution.
4. Incubate overnight at 42°C in a shaking water bath.
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5. Wash the filter with 4xSSC at room temperature until most of the activity
has been removed.
6. Wash the blot at successively higher temperatures and lower
concentrations of SSC until a desired signal is attained, this is seen by
autoradiography or by estimating the residual activity by mini-monitor. If the
desired stringency of washing is unknown it is best to proceed slowly by
increasing the temperature by increments of 5°C, and/or decreasing the
concentration of SSC by increments of 0.5.
Stock solutions.
20xSSC: 175.3 g NaCI and 88.2 g Na Citrate per liter H20, pH(7.0),
2% Na Ppj, 10% SDS, Formamide 100% deionised, Heparin 50mg/ml in
H20.
Hybridisation Solution (HS)
For 10ml HS
2ml 20xSSC, 500ul 2% NaPpj, 5ml Formamide, 40pl Heparin solution,
460(0.1 SDW
2.2.9 Preparation and Transformation of competent cells.
Sambrook etal.,{ 1989)
1 Innoculate 10ml of broth with a single colony of the desired E.coli strain,
and grow overnight.
2 In the morning, use this culture to innoculate 100ml of broth. Grow until the
O.D.550 is between 0.3 and 0.4. Quickly chill the culture in an ice bath and
harvest the cells in a Beckman JA14 rotor (or equivalent) at 4,000 r.p.m. at
4°C.
3 Resuspend the cells in 50ml of 100mM ice cold CaCI2 and leave on ice for
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30 minutes.
4 Spin the cells in the JA14 at 3,000 r.p.m. for 5 minutes and resuspend in
4ml of 100mM ice cold CaCI2. The cells should be left on ice for an hour
before use. They are best after 24 hours after which they begin to lose
transformation efficiency.
Transforming competent cells.
5 Add ~10ng of DNA per transformation reaction. This should be done in
precooled test tubes. Use 10Opil of cells per reaction. The cells should be
treated gently and transferred in a wide bore pipette. If the DNA is from a
ligation reaction then up to 100pg can be used.
6 Place the cells on ice for at least 15 minutes and then heat shock the cells
for 3 minutes at 42°C. Place the cells back on ice for a few minutes and then
add 1 ml of LB.
7 Incubate the cells for 1 hour at 37°C without the relevant antibiotic.
8 Spin down the cells at 12,000 r.p.m. for 30 seconds and resuspend in
~150|il of the LB.
9 Pipette the cells onto an agar plate with the relevant antibiotic or selection
medium and spread the cells evenly with a glass spreader.
10 Incubate the plates at 37°C overnight. Transformants are picked and
miniprepped to check for the relevant plasmid.
A common selection uses the fact that insertion into the polylinker
region of some plasmids (pUC,pK,pGEM,M13 phage) disrupts the coding
region of lacZ and gives a colour test for recombinants. Wild type plasmid
gives a blue colony or plaque with M13 while recombinants are white.
2.2.10 Polyacrylamide gel electrophoresis (PAGE). Sambrook et al.
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(1989).
1 Wash glass plates in hot Decon and rinse with distilled water. Wipe the
plates with ethanol making sure the plates are completely clean.
2 Assemble the plates with vacuum grease, spacers and clips.
3 For a 16x16cm gel, use the following amount of separating solution.
Acrylamide 30% 10%
concentration Acrylamide Buffer H20 APS TEMED
6 6 7.5 16.5 0.05 0.01
7 7 7.5 15.5 0.05 0.01
8 8 7.5 14.5 0.05 0.01
9 9 7.5 13.5 0.05 0.01
10 10 7.5 12.5 0.05 0.01
12 12 7.5 10.5 0.05 0.01
13 13 7.5 9.5 0.05 0.01
15 15 7.5 7.5 0.05 0.01 (ml)
The required mixture should be poured immediately in to the gel cast
leaving ~3cm for the stacking gel and comb. The gel should be carefully
overlayed with distilled water or propan-2-ol.
4 Keep back a little of the mixture to see when the gel has set. Pour off the
water or propan-2-ol The stacking gel consists of:
30% acrylamide buffer water 10% APS TEMED
1.5 2.5 5.97 0.03 0.01 (ml)
2.2.11 Media.
LB per liter, 2xTY per liter NZ per liter
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10g. Tryptone 16g. tryptone 10g. casein enzymatic
5g. Yeast Extract 8g. Yeast Extract 5g. NaCI
5g. NaCi 5g. NaCI MgS04 - 10mM
pH 7.2 pH. 7.5
Solid Media.
Agar. Add 15g. agar or agarose per liter for bottom agar.
Add 7.5g. agar or agarose per liter for top agar.
2.2.12 Isolation of Onchocerca gibsonii.
The worms were a kind gift of Dr. John Comley of Wellcome research
laboratories.
Frozen nodules containing the worms were thawed overnight in 70%
ethanol at 4°C They were then transferred to PBS and left for 24 hours at
4°C with at least three changes of PBS. They were then transferred to a
0.1% collagenase solution in PBS containing gentamicin at 0.2 mg/ml and
incubated at 37°C. The worms could be gently removed from host tissue
using a dissecting microscope after about two days. Loose worms were
washed in PBS until no host tissue could be observed. Worms were
dropped into liquid nitrogen and stored at -70°C until required.
Worm tissue was prepared for SDS-PAGE and subsequent Western
blotting by boiling the protein sample for five minutes with SDS and (3-
mercaptoethanol as described in Sambrook et al. (1989).
Worm DNA was isolated in the presence of SDS, proteinase K and
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RNA'se as described by Sambrook et al. (1989), after the tissue had been
ground to a fine powder with liquid nitrogen using a mortar and pestle.
2.2.13 Western Blots
SDS polyacrylamide gels were prepared according to Laemlli &
Favre (1973). Gels were run on home made plates or on the Hoefer Mighty
Tall apparatus. Protein was transferred onto nitrocellulse filters using the
LKB semi-dry apparatus. The filters were incubated with TBST for 1 hr with
two changes. The filters were then incubated with TBST plus 1° antibody for
at least 1 hr and then washed thoroughly in TBST three times before
incubating with TBST plus 2° antibody for 1 hour. They were then washed at
least three times in TBST. The filters were then developed with H202 and
chloronapthol or diaminobenzidine for Horse Radish Peroxidase
streptavidin conjugated 2° antibody or NBT and BCIP for Alkaline
Phosphatase conjugated 2° antibody. Filters were washed in distilled water,
allowed to dry and stored in the dark.
2.2.14 Polymerase Chain Reactions
PCR was done according to the protocol suggested by Promega on a Biorad
thermal cycler. Light mineral oil (Sigma) was used as an overlay to prevent
evaporation of the sample. An initial 95°C denaturation step was run for five
minutes before adding Taq polymerase (2 units) (Promega). The reactions
were then run in a water cooled thermal cycler (Biorad), at 55°C for two
minutes followed by polymerisation at 72°C for one and a half minutes and
denaturation at 95°C for 1 minute. Twenty five cycles were usually
performed.
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Chapter 3. Creation of a human genomic library, and screening
of Onchocerca cDNA ibraries.
3.1 Creation of a human genomic library.
As a first step towards characterising HMPFK, a human genomic
library was created in X EMBL3 by the method of Zabarovsky & Allikmets
(1986). Human DNA extracted from blood was partially digested with
Sau3AI to give fragments of an average size of 15kbp. Klenow enzyme was
used to partially fill in these digested fragments with dATP and dGTP. They
were ligated to EMBL3 which had been digested with Sail and EcoRI and
partially filled in with dTTP and dCTPas seen in figure 6. The ligations were
packaged using X packaging extracts prepared by the method of Hohn
(1979). This produced 104pfu/pg of ligated DNA when plated on E. coli
NM538.
93
Figure 6. Analysis of the partial filling in and ligation products of human and
EMBL3 DNA by electrophoresis in a 0.7% agarose gel
Lane 1. HinDIII digested Xclfe857 molecular weight markers
Lane 2. Sail + EcoRI digested EMBL3
Lane 3. Ligation of the fragments from lane 2
Lane 4. Partially filled in and ligated fragments from lane 2
Lane 5. Human placental genomic DNA
Lane 6. Sau3AI partial digest of DNA from lane 5
Lane 7. Ligation of DNA from lane 5
Lane 8. Partially filled in and ligated DNA from lane 6
Lane 9. Ligation of DNA from lanes 2 and 6
Lane 10. Lamda clfc857
Lane 11. Ligation of partially filled in human and EMBL3 DNA at a 1:1 molar
ratio
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3.2 Screening of Onchocerca volvulus libraries
At this point of the project however, the sequence of genomic HMPFK
was published and it was decided to focus the aims of the project towards
characterising PFK from O. volvulus. We received four cDNA libraries in
A,gt11 (named Mali, Kumba, Guatemala and Toborou) a kind gift from Dr.
John Donelson (University of Iowa). Genomic DNA corresponding to exon
22 of RMPFK was kindly made available by Dr. Simon Chang (Louisiana
State University). Six positive clones were isolated from the libraries using
the rabbit muscle DNA as a probe. Mini preps of the phage yielded about
5(ig of DNA for each clone. The DNA from each positive clone were digested
with EcoRI and run on an agarose gel. Only clone 2 contained an insert
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Figure 7a. EcoRI digest of positive
onchocerca clones.
Lanes 1-6 Clones 1-6 Lane 2 contains
an insert of -2.4 kbp.
Lane 9. HinDIII digested Xc\ts857
molecular weight markers labelled
with Klenow enzyme and [32P]dATP
Figure 7b. Southern blot of the gel in Figure 7a probed with DNA
corresponding to exon 22 of rabbit muscle PFK labelled with Klenow
enzyme and [32P]dATP
Figure 8a.
Lanes 1-6, Kpnl + Sacl digests of clones 1-6
Lane 9. HinDIII digested X clte857 molecular weight markers
Figure 8b
Southern blot of gel in figure 8a probed with DNA from exon twenty two of
RMPFK labelled with [32P] and Klenow enzyme
which was released by EcoRI, (figure- 7^).Digestion with Kpnl and SstI
produced a variety of fragments which suggested that out of the six, three
different clones were present - figure 8a. A Southern of the EcoRI digested
DNA showed that RMPFK bound to the insert of clone 2 and to the arms of
the digested vector for the other clones - figure 7b. A Southern of the Kpnl
and SstI digested DNA showed binding of RMPFK in three different patterns
- figure 8b. These fragments were electroeluted onto DE81 paper placed in
the gel and purified by phenol extraction and ethanol precipitation, before
ligation to pUC19 cut with the appropriate restriction enzyme. All attempts to
clone these fragments failed. Fragments were extracted from low melting
agarose gels, phosphatased vectors and different E. colicells (NM539, TG1,
HB101, NM522) were used, but the inserts were refractory to subcloning.
After some time, inserts were digested with Sau3AI and ligated to
M13mp18 and M13mp19 digested with BamHI. White plaques were picked
and single stranded DNA was extracted. The DNA was sequenced
according to the method of Sanger et al. (1977). Almost immediately, it was
found that the inserts were made up of random fragments of pBR322 and
lambda DNA.
The cells in which gt11 are grown (E. coli Y1090) contain the plasmid
pMC9 which can recombine with lambda DNA in the cell. Although the
RMPFK probe was excised from pBR322 and purified on a low melting point
agarose gel, it must have contained some contaminating pBR322 DNA and
it was this which gave a signal with the positive clones. In attempting to
minimise such problems, the Southern which gave a signal for the EcoRI
digested clones was probed with pBR322 and did not produce a signal. It
seems however that this Hybond-N filter had been treated with alkali to
remove the RMPFK probe, but had been left in alkali solution for too long
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and been allowed to dry out. Also, the pBR322 DNA used as a positive
control for the hybridisation of radiolabeled pBR322 was placed on a fresh
filter and yielded a positive result. Obviously, if pBR322 had been on the
same filter as clones 1-6, then this problem would have been eliminated
earlier.
Two oligonucleotides were designed to allow PCR of fragments
inserted into the multiple cloning site of pUC type plasmids. At this time, DNA
representing exon I of genomic RMPFK was made available by Dr. Simon
Chang and an O. volvulus cDNA library was kindly made available by Dr.
Tom Unnasch (Case Western University, Ohio). Both RMPFK fragments were
produced using PCR, cut with EcoRI and eluted from low melting point
agarose gels. About 106 phage from each library were screened with both
PCR products. Several possible positive clones were produced but none
proved positive after secondary screening even at low stringencies. Several
attempts to determine the conditions for screening by probing Southern blots
of Onchocerca DNA proved fruitless and it seems that either the probes were
too dissimilar to an Onchocerca PFK or that Onchocerca PFK sequences are
not present in the libraries. Onchocerca DNA was never of good quality,
being extracted from frozen nodules containing adult onchocerca gibsonni
which had been kept at -70° for over two years. These nodules had also
been transported from Australia under unknown conditions. A tubulin clone
and a putative hexokinase clone were identified from genomic libraries
constructed from DNA from these nodule worms in this laboratory These
clones were used to probe genomic onchocerca gibsonni Southern blots
and gave very poor quality results. Bands were often badly smeared and did
not give a good signal. The Southern blots for these hybridisations are seen
in figures 9a and 9b.
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Figure 9a.
Southern blot of human placenta and Onchocerca gibsonni DNA probed
with a putative hexokinase clone from Onchocerca gibsonni.
Lane 1. Human + EcoRI
Lane 2. Human + HinDIII
Lane 3. O. gibsonni + EcoRI
Lane 4. O. gibsonni + HinDIII
Lane 5. A,clfs857 HinDIII molecular weight markers
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Figure 9b.
Southern blot of human placenta and Onchocerca gibsonni DNA probed
with a tubulin clone from Onchocerca gibsonni.
Lane 1. Human + EcoRI
Lane 2. Human + HinDIII
Lane 3. O. gibsonni + EcoRI
Lane 4. O. gibsonni + HinDIII
Lane 5. Xc\ts857 HinDIII labelled with [32P] and Klenow enzyme
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3.3 Screening of libraries with anti Ascaris PFK polyclonal
serum.
HPLC purified Ascaris suum PFK was a kind gift of Dr. Werner Hofer
(University of Konstanz). One mg. of this PFK was emulsified with 0.5 ml. of
Freund's complete adjuvant (Sigma) and injected into the dorsal
subcutaneous tissue of a New Zealand White rabbit. Booster injections
containing 0.5 mg. of Ascaris suum PFK in Freund's incomplete adjuvant
(Sigma) were similarly administered at three weekly intervals on three
occasions. One week after the third booster injection, the animal was bled
and serum purified by allowing the blood to clot at room temperature for one
hour and then overnight at 4°. The clot was removed and cellular debris was
removed by centrifugation at 20,000 r.p.m. in a JA-20 rotor for ten minutes.
Serum was aliquoted and frozen at -70°C.
A.sw.^E. coli, rat muscle and O.guttorosa protein was separated on a 6%
SDS-PAGE gel (Laemmli & Favre, 1973; Sambrook et ai, 1989), and
transferred to nitrocellulose on a LKB semi-dry electrophoresis unit (model
7112) by the method supplied by the manufacturer. These blots were
incubated with varying dilutions of rabbit serum from a 1:500 to a 1:500,000
dilution. The serum only produced a signal specific for Ascaris PFK. The blot
was developed using anti-rabbit IgG coupled to alkaline phosphatase (BIO-
RAD) and BCIP with NBT by the method of Sambrook et al. (1989).
No convincing signal could be obtained for rat or onchocerca protein
using this anti ascaris PFK serum. A representative Western blot is shown in
Figure 10. While signal of a diffuse nature was found for E.coli protein at a
serum dilution of 1:200, the ascaris PFK signal could be generated at a
1:500,000 dilution indicating the specificity of the antibody. Because
Onchocerca material was available in limited quantities, only 100ng was
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Figure 10.
SDS-PAGE gel and Western blot of rat muscle, Onchocerca
gutturosa, Ascaris suum PFK and E. coli probed with anti Ascaris
suum polyclonal serum
Lane 1. Rat muscle, ~500pg
Lane 2. Ascaris suum PFK, -1 mg
Lane 3. Onchocerca gutturosa, ~50|ig (gel) ~500|ig (Western)
Lane 4. E. coli, ~500|ig
Lane 5. Molecular weight markers
loaded onto the gel stained with coomassie blue. The gel intended for
Western blotting was loaded with ~500ng of sample. Although no signal was
seen for Western blots directed against the Onchocerca material, the
libraries were screened using serum at a dilution of 1:2000. Approximately
109 plaques were screened from each of the onchocerca libraries, but no
positive plaques were found after a secondary screening.
\ereA-^-d/p m7)
3.4 Complementation studies on PFK deficient E. coli
Bacteriophage lambda gt11 carries the mutation cl857 of the cl gene.
Lysogens of gt11 may be grown at 32-34°C and the prophage can be
induced by growth above 37°C. The E. coli strain DF1020 which lacks both
the major and minor forms of PFK (recA pro82 ApfkB20'\ recA56 A{rhaptkA)
endA1 hsd^7 supEAA) cannot grow on mannitol but it can grow
gluconeogenically (Hellinga & Evans, 1985). It was possible even though
unlikely, that Onchocerca volvulus PFK might be able to complement this
deficiency as a lysogen containing the PFK sequence. The procedure for
creating a lysogen was that of Huynh et al. (1985) except that cells infected
with gt11 were grown at 32°C on mannitol plates supplemented with proline
and thiamine hydrochloride (Hellinga & Evans, 1985). Over 109 plaque
forming units from each of the five gt11 libraries were used to infect DF1020
but no viable bacteria were seen on the mannitol plates.
The failure to complement DF1020 could be due to a variety of
factors. The most likely explanation is that a full length clone coding for
Onchocerca volvulus PFK in the correct reading frame, may not be present
in any of the libraries. It may not be physiologically possible for O. volvulus
PFK to complement DF1020 or DF1020 may not be capable of forming a
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lysogen with gt11.
3.5 Use of an AT rich oligonucleotide to probe Onchocerca
libraries
The majority of clones from Onchocerca volvulus identified and
sequenced to date derive from surface antigen genes and include a heat
shock protein (Rothstein et al., 1989), myosin (Erondu & Donelson, 1990),
paramyosin (Limberger & McReynolds, 1990), major sperm protein (Scott et
al., 1989), ribosomal genes (Gill et al., 1988). They have usually been
isolated by screening expression libraries with antisera often taken from
immune adults in endemic malarious areas. This procedure is not suited to
identifying genes coding for cytosolic proteins which do not normally
stimulate a significant immune response in the host. There have been
successes in the isolation of HPRT and actin genes from P. falciparum (King
& Melton, 1987; Wesseling et al., 1988) by the use of radiolabeled
heterologous hybridisation probes but this method has not proved to be very
useful. P. falciparum is the eukaryote with the most A + T rich genome (81%)
yet characterised (Goman et al., 1982) and exhibits this most strongly in the
choice of the third base for a particular codon, but there is a dearth of probes
derived from A + T rich organisms. The majority have been derived from
higher eukaryotic genes. The large evolutionary distance between P.
falciparum and higher eukaryotes increases the likelihood that the
divergence between the heterologous probe and the target sequence will be
too great to allow successful hybridisation. The RMPFK gene has a G + C
richness of 58%. It seemed possible that the corresponding PFK from
onchocerca might also have an AT rich sequenceand this would reduce the
usefulness of the rabbit gene as a probe. Rothstein et al. (1988) have
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estimated the A+T content of the filarial nematodes Brugia malayi, Brugia
pahangi and Dirofilaria immitis to be 72%-74%. They also estimated the A+T
content of the free living nematode to be 64%. They used histone, actin and
myosin probes from C. elegans to probe genomic Southern blots of filarial
nematodes and found essentially no hybridisation. They also found that
codon usage in the filarial nematodes was heavily biased to A or T in the
third codon position. Hyde et al. (1989) constructed a table using 10,000
codons from P. falciparum to take into account the probability that the choice
of codon for a particular amino acid will result in a perfect match and also the
probabilities of 2 and 1 base pair matches occurring if the codon selected is
wrong. A 51 mer oligonucleotide was designed according to this table which
corresponded to a PFK sequence and contains amino acids which have a
low number of codon usage possibilities and which is identical for all
mammalian PFK's. The conserved peptide has the sequence His-Gln-Arg-
Thr-Phe-Val-Leu-Glu-Val-Met-Gly-Arg-His-Cys-Gly-Tyr-Leu which begins at
position 160. The reverse complement of this peptide was synthesised and
has the sequence, TAAATATCCACAATGACGTCCCATTACT
TCTAGTACAAATGTACGTTGATG. The oligonucleotide was
radiolabeled with y^PATP by polynucleotide kinase (Sambrook etal., I989)
and used to probe the onchocerca libraries from Mali and the library from
Tom Unnasch. Plaque lift filters were incubated overnight in 6xSSC-0.2%
SDS, at 50°C. Incorporation of i*2P ATP was ascertained by ammonium
formate chromatography on DE81 paper (Rigby et al., 1977). Filters were
washed in 6xSSC-0.2%NaPpj for fifteen minutes four times at room
temperature, and then for thirty minutes at 50°C. Several positives were
isolated from the onchocerca libraries but none proved positive in a
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secondary screen.
Recently a tubulin genomic clone has been isolated in this laboratory
by Dr. B.M. Pinto using the P. falciparum tubulin gene as a probe. This clone
is 60% A + T rich in the coding region and 74.5% of the codons possess A or
T in the third position, whilst in the noncoding region, the A + T richness is
elevated to 80%,. I have composed a codon usage table on the basis of this
tubulin clone and used it to backtranslate the sequences of known PFK's
from different organisms. Gapping of the oligomer to these backtranslated
sequences shows that if O. volvulus PFK is identical to the conserved
sequence in this region and has a codon usage consistent with that of
tubulin then the 51mer oligomer would have 84% identity to all mammalian
sequences. The 51mer oligomer shows 67% and 74.5% identity to the
enzymes from E. coliand B. stearothermophilus respectively.
PFK from Onchocerca may not have the same codon usage as tubulin
and might also differ in its amino acid sequence to the other known
sequences. Codon usage for oncho tubulin was used to backtranslate a
variety of PFK's. The RMPFK genomic clone (exon twenty two) used as a
probe was then compared to the backtranslated PFKs. The identities are
shown in Table 3.
If Onchocerca! PFK has a similar codon usage the that of the tubulin
clone, then it is probable that using RMPFK as a probe would decrease the
likelihood of detecting PFK in the onchocerca libraries.
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% SIMILARITY TO % ACTUAL
BACKTRANSLATED SIMILARITY
SEQUENCE
HMPFK 70% 89%
RMPFK 71% 100%
SHPFK 66%
SLPFK 54%
HLPFK 53% 68%
MLPFK 54% 69%
HPPFK 56% 71%
Table 3
Backtranslated PFK sequences using Onchocerca gibsonni
tubulin codon usage with comparison to RMPFK
3.6 PCR of onchocerca libraries using degenerate
oligonucleotides.
Oligos were designed against a conserved area of PFK to see if it was
possible to use PCR to amplify a PFK sequence directly from the library.
Oligo I corresponds to the sequence
Ser-lle-Asp-Asn-Asp-Phe-Cys-Gly-Thr beginning at position
125. The oligo was made with the majority of possible codon usage built in.
This oligo was:
TCN ATY GAY AAY GAY TTY TGY GGR ACN G
Oligo 2 corresponds to the sequence
Ser-Arg-Met-Gly-Val-Glu-Ala-Val-Met-Ala
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Oligo 2 is GCC ATN ACN GGY TCN ACN CCC ATY CTN C
The reverse complement of this is
GN AGR ATG GGN GTN GAR GCN GTN ATG GC
Key: Y = C or T, R = A orG, N = A, C, GorT.
If onchocerca PFK corresponds to the sequence of mammalian PFK
and is present in the libraries then a PCR product of ~ 470 bp would be
amplified.
The conditions for the reaction were; 10pl oligo 1 ~3pg, 7.5|il of oligo
2 ~3|ig, 20pl 5 x amplification buffer, 2\i\ of each dNTP at 10mM, 2 units of
Taq polymerase, 40pl of amplified library. Oligonucleotides were kinased
with ATP and polynucleotide kinase before use (Sambrook et a!., 1989).
The mix was denatured for 10 minutes at 95°C before adding Taq
polymerase and was then subjected to 25 cycles of 1 minute at 95°C, 2
minutes at 55°C and 1.5 minutes at 72°C. The Mali library gave the largest
yield of a product ~ 500 bp but no single band. The human liver cDNA
library, and onchocerca libraries (Toborou & Tom Unnasch) gave a variety of
bands below 1kbp, Figures 11a and 11b show a representative sample of
these PCR products.
Bands of ~500bp were excised from a low melting agarose gel and
phenol chloroform extracted. Initial attempts to subclone these fragments
into Smal cut, phosphatased M13mp8 were unsuccessful so the
fragmentswere "polished" with T4 DNA polymerase and Klenow enzyme
and dNTP but proved to be unclonable for some reason. There have been
reports that Taq polymerase contains a template independent polymerase
activity and adds an extra dATP onto the ends of PCR products which will
often prove to be unclonable. If this experiment were to be repeated, then
the addition of a restriction enzyme site(s) to the 5' end of the oligos might
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Figure 11a.
Agarose gel electrophoresis of PCR products from human liver cDNA
andOnchocerca volvulus cDNA libraries and from genomic Onchocerca
guttorosa DNA generated by using degenerate oligonucleotides
corresponding to conserved areas of PFK.
Lane 1. Guatemala library
Lane 2. Human liver library
Lane 3. Kumaba library
Lane 4. Mali library
Lane 5. Xclfs857 HinDIII markers
Lane 6. Toborou library
Lane 7. Tom Unnasch library
Lane 8. Onchocerca gibsonni genomic DNA
Lane 10. Xclte857 HinDIII markers
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Figure 11b.
Agarose gel electrophoresis of PCR products from human liver cDNA
andOnchocerca volvulus cDNA libraries and from genomic
Onchocerca gutturosa DNA generated by degenerate
oligonucleotides corresponding to conserved areas of PFK, and of
rabbit muscle DNA PCR products generated for use as probes.
Lane 1. Onchocerca guttorosa genomic DNA
Lane 2. RMPFK exon one
Lane 3. Onchocerca gibsonni genomic DNA
Lane 4. Human liver library
Lane 5. \c\ts857 HinDIII markers
Lane 6. Mali library
Lane 7. RMPFK exon twenty two
Lane 8. Tom Unnasch library
Lane 9. 3pg PCR oligo
improve the 'clonability' of these fragments. PCR DNA might also be further
purified by isolating bands from an agarose gel and subjecting a small
amount of the DNA to a further round of PCR amplification.
Unfortunately the use of these fragments as probes back into the
libraries resulted in all plaques giving a very strong signal after a high
stringency wash. There may have been contamination of probe DNA by
small amounts of X DNA from the libraries which was present at the 500 bp
level as a result of thermal scission or it may be that some part of the X
molecule has been amplified during the PCR reaction.
The fact that 500 bp fragments were generated as expected in some
of the libraries makes it probable that thermal scission of X DNA has taken
place giving a background of X DNA in the PCR product. The 500bp PCR
fragment generated from the Mali library hybridises to the PCR reaction
oligos indicating that the reverse complement DNA to the oligos is present in
the probe DNA (results not shown). This indicates that some component of
the library has been amplified.
It is possible that human PFK was amplified, as the libraries are
reported to be contaminated by human PFK (John Donelson, personal
communication). The Guatemala library is thought to comprise 6%
human DNA and the other libraries may comprise about 1% human DNA. By
its very nature, PCR would tend to amplify any contaminating human PFK
but this must remain speculative as no sequence data is available on these
PCR fragments.
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CHAPTER FOUR
ISOLATION OF A cDNA ENCODING HUMAN MUSCLE PFK
4.1 Use of a genomic clone encoding HMPFK.
A genomic clone of HMPFK was isolated in this laboratory using
RMPFK exon twenty two as a probe. The organisation of this clone is shown
in figure 12. The clone was 19 kbp long and was thought to contain 7 kbp of
PFK sequence. Several plasmids were generated with fragments of the 7 kb
region and used as probes in the libraries. No definite positives could be
found. After some time it was learned that the orientation of the coding
region was incorrect and that previous plasmids contained non-coding
sequence DNA. Some other fragments were subcloned and five were
sequenced to ascertain the usefulness of the insert DNAs as probes.
The entire fragment containing the HMPFK genomic sequence was
subcloned as pPH4, and used as a probe with the human liver gt10 library
Ten positives were picked and 2 positives remained after a 4° screen.
One positive clone proved to be a fragment of A. The other positive,
pCS8, contained a fragment which contained two Alu sequences. This was
used as a probe against six fragments of the HMPFK genomic clone to find
out which contained Alu sequences. A dot blot of the HMPFK genomic
subclones probed with pCS8 is shown in figure 13. A signal was obtained
for pCS8, pPH2 and pPH6 indicating that two Alu sequences were present
in the HMPFK genomic clone or that one Alu sequence spanned the junction
of clones pPH2 and pPH6. pCS7, pPH3 and pPH9 did not contain Alu
sequences and could be used as probes.
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pPH4
<f 1>
pPH6 pPH2
<j ixi i>
pCS7 pPH3pPH9
<f i> <f—ixj—t>
S E B H B H S
I I I I I I I
04 8 12 16 20
4 9 12 18 22
Exon position, 4, 9, 12, 18, 22.
S = Sail, E = EcoRI, B = BamHI, H = HinDIII.
Figure H. Gene structure of the human genomic clone
and names of subclones.
pP«3 pPH& CS7
pes? ,PH^
Figure 13
Dot blot of the subcloned fragments of the HMPFK genomic clone inserts from figure
10 probed with pCS8 labelled with Klenow enzyme and [32P]. pPH2, pPH6 and
pCS8 contain Alu sequences.
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4.2 Isolation of a partial cDNA encoding HMPFK.
An HT1080 tumour cell line of fibrosarcoma in gt11 was a kind gift of
Dr. Nigel Spurr ( ICRF Clare Hall). This was probed with pPH3 and pPH9.
Of four positives, one was HMPFK cDNA from the EcoRI site at 948 bp to
2750bp in the non-coding 3' end. This was designated pCS10.
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Chapter FIVE
ISOLATION OF A cDNA ENCODING HUMAN PLATELET PFK
5.1 Isolation of a cDNA clone encoding human platelet PFK
pCS10 was used to probe a Raji B lymphocyte cell library in ?igt10 (a
kind gift of Dr. Nigel Spurr ICRF Clare Hall) and generated six positives. Two
of these gave a strong signal which was not washed off at 1 x SSC, 70°C.
The other four were washed off at the higher stringency. These were named
R5-R8. R6-R8 proved difficult to sublcone. R5 was subcloned into pK19 and
named pCS11. The initial sequence showed 66% identity to MLPFK and
64% identity to HMPFK. Amino acid identities were similar to DNA identities.
5.2 The sequence of the partial cDNA encoding HPPFK.
The sequence corresponded to HMPFK from 1500 bp to its 3' end. It
contained a poly A site, a polyadenylation signal, 900bp. of coding region
and 238bp. of downstream untranslated sequence. The DNA sequence and
inferred amino acid sequence is shown in figure 14.
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60
ATTCCGAAGTACTTGGAAGAGATCGCCACACAGATGCGCACCAGCATCAACGCGCTGCTG
IPKYLEEIATQMRTSINALL
120
ATCATCGGTGGATTCGAGGCCTACCTGGGACTCCTGGAGCTGTCAGCCGCCCGGGAGAAG
I IGGFEAYLGLLELSAAREK
180
CACGAGGAGTTCTGTGTCCCCATGGTCATGGTTCCCGCTACTGTGTCCAACAATGTGCCG
HEEFCVPMVMVPATVSNNVP
240
GGTTCCGATTTCAGCATCGGGGCAGACACCGCCCTGAACACTATCACCGACACCTGCGAC
GSDFS IGADTALNT ITDTCD
300
CGCATCAAGCAGTCCGCCAGCGGAACCAAGCGGCGCGTGTTCATCATCGAGACCATGGGC
R IKQSASGTKRRVF I I ETMG
360
GGCTACTGTGGCTACCTGGCCAACATGGGGGGGCTCGCGGCCGGAGCTGATGCCGCATAC
GYCGYLANMGGLAAGADAAY
420
ATTTTCGAAGAGCCCTTCGACATCAGGGATCTGCAGTCCAACGTGGAGCACCTGACGGAG
IFEEPFDIRDLQSNVEHLTE
480
AAAATGAAGACCACCATCCAGAGAGGCCTTGTGCTCAGAAATGAGAGCTGCAGTGAAAAC
KMKTTIQRGLVLRNESCSEN
540
TACACCACCGACTTCATTTACCAGCTGTATTCAGAAGAGGGCAAAGGCGTGTTTGACTGC
YTTDFIYQLYSEEGKGVFDC
600
AGGAAGAACGTGCTGGGTCACATGCAGCAGGGTGGGGCACCCTCTCCATTTGATAGAAAC
RKNVLGHMQQGGAP S P FDRN
660
TTTGGAACCAAAATCTCTGCCAGAGCTATGGAGTGGATCACTGAAAAACTCAAGGAGGCC
FGTKISARAMEWITEKLKEA
720
CGGGGCAGAGGAAAAAAATTTACCACCGATGATTCCATTTGTGTGCTGGGAATAAGCAAA
RGRGKKFTTDDS ICVLGISK
780
AGAAACGTTATTTTTCAACCTGTGGCAGAGCTGAAGAAGCAAACGGATTTTGAGCACAGG
RNVIFQPVAELKKQTDFEHR
840
ATTCCCAAAGAACAGTGGTGGCTCAAGCTACGGCCCCTCATGAAAATCCTGGCCAAGTAC
I PKEQWWLKLRP LMK I LAKY
900
AAGGCCAGCTATGACGTGTCGGACTCAGGCCAGCTGGAACATGTGCAGCCCTGGAGTGTC
KASYDVSDSGQLEHVQPWSV
960
tgacccagtcccgcctgcatgtgcctgcagccaccgtggactgtgtctgtttgtaacact
taagttattttatcagcactttatgcacgtattattgacattgaatacctaatcggcgag
tgcccatctgccccaccagctcccagtgcgtgctgtctgtggagtgtgtctcatgctttc
agatgtgatatgagcagaattaattaaacatttgcctatgAn
Figure 14. Partial DNA sequence and inferred amino acid sequence
of human platelet phosphofructokinase
R5-R8 were probed as plaques with pCS11 and pCS10. Only R5 gave a
strong signal to pCS11 after washing filters at 0.1 x SSC 0.1% SDS at 65°C.
The EcoRI insert of pCS11 was digested with Sau3A1 and subcloned into
M13mp18 and M13mp19 for DNA sequencing. Sequencing was also
performed on pCS11 directly using forward and reverse sequencing primers
originally designed as PCR primers for inserts in pUC type plasmids. The
insert was digested with Sma1 to produce two fragments which were
subcloned into Bluescript K5+ (Stratagene), designated pCS17 and pCS18.
The sequencing strategy is shown in Figure 15.
One oligo was synthesised to sequence across the area covered by the
internal Sma1 site, and a Sau3A1 site just upstream of it.
The putative HPPFK sequence begins at position 1417 when
compared to the FIMPFK DNA sequence and at position 1414 when
compared to the HLPFK sequence. The HPPFK sequence is shown in figure
15 along with the comparable sequence from HMPFK and HLPFK. The
HPPFK sequence contains an open reading frame of 900 bp followed by a
3' downstream untranslated non-coding region of 238 bp, with the rare
polyadenylation signal AATTAAA 12 bp before a poly A tail of 16 residues.
HLPFK has a non-coding 3' region of 515 bp with a polyadenylation signal
AATAAA 37 bases before the poly (A) tract. HMPFK has a 399 bp
untranslated 3' region with the polyadenylation signal AATAAA 18 bp before
the poly A tract.
The platelet amino acid sequence is 5 amino acid residues shorter
than the muscle PFK and 6 residues shorter than liver PFLK. HPPFK is
forecast to have a Mr of 86,500±1,500, HLPFK to have a Mr of 76,700±1,400
and HMPFK to have a Mr of 82,500±1,600 (Dunaway et al., 1988). HMPFK
and HPPFK have also been predicted to have Mr values of
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Figure 15. Sequencing strategy for the human platelet clone
E = EcoRI
S = Smal
120
HMPFKN MTHEEHHAAKTLGIGKAIAVLTSGGDAQGMNAAVRAWRVGIFTGARVFFVHEGYQGLVDG
HLPFKN MAAVDLEKLRASGAGKAIGVLTSGGDRQGMNAAVRAVTRMGIYVGAKVFLIYEGYEGLVEG
HMPFKC AVMNVGAPAAGMNAAVRSTVRIGLIQGNRVLWHDGFEGLAKG
HLPFKC AILNVGAPAAGMNAAVRSAVRTGISHGHTVYWHDGFEGLAKG
* ******* * * * * * ** *
• ••• • • ••• • ••••• ••
46
HMPFKN GDHIKEATWESVSMMLQLGGTVIGSARCKDFREREGRLRAAYNLVKRGITNLCVIGGDGSL
HLPFKN GENIKQANWLSVSNIIQLGGTIIGSARSKAFTTREGRRAAAYNLVQHGITNLCVIGGDGSL
HMPFKC —QIEEAGWSYVGGWTGQGGSKLGTKRT LPKKSFEQISAN ITKFNIQGLVIIGGFEAY
HLPFKC —QVQEVGWHDVAGWLGRGGSMLGTKRT LPKGQLESIVENIRIYGIHALLWGGFEAY
HPPFKC IPK-YLEEIATQMRT-SINALLIIGGFEAY
* *
# **_ * * t _ ,*.*..**..
106
HMPFKN TGADTFRSEWSDLLSDLQKAGKITDEEATKSSYLNIVGLVGSIDNDFCGTDMTIGTDSALH
HLPFKN TGANIFRSEWGSLLEELVAEGKISETTAWTYSHLNIAGLVGSIDNDFCGTDMTIGTDSALH
HMPFKC TGGLELMEGRKQF DELCIPFWIPATVSNNVPGSDFSVGADTALN
HLPFKC EGVLQLVEARGRY EELCIVMCVIPATISNNVPGTDFSLGSDTAVN
HPPFKC LGLLELSAAREKH EEFCVPMVMVPATVSNNVPGSDFSIGADTALN
★
.. • ••••*•
144
HMPFKN RIMEIVDAIT-TTAQSHQRTFVLEVMGRHCGYLALVTSLSCGADWVFIPECPPDDDWEEHL
HLPFKN RIMEVIDAIT-TTAQSHQRTFVLEVMGRHCGYLALVSALASGADWLFIPEAPPEDGWENFM
HMPFKC TICTTCDRIKQSAAGTKRRVFIIETMGGYCGYLATMAGLAAGADAAYIFEEPFTIRDLQAN
HLPFKC AAMESCDRIKQSASGTKRRVFIVETMGGYCGYLATVTGIAVGADAAYVFEDPFNIHDLKVN
HPPFKC TITDTCDRIKQSASGTKRRVFIIETMGGYCGYLANMGGLAAGADAAYIFEEPFDIRDLQSN
204
HMPFKN CRRLSETRTRGSRLNIIIVAEGAIDKNGKPITSEDIKNLWK—RLGYDTRVTVLGHVQRG
HLPFKN CERLGETRSRGSRLNIIIIAEGAIDRNGKPISSSYVKDLWQ—RLGFDTRVTVLGHVQRG
HMPFKC VEHLVQKMKTTVKRGLVLRNEKCNEN YTTDFIFNLYSEEGKGIFDSRKNVLGHMQQG
HLPFKC VEHMTEKMKTDIQRGLVLRNEKCHDY YTTEFLYNLYSSEGKGVFDCRTNVLGHLQGG
HPPFKC VEHLTEKMKTTIQRGLVLRNESCSEN YTTDFIYQLYSEEGKGVFDCRKNVLGHMQQG
t t * f
253
HMPFKN GTPSAFDRILGSRMGVEAVMALLE GTPDTPACWSLSGNQAVRRLPLM
HLPFKN GTPSAFDRILSSKMGMEAVMALLE ATPDTPACWTLSGNQSVRRLPLM
HMPFKC GSPTPFDRNFATKMGAKAMNWMSGKIKESYRNGRIFANTPDS-GCVLGMRKRALVFFQPVA
HLPFKC GAPTPFDRNYGTKLGVKAMLWLSEKLREVYRKGRVFANAPDS-ACVIGLKKKAVAFFSPVT
HPPFKC GAPSPFDRNFGTKISARAMEWITEKLKEARGRGKKFT-TDDS-ICVLGISKRNVIFFQPVA
**
292
HMPFKN ECVQVTKDVTKAMDEK KFDEALKLRGRSFMNNWEVYKL—LAHVRPPVSKSGSHTV
HLPFKN ECVQMTKEVQKAMDDK RFDEATQLRGGSFENNWNIYKL—LTHQKPPKEKSNFSL
HMPFKC ELKDQTDFEHRIPKEQWWLKLRPILKILAK-YEIDLDTSDHAHLEHITRKRSGEAAV
HLPFKC ELKKDTDFEHRMPREQWWLSLRLMLKMLAQ-YRISMAAYVSGELEHVTRRTLSMDGGF
HPPFKC ELKKQTDFEHRIPKEQWWLKLRPLMKILAK-YKASYDVSDSGQLEHVQPWSV
.. *
319
Key.
* = identity
. = similarity
N = AMINO HALF
C = CARBOXYL HALF
HMPFK = HUMAN MUSCLE PFK
HLPFK = HUMAN LIVER PFK
HPPFK = HUMAN PLATELET PFK
Numbering is according to B.stearothermophilus PFK
FIGURE 16. ALIGNMENT OF THE HUMAN PHOSPHOFRUCTOKINASES.
85,000 and HLPFK is given a Mr of 80,000 (Karadsheh et al., 1977; Vora,
1982). The DNA sequence of HLPFK implies a Mr of 85,146 (Levanon et al.,
1989) while the DNA sequence for HMPFK implies a Mr of 85,050 (Nakajima
et al., 1987).
On the assumption that HPPFK has a similar amino acid
sequence to the other human sequences, it is possible to speculate on the
Mr of HPPFK. Adding the Mr of the muscle or liver enzyme residues proximal
i.e. more amino to the platelet residues to the Mr of the known platelet
sequence gives a Mr of 84,147 for HLPFK + HPPFK and 84,464 for HMPFK
+ HPPFK. This could possibly be interpreted as five to eight residues being
missing from the HPPFK sequence. The area around the TGA stop codon
was sequenced 4 times on each strand and the 3' sequence shows no
obvious similarity to the other PFK DNA sequences or to amino acid
sequences in any of the reading frames.
A codon usage table created from the HPPFK sequence by the
UWGCG program CODONFREQUENCY was used to scan HPPFK with the
UWGCG program CODONPREFERENCE . The output of this program is
shown in Figure 16. The presumed open reading frame stops at position
904. A possible open reading frame starts at position 924 and continues for
about 40bp. The 20 or so amino acids they represent do not have any
similarity to other PFK sequences and it seems likely that the stop codon for
HPPFK has been identified correctly.
The partial HPPFK has an isoelectric point of pH 6.98. This compares
to isoelectric points of pH 8.68 and pH 7.91 for the partial homologous
sequences from HMPFK and HLPFK respectively. The isoelectric points for
the complete sequences are pH 7.92 and pH 7.47 for HMPFK and HLPFK
respectively. This implies that the amino half of the human enzymes may
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have more acidic residues than the carboxyl halves. HPPFK levels are high
in some cancerous cells (Vora, 1982, 1985o^and a low isoelectric point might
thus be expected for this isoenzyme, given the high rates of glycolysis and
low pH levels seen in these cells.
The partial HPPFK sequence has a G + C content of 54%. Sequence
analysis shows that 71% of the bases at the third position of codons are
either G or C. HLPFK is even more biased in this regard, with a G + C
content of 60% and 85% third position G or C (Levanon et al., 1989).
Newgard et al. (1986) predicted that a high G + C content with G or C in the
third codon position, is a hallmark of sequences coding for proteins
expressed in muscle tissues. This was based on coding sequences for
twenty four liver, and thirteen muscle proteins from human, rat and rabbit
sources. Liver sequences were found to contain an average of 51 ±6%
overall and 59±12% in the third codon position whereas muscle sequences
contained 58±4% and 80±10% respectively.
If this theory is correct, then PFK sequences (especially HMPFK and
HLPFK) would seem to break the rules. Table 4 gives the relative G + C
contents of mammalian PFK's.
CODING SEQUENCE THIRD CODON
G + C POSITION G + C
HMPFK 53% 59%
RMPFK 59% 75%
HPPFK 54% 71%
HLPFK 60% 84%
MLPFK 60% 72%
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Berget (1984) has implicated the sequence CAYCG as being
important for mRNA polyadenylation and processing. It lies just upstream or
downstream of the polyA addition site. HPPFK has the sequence CATTTG
which lies just upstream of the polyadenylation signal AATTAAA. HMPFK
has the sequence CACTG and HLPFK has the sequence CATCG, both of
which lie just upstream from the polyA addition site. The significance of the
rare polyadenylation signal AATTAAA is unknown.
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CHAPTER SIX.
COMPARISON OF HUMAN PLATELET PFK TO PROKARYOTIC
AND EUKARYOTIC PFK
6.1. Similarities between human platelet PFK and other PFK's.
The sequences and tertiary structures of prokaryotic PFK's are known
from E. coli and B. stearothermophilus. The sequences are also known for
S. citri and T. thermophilus PFK. The subunit Mr of the bacterial enzymes is
~35,000 whereas that of the mammalian enzymes are -78,000 - 86,000.
Strong sequence similarity has been observed between the bacterial
enzymes and between the amino and carboxyl halves of RMPFK. The
pattern of sequence conservation suggests that the mammalian enzyme
arose from a prokaryotic progenitor by gene duplication, fusion and
divergence (Poorman et al., 1984). The amino halves of mammalian PFK
are more similar to the bacterial enzyme than are the carboxyl halves. The
partial sequence of HPPFK shows -30% identity to the bacterial enzymes
and -55% similarity if matched to conserved mutations.
Table 5 gives percentage similarities and percentage identities
between all N and C halves of the eukaryotic enzymes. It can be seen that
the platelet enzyme is more similar to HMPFK than HLPFK. Different
explanations can be given for the differences between the liver and
muscle/platelet types. The gene duplications to form three enzymes from
one enzyme might have occurred at different times. Thus the platelet or
muscle gene might have diverged more recently than the liver gene. It is
also possible that the liver enzyme is evolving at a faster rate than the other
isoenzymes.
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% SIMILAR % IDENTICAL
HMC 83.3 70.7
RMC 82.7 69.7
HLC 80.3 63.3
MLC 80.1 63.7
SHC 79.2 64.4
SLC 77.0 62.3
Y2C 60.0 34.7
Y1C 58.5 35.7
Y1N 51.2 26.0
MLN 50.2 27.6
SLN 49.6 29.3
HLN 49.1 27.5
Y2N 49.0 22.6
RMN 48.4 27.2
HMN 47.5 26.9
SHN 45.5 20.9
Table 5. Pairwise comparisons betwen eukaryotic amino and carboxyl
halves of PFK against HPPFKC. Alignments were performed using the
modified GAP program from UWGCG version. 6.0,. Default gap weight 3.00,
default gap length weight 0.10.
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The aligned sequences of phosphofructokinase
GAPS ARE REPRESENTED AS —.
UNKNOWN SEQUENCE IS REPRESENTED AS A SPACE.
APPROXIMATELY THE FIRST 200 RESIDUES OF THE YEAST GENES ARE NOT INCLUDED
THE E.COLI SEQUENCE IS FROM FRENCH & CHANG, (1987). THE E.COLI SEQUENCE IN
THE SEQUENCE DATABASES IS INCORRECT, PERSONAL COMMUNICATION, EVANS, P.R.
(MRC,CAMBRIDGE)
I i
A 1 B 2
bbbbbb aaaaaaaaaaaaaaaa bbbbbb aaaaaaa
HUMUSCL-N MTHEEHHAAKTLGIGKAIAVLTSGGDAQGMNAAVRAWRVGIFTGARVFFVHEGYQGLVDGG-D
RABMUSCL-N MTHEEHHAARTLGVGKAIAVLTSGGDAQGMNAAVRAWRVGIFTGARVFFVHEGYQGLVDGG-D
SHEHEART-N MTHEEHHEAKTLGIGKAIAVLTSGGDAQGMNAAVRAWRVGIYTGARVFFVHEGYQGLVDGG-D
SHELIVER-N TSGAGKAIGVLTSGGDAQGMNAAVRAVTRMGIVTGAKVFLIYEGYEGLVEGG-E
HUMLIVER-N MAAVDLEKLRASGAGKAIGVLTSGGDRQGMNAAVRAVTRMGIYVGAKVFLIYEGYEGLVEGG-E
MUSLIVER-N MATVDLEKLRMSGAGKAIGVLTSGGDAQGMNAAVRAVTRMGIYVGAKVFLIYEGYEGLVEGG-E
YEAST1-N K-IAVMTSGGDSPGMNAAVRAWRIGIHFGCDVFAVYEGYEGLLRGG-K
YEAST2-N KAIAVMTSGGDAPGMNSNVRAIVRSAIFKGCRAFWMEGYEGLVRGGPE
HUMUSCL-C AVMNVGAPAAGMNAAVRSTVRIGLIQGNRVLWHDGFEGLAKG
RABMUSCL-C AVMNVGAPAAGMNAAVRSTVRIGLIQGNRVLWHDGFEGPAKG
SHEHEART-C AVMNVGAPAAGMNAAVRST RIGLIQGNAVLWHDGFEGLAKG
SHELIVER-C VMNVGAPAAGMNAAVRSAVRSGISQGHTVYWHDGFEGLAKN
HUMLIVER-C AILNVGAPAAGMNAAVRSAVRTGISHGHTVYWHDGFEGLAKG
MUSLIVER-C AILNVGAPAAGMNAAVRSAVRTGISEGHTVYIVHDGFEGLAKG
YEAST1-C GIVHVGAPSAALNAATRAATLYCLSHGHKPYAIMNGFSGLIQTG—
YEAST2-C AIVNVGAPAGGINSAVYSMATYCMSQGHRPYAIYNGWSGLNRHE—
E .COLI MIKKIGVLTSGGDAPGMNAAIRGWRSALTEGLEVMGIYDGYLGLYE D
B . ST MKRIGVLTSGGDSPGMNAAIRSWRKAIYHGVEVYGVYHGYAGLIA G
S .CITRI MLKKIGILTSGGDSQGMNAAIAGVIKTAHAKGLETYIIRDGYLGLIN N
T . THERM MKRIGVFTSGGDAPGMNAAIRAWRQAHALGVEVIGIRRGYAGMIQ G
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HUMUSCL-N HIKEATWESVSMMLQLGGTVIGSARCKDFRE-REGRLRAAYNLVKRGITNLCVIGGDGSLTGAD
RABMUSCL-N HIREATWESVSMMLQLGGTVIGSARCKDFRE-REGRLRAAHNLVKRGITNLCVIGGDGSLTGAD
SHEHEART-N NIREATWES CKDFRE-REGRLAAAHNLVK GIGNLCVIGADGSLTGGD
SHELIVER-N NIR CKAFTT-R AAHNLVKRGITNLCVIGGDASLTGAN
HUMLIVER-N NIKQANWLSVSNIIQLGGTIIGSARSKAFTT-REGRRAAAYNLVQHGITNLCVIGGDGSLTGAN
MUSLIVER-N NIKPANWLSVSNIIQLGGTIIGSARCKAFTT-REGRLAAAYNLLQHGITNLCVIGGDGSLTGAN
YEAST1 -N YLKKMAWEDVRGWLSEGGTLIGTARSMEFRKGREGRRQAAGNLISQG IDALWCGGDGSLTGAD
YEAST2-N YIKEFHWEDVRGWSAEGGTNIGTARCMEFKK-REGRLLGAEHLIEAGVDALIVCGGDGSLTGAD
HUMUSCL-C QIDEAGWSYVGGWTGQGGSKLGTKRTLPK-KSFEQ ISANITKFNIQGLVIIGGFEAYTGGL
RABMUSCL-C QIEEAGWSYVGGWTGQGGSKLGSKRTLPK-KSFEQ ISANITKFNIQGLVIIGGFEAYTGGL
SHEHEART-C TLPK- SFEE ITADI
SHELIVER-C QVQEVSWHDVAGWLGRGGSMLGTKRTLPK-GYMEQ IVESIRLHNIHALLVIGGFEAYEGVL
HUMLIVER-C QVQEVGWHDVAGWLGRGGSMLGTKRTLPK-GQLES IVENIRIYGIHALLWGGFEAYEGVL
MUSLIVER-C QVQEVGWHDVAGWLGRGGSMLGTKRTLPK-PHLEA IVENLRTYNIHALLVIGGFEAYEGVL
HUMPLATE-C IPK-KYLEE IATQMRT-SINALLIIGGFEAYLGLL
YEAST1-C EVKELSWIDVENWHNLGGSEIGTNRSVASE-DLGT IAYYFQKNKLDGLIILGGFEGFRSLK
YEAST2-C SVRSLNWKDMLGWQRSGGSEIGTNRVTPEEADLGM IAYYFQKYEFDGLIIVGGFEAFESLH
E. COLI RMVQLDRYSVSDMINRGGTFLGSARCPEFRDE-NIRAVAIENLKKRGIDALWIGGDGSYMGAM
B. ST NIKKLEVGDVGDIIHRGGTILYTARCPEFKTE-EGQKKGIEQLKKHGIEGLWIGGDGSYQGAK
S .CITRI WIEWDNNFADSIMLLGGTVIGSARLPEFKDP-EVQKKAVDILKKQEIAALWIGGDGSYQGAQ
T. THERM EMVPLGVRDVANIIQRGGTILLTARSQEFLTE-EGRAKAYAKLQAAGIEGLVAIGGDGTFRGAL
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HUMUSCL-N TFRSEWSDLLSDLQKAGKITDEEATKSSYLNIEGLVGSIDNDFCGTDMTIGTDSALHRIMEIVD
RABMUSCL-N TFRSEWSDLLSDLQKAGKITAEEATRSSYLNIVGLVGSIDNDFCGTDMTIGTDSALHRITEIVD
SHEHEART-N TFRSEWGDLLSDLQKSGKITAEEATKSSYLNIV MTIGTDSAL
SHELIVER-N TFRSEWGSLLEELVSEGKISEGTAQYRSHLNIAGLVGSIDNDFCGTDMTIGTDSALHRIMEVID
HUMLIVER-N IFRSEWGSLLEELVAEGKISETTAWTYSHLNIAGLVGSIDNDFCGTDMTIGTDSALHRIMEVID
MUSLIVER-N IFRNEWGSLLEELVKEGKISESTAQNYAHLTIAGLVGSIDNDFCGTDMTIGTDSALHRIMEVID
YEAST1-N LFRHEWPSLVDELVAEGRFTKEEVAPYKNLSIVGLVGSIDNDMSGTDSTIGAYSALERICEMVD
YEAST2-N LFRSEWP SLIEELLKTNRISNEQYERMKHLNICGTVGSIDNDMSTTDATIGAYSALDRICKAID
HUMUSCL-C EIMEGRKQF DELCIPFWIPATVSNNVPGSDFSVGADTALNTICTTCD
RABMUSCL-C ELMEGRKQF DELCIPFWIPATVSNNVPGSDFSVGADTALNTICTTCD
SHEHEART-C EGRKQY DELCIPFWIPATVSNNVPGSDFSFGADTALNTICMTCD
SHELIVER-C QLVEARGRY EETCIRMLVIPATLSNNVPGTDFSVASDTALNT
HUMLIVER-C QLVEARGRY EELCIVMCVIPATISNNVPGTDFSLGSDTAVNAAMESCD
MUSLIVER-C QLVEARGRY EELCIVMCVIPATISNNVPGTDFSLGSDTAVNAAMESCD
HUMPLATE-C ELSAAREKH EEFCVPMVMVPATVSNNVPGSDFSIGADTALNTITDTCD
YEAST 1-C QLRDGRTQH PIFNIPMCLIPATVSNNVPGTEYSLGVDTCLNALVNYTD
YEAST2-C QLERARESY PAFRIPMVLIPATLSNNVPGTEYSLGSDTALNALMEYCD
E . COL I RLTEMG FPCIGLPGTIDNDIKGTDYTIGFFTALSTWEAID
B. ST KLTEHG FPCVGVPGTIDNDIPGTDFTIGFDTALNTVIDAID
S .CITRI RLTELG INCIALPGTIDNDITSSDYTIGFDTAINIWEAID
T . THERM FLVEEHG MPWGVPGTIDNDLYGTDYTIGFDTAVNTALEAID
*
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HUMUSCL-N AITTTAQS-HQRTFVLEVMGRHCGYLALVTSLSCGADWVFIPECP PDDDWEEHLCRRLSE
RABMUSCL-N AITTTAQS-HQRTFVLEVMGRHCGYLALVTSLSCGADWVFIPECP PDDNWEDHLCRRLSE
SHEHEART-N HCGYLALVTSLSCGADWVFIPQCP PDDNWEDHLC LSE
SHELIVER-N AITTTAQS-HQRTFVLEVMGRHCGYLALVTSLACGADWVFIPECP PNIQW MCERLGE
HUMLIVER-N AITTTAQS -HQRTFVLEVMGRHCGYLALVSALASGADWLFIPEAP PEDGWENFMCERLGE
MUSLIVER-N AITTTAQS-HQRTFVLEVMGRHCGYLALVSALASGADWLF IPEAP PEDGWENFMCERLGE
YEAST1-N YIDATAKS-HSRAFWEVMGRHCGWLALMAGIATGADYIFIPERAV PHGKWQDELKEVCQR
YEAST2-N YVEATANS-HSRAPWEVMGRNCGWLALLAGIATSADYIFIPEKPA TSSEWQDEMCDIVSK
HUMUSCL-C RIKQSAAGTKRRVFIIETMGGYCGYLATMAGLAAGADAAYIFEEP FT IRDLQANVEHLVQ
RABMUSCL-C RIKQSAAGTKRRVFIIETMGGYCGYLATMAGLAAGADAAYIFEEP FT IRDLQANVEHLVQ
SHEHEART-C RIK IETMGGYCGYLATMAGLAAGADAAYIFEEP FTVRDLQANVEHLVQ
SHELIVER-C IKQSAAGTVQRTLSIETGFR ANVEHMTE
HUMLIVER-C RIKQSASGTKRRVFIVETMGGYCGYLATVTGIAVGADAAYVFEDP FNIHDLKVNVEHMTE
MUSLIVER-C RIKQSASGTKRRVFIVETMGGYCGYLATVTGIAVGADAAYVFEDP FNIHDLKANVEHMTE
HUMPLATE-C RIKQSASGTKRRVFIIETMGGYCGYLANMGGLAAGADAAYIFEEP FDIRDLQSNVEHLTE
YEAST1-C DIKQSASATRRRVFVCEVQGGHSGYIASFTGLITGAVSVYTPEKKIDLASIREDITLLKENFRH
YEAST2-C WKQSASSTRGRAFWDCQGGNSGYLATYASLAVGAQVSYVPEEGISLEQLSEDIEYLAQSFEK
E .COLI RLRDTSSS-HQRISWEVMGRYCGDLTLAAAIAGGCEFVWPEVEF SREDLVNEIKAGIA
B . ST KIRDTATS-HERTYVIEVMGRHAGDIALWSGLAGGAETILIPEADY DMNDVIARLKRGHE
S.CITRI RLRDTMQS-HNRCSIVEVMGHACGDIALYAGIAGGADIISINEAAL SETEIADRVAMLHQ
T.THERM RIRDTAAS-HERVFFIEVMGRHAGFIALDVGLAGGAEVIAVPEEPV DPKAVAEVLEASQR
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HUMUSCL-N TRTRGSRLNIIIVAEGAIDKNGKPITSEDIKNLWKRLG-YDTRVTVLGHVQRGGTPSAFDRI
RABMUSCL-N TRTRGSRLNIIIVAEGAIDRNGKPITSEGVKDLWRRLG-YDTRVTVLGHVQRGGTPSAFDRI
SHEHEART-N TRILGSR PITSEGVKDLWKRLG-YDTAVTVLGVEHRGGTPSAFDRI
SHELIVER-N TRSRGSRLNI11IAEGAIDRNGKSITSRYVKDLWGRLG-FDTAVTVLGHVQRGGTPSAFDRI
HUMLIVER-N TRSRGSRLNI 11IAEGAIDRNGKPISSSYVKDLWQRLG-FDTRVTVLGHVQRGGTPSAFDRI
MUSLIVER-N TRSRGSRLNI11IAEGAIDRHGKPISSSYVKDLWQRLG-FDTRVTVLGHVQRGGTPSAFDRI
YEAST-IN HRSKGRRNNTIIVAEGALDDQLNPVTANDVKDALIE-LG-LDTKVTILGHVQRGGTAVAHDRW
YEAST2-N HRSRGKRTTIVWAEGAIAADLTPISPSDVHKVLVDRLG-LDTRITTLGHVQRGGTAVAYDRI
HUMUSCL-C KMKTTVKRGLVLRNEKCNENYTT DFIFNLYSEEGKGIFDSRKNVLGHMQQGGSPTPFDRN
RABMUSCL-C KMKTTVKRGLVLRNEKCNENYTT DFIFNLYSEEGKGIFDSRKNVLGHMQQGGSPTPFDRN
SHEHEART-C MKTTVKAGLVLRDEKCNENYTT DFNFILYSEEGKGIFDSRKNVLGHMQQGGSPTPFDRN
SHELIVER-C KMKTEIQKGLVLRNEKCNENYTT EFIYNLYSEEGKG FDSRLNVLGHLQQGGAPTPFDR
HUMLIVER-C KMKTDIQRGLVLRNEKCHDYYTT EFLYNLYSSEGKGVFDCRTNVLGHLQQGGAPTPFDRN
MUSLIVER-C KMKTDIQRGLVLRNEKCHEHYTT EFLYNLYSSEGRGVFDCRTNVLGHLQQGGAPTP FDRN
HUMPLATE-C KMKTTIQRGLVLRNESCSENYTT DFIYQLYSEEGKGVFDCRKNVLGHMQQGGAPSPFDRN
YEAST1-C DKGENRNGKLLVRNEQASSVYST QLLADIISEASKGKFGVRTAIPGHVQQGGVTSSKDRV
YEAST2-C AEGRGRFGKLILKS TNASKALSA TKLAEVITAEADGRFDAKPAYPGHVQQGGLP SPIDRT
E . COLI KGKK HAIVAITEHMC DVDELAHFIEKETG-RETRATVLGHIQRGGSPVPYDRI
B. ST RGKK HSIIIVAEGVG SGVDFGRQIQEATG-FETRVTVLGHVQRGGSPTAFDRV
S .CITRI AQKR SVIVWSEMIYP DVHKLAKLVESKSG-YITRATVLGHTQRGGNPTAMDRY
T . THERM RGKK SSIVWAEGAYPG GAAGLLAAIREHLQ-VEARVTVLGHIQRGGSPTAKDRI
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HUMUSCL-N LGSRMGVEAVMALLE GTPDTPACWSLSGNQA
RABMUSCL-N LGSRMGVEAVMALLE GTPDTPACWSLSGNQA
SHEHEART-N LGSRMGVEAVMALLE GTPQTPACWSLSGNQA
SHELIVER-N LGSR ALLE ATPDTPACWSLSGNQA
HUMLIVER-N LS SKMGMEAVMALLE ATPDTPACWTLSGNQS
MUSLIVER-N LSSKMGMEAVMALLE ATPDTPACWSLSGNQS
YEAST1-N LATLQGVDAVKAVLE FTPETPSPLIGILENKI
YEAST2-N LATLQGLEAVNAVLE STPDTPSPLIAVNENKI
HUMUSCL-C FATKMGAKAMN WMSGKIKESYRNGRIFA NTPDS-GCVLGMRKRAL
RABMUSCL-C FATKMGAKAMN WMAGKIKESYRNGRIFA NTPDS-GCVLGMRKRAL
SHEHEART-C FATKMGAKAMN WMSGKIKESYRNGRIF NTPDS-GCVLGM-KRAL
SHELIVER-C AIL WMSEKLRAVYRNGRVFA NAPDS-ACVIGLQKKW
HUMLIVER-C YGTKLGVKAML WLSEKLREVYRKGRVFA NAPDS-ACVIGLKKKAV
MUSLIVER-C YGTKLGVKAML WVSEKLRDVYRKGRVFA NAPDS-ACVIGLRKKW
HUMPLATE-C FGTKISARAME WITEKLKEARGRGKKFT TDDS-ICVLGISKRNV
YEAST1-C TASRFAVKCIKFIEQWNKKNEASPNTDAKVLRFKFDTHGEKVPTVEHEDDS-AAVICVNGSHV
YEAST2-C ARTRMAIKAVGFIEDNQ AAIAEARAAEEDFNADDKTISDT -AAWGVKGSHV
E .COLI LASRMGAYAIDLLLA GYGGR—CVGIQNE-QL
B. ST LASRLGARAVELLLE GGKGR—CVGIQNN-QL
S .CITRI RAFQMAQFAVEQIIA GVGGL—AIGNQGD-QI
T. THERM LASRLGAPAVEALVG GASGV—MVGEVEG-EV
.272 .285
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HUMUSCL-N VRLPLMECVQVTKDVTKAMDEKKFDEALKLTGRSFMNNWEVYKLLAHVRPPVSKSGSHTV
RABMUSCL-N VRLPLMECVQVTKDVTKAMDEKRFDEAMKLRGRSFMNNWEVYKLLAHIRPPAPKSGSYTV
SHEHEART-N VALPLMECVQVTKDVTRAMDERRFDEAMKLAGRSFMNNWEVYKLLAHVRPPKSKSGLHTV
SHELIVER-N VRLPLMECVQMTKEVQKAMDEKRFDEAIQLRGRSFENNWNIYKLLAHKIS KENTWNGGAV
HUMLIVER-N VRLPLMECVQMTKEVQKAMDDKRFDEATQLRGGSFENNWNIYKLLTHQKPPKEKSNFSL
MUSLIVER-N VRLPLMECVQVTKDVQKAMDEERFDEAIQLRGRSFENNWKIYKLLAHQKVSKEKSNFSL
YEAST1-N IRMPLVESVKLTKSVATAIENKDFDKAISLRDTEFIELYENFLSTTVKDDGSELLPV
YEAST2-N VRKPLMESVKLTKAVAIEAKDFKRAMSLRDTEFIEHLNNFMAINSADHNEPKLPKDKRLKI
HUMUSCL-C VFQPVAELKDQTDFEHRIPKEQWWLKLRPILKILAKYEIDLDTSDHAHLEHITRKRSGEAAV
RABMUSCL-C VFQPVTELQNQTDFEHRIPKEQWWLKLRPILKILAKYEIDLDTSEHAHLEHISRKRSGEATV
SHEHEART-C LFQPVTELQEQTDFEHRIPKEQWWLK RPILK LAKYEIDLDTSEHAHLEHITRKASGEADI
SHELIVER-C AFSPVTELQEQTDFEHR EQWWLNLR MLAHYRISMADYVSGELEHVTRR
HUMLIVER-C AFSPVTELKKDTDFEHRMPREQWWLSLRIMLKMLAQYRISMAAYVSGELEHVTRRTLSMDKGF
MUSLIVER-C AFSPVTELKKETDFEHRMPREQWWLNLRIMLKMLAHYRISMADYVSGELEHVTRRTLSIDKGF
HUMPLATE-C IFQPVAELKKQTDFEHRIPKEQWWLKLRPLMKILAKYKASYDVSDSGQLEHVQPWSV
YEAST1-C SFKPIANLWENETNVELRKGFEVHWAEYNKIGDILSGRLKLRAEVAALAAENK
YEAST2-C VYNSIRQLYDYETEVSMRMPKVIHWQATRLIADHLVGRKRVD
E.COLI VHHDIIDAIENMKRPFKGDWLDCAEKMY
B.ST VDHDIAEALANKHTIDQRMYALSKELSI
S.CITRI IARPIMEALSIPRSSRKEIWAKFDQLNQNIYQKS
T.THERM DLTPLKEAVERRKDINRALLRLSQVLAL
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Key:
Identity: *
Conservative: .
HUMUSCL HUMAN MUSCLE PFK
RABMUSCL RABBIT MUSCLE PFK
SHEHEART SHEEP HEART PFK
SHELIVER SHEEP LIVER PFK
HUMLIVER HUMAN LIVER PFK
MUSLIVER MOUSE LIVER PFK
YEAST1 SACCHAROMYCES CEREVISIAE PFK SUBUNIT 1
YEAST2 SACCHAROMYCES CEREVISIAE PFK SUBUNIT 2
HUMPLATE HUMAN PLATELET PFK
E.COLI ESCHERICHIA COLI PFK
B.ST BACILLUS STEAROTHERMOPHILUS PFK
S.CITRI SPIROPLASMA CITRI PFK
T.THERM THERMUS THERMOPHILUS PFK
! INDICATES THE POSITION OF INTRONS IN MAMMALIAN PFK.
aaaaa = alpha helix
bbbbb = beta sheet
Figure 18. The aligned sequences of phosphofructokinase
Similarities between muscle and liver C halves and HPPFK-C are
-80%. The muscle enzymes retain 70% identity to HPPFKC but the liver
enzymes only retain 63% identity. This would imply that the platelet enzyme
is more closely related to the muscle enzymes and that the liver enzymes
have evolved further than muscle and platelet and have accumulated more
conservative mutations.
6.2 Differences between eukaryotic and prokaryotic PFK's.
An alignment of the known sequences of PFK is shown in figure 18 and the
known secondary structural positions are indicated.Because of insertions
and deletions the numbering of residues is according to BPFK. This means
that an extra number of residues will be referred to as n+the extra number of
residues. Table 6 gives the number of insertions and deletions when the
eukaryotic and prokaryotic enzymes are compared.
Whereas the amino half residues of the mammalian enzymes at the
various catalytic and effector sites are virtually all identical to those found in
the bacterial enzyme, these residues are often different in a mammalian
carboxyl half. The bacterial and amino halves of the enzyme have Asp-103
and Gly-104. Asp 103-N coordinates a Mg2+ ion and Gly 104-N forms
hydrogen bonds to the (3-phosphate and '1'-oxygen of ATP which leaves no
room for a side chain in this position (Hellinga & Evans, 1985). The carboxyl
half of the mammalian enzymes have phenylalanine and glutamate at 103C
and 104C respectively. This will probably mean that ATP cannot be bound
by the carboxyl half and has changed its function from that of a catalytic to a
regulatory site.
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Relationship to
B. Stearotherm-
ophilus secondary
structure amino half of
enzymes
No. of. Probable
Residues Effects/Conformation
N-Terminus
Between a2 & pC
Between a-5 & pE
Between a8 - pH
Between pH & a9
Proposed Hinge Segment
Carboxyl half of enzymes
1 residue proximal to a4
In a4
1 Residue proximal of a4 in HPPFK
Between a5 & pE
Distal end of a6
Between a8 & pH
Between pH & a9
Between a11 & pj
1 Residue proximal to pJ
C terminus
+ 14
+2
+23
+3
+7
+30-33
-1
-3
-1
+7
+ 1
+3
+5
+17-18
+ 1
+17-23
Exterior Structure
Exterior Loop
Exterior Structure
Exterior Loop at effector site
Exterior Loop
Exterior secondary structure
at end of a13
Exterior, unknown as
gapping is poor here and
may not be significant,
might shorten exterior
loop.
Exterior Loop
Close to residue 162-C (FBP
binding site) and residue
154-C (ATP inhibition site)
Exterior Loop at ATP inhibition site
Exterior Loop
Exterior Loop
Unknown
Exterior secondary
structure
Table 6: Insertions and Deletions of Amino Acids For Mammalian PFK
Compared to B. Stearothermophilus.
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Possible nature of insertions and deletions of residues in mammalian
PFK compared to bacterial PFK.
N-half: Three extra residues are present in mammalian PFK-N
between a8 and (3H at positions 214+1, +2 and +3. Lys 213-N, Lys 214-N
and His 215-N are proposed to be residues involved at the effector site of B.
stearothermophilus PFK (Schirmer & Evans, 1990). The extra three residues
may account for the lack of inhibition of the mammalian enzymes by PEP
The 8H loop at position 213-216 shows the only major movement at the
allosteric effector site in the change from the T to the R state. This is coupled
to a rearrangement of the 6F loop which determines the quaternary structure
of the T or R states.
The seven extra residues between (3H and a9 are close to Glu-222
which is involved with binding F6P.
Carboxyl half: One extra residue is present in mammalian
enzymes at position 159+1. This area is crucial for the binding of F6P and is
proposed to be a major part of the FBP activation site for the carboxyl half. It
is also proposed to form part of the citrate binding site. Three extra residues
are found between a8 and £H as is the case for the amino half and are
presumably important for any movement of the 8H loop between the R and T
states.
Four extra residues are present between PH and a9 whereas seven
extra residues are present in the amino half compared to the bacterial
enzymes. These residues may also contribute to the FBP binding site or may
take part in changes to quaternary structure during inhibition or activation.
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6.3.1 Major differences of residues between mammalian PFK
and human platelet PFK.
An alignment of mammalian PFK is shown in figure 13. Numbering of
residues is according to BSPFK.
It is important to notice major changes of charge e.g. between an
arginine and a glutamate, or similarities such as between isoleucine and
leucine. Residues may exhibit different properties in the microenvironment of
a folded protein chain than those expected of an isolated amino acid. Bordo
& Argos (1991) have compiled matrices for the preferred amino acid
substitutions of fifty five sequences from nine groups of proteins including
haemoglobin, immunoglobulins and serine proteases. The intention of these
matrices is to allow the design of "safe" residue substitutions in site directed
mutagenesis experiments. They are equally valid to use in comparing those
residues which are the result of in vivo mutagenesis in enzymes such as
mammalian phosphofructokinases. Preferred and non preferred
substitutions vary according to whether the residue is buried or exposed.
Buried residues are more constrained in their choice of replacement than
exposed residues. On this basis, the differences between HPPFK and the
other mammalian enzymes is shown in Table 7
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UPC HMC RMC SHC SLC HLC MLC
92 Residue not present in HPPFK
113 S MM V V V
POSITION
end of a4
end of a5
277 + 10 R Y Y Y Y Y Y between a11 and pj
277 + 15 K I I I V V V between a11 and pj
278 Residue not present in HPPFK.
N N N N N N between a11 and pj
280 D P P P P P P between a11 and pj
282 + 1 I G G G A A A start of pj
319 + 1 Y L L L M M M C terminus
319 + 13 Y L L L M M M C terminus
319 + 25 Q T S T T T T C terminus
319 + 26 P R R R R R R C terminus
319 + 27 W K K K R R R C terminus
316 + 28 S R R A T T C terminus
319 + 29 V S S S L K C terminus
Table 7. The differences between HPPFK and the other mammalian
enzymes The majority of these changes occur in those residues which
may continue alpha helix 11, and in the carboxyl tail. They may form part of
an ATP inhibition site, or they may be involved in tetramer aggregation. A
helical extension of a11 would probably project out towards the amino and
carboxyl terminii, which may be involved in tetramer-tetramer association.
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Acceptable residue changes.
Table 8 gives "acceptable" mutations.
On the assumption that a negative figure is an "unacceptable" mutation.
A = S, T, P, V, Q, E, D, N, G.
C = W, S.
D = K, H, Q, S, T, A, G, N, E.
E = S, T, A, G, N, D, K, H, Q.
F = M, I, L, Y, W.
G = S, T, A, E, D, N.
H = P, N, D, E, Q, W, K, R.
I = T, M, F, V, L.
K = S.T.N.D, E,Q,W,H, R-
L = M, I, F, V.
M = R, K, F, V, L, I.
N = S, T, A, G, K, R, H, Q, E, D.
P = S, T, R, H, Q, A.
R = Y, M, K, S, P, N, Q, H.
S = C, K, R, E, D, N, G, A, P, T.
T = S, V, I, K, E, D, N, G, A, P.
V = T, A, M, I, L.
W = *, C, H, F.
Y = F, W.
This gives similarities to FIPPFK of
HMC RMC SHC SLC HLC MLC
Similarity 78% 78% 77% 71% 77% 77%
Total No. of 82 82 78 86 103 103
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residue changes
Yet another description of acceptable mutations of residues is
described by the programme Simplify, available in the UWGCG suite.
Residues which are similar are:
P, A, G, S + T - neutral, weakly hydrophobic
Q, N, E + D - hydrophilic, acid amine
H, K + R - hydrophilic, basic
I, L, V + M - hydrophobic
F, Y + W - hydrophobic, aromatic
Cysteine is considered to be unique.
This gives similarities to HPPFK of
HMC RMC SHC SLC HLC MLC
Acceptable 85% 85% 82% 79% 83% 84%
Whichever method is used to look at the similarity of the HPPFK
amino acid sequence, to other mammalian PFK carboxyl halves, it is
apparent that they share about 80% similarity. If all the other mammalian
PFK carboxyl halves have similar residues but the HPPFK has a non-
conserved residue (assuming a correct sequence and sequence lineup) at
the same position, then there are fourteen differences. All occur between
those residues predicted to form regular secondary structural components.
Three major differences occur at the carboxy terminals. One of the more
interesting differences is at position 280 where HPPFK has an aspartate
residue whereas a proline is present in both the amino and carboxyl
mammalian halves of the mammalian enzymes. A proline is also present in
the amino halves of both yeast sequences. HPPFK has an aspartate residue
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at this position as does YPFK1-C sequence, whereas YPFK2-C has a serine
residue. This residue is just before pj in the bacillus structure where the loop
from helix eleven makes a sharp turn around beta sheet E. The 17 extra
residues in the carboxy halves of the other mammalian sequences may be
forced to make a sharp turn at position Pro 280-C
6.3.2 Secondary structural predictions for mammalian residues
not directly comparable to bacterial PFK.
The ELIAS program is a modified version of Eliopoulos etal., (1982)
which includes the procedures of McLachlan (1978) and Kabat & Wu (1973).
A reference for the modified version appears in Sawyer et al. (1987). Using
the ELIAS program, the muscle, liver and platelet enzymes are predicted to
continue a-11 to about position 277 + 10. The muscle and liver enzymes are
then predicted to have a turn or coil followed by a p sheet then a turn or coil
followed by pj. The platelet prediction is similar but the probability for a p
sheet is lower and is shown in figure 19.
These residues are on the exterior of the enzyme near the proposed
ATP inhibition site (Poorman etal., 1984). Lys 266-C is thought to be part of
this site and the elongation of alpha helix 11 may be important for this site.
The muscle and liver sequences are more alike between a 11 and pJ. The
difference in sequence and number of residues may be important for the
increased sensitivity of HPPFK to inhibition by ATP. Differences in the
sequence and length of the carboxyl terminus after residue 319 may also
explain variations between isoenzymes. The program is reasonably correct
in its prediction of the 2° structure of BPFK when compared to crystal
structure data. It must be borne in mind that the sequence alignment of the
139
mammalian enzymes may be incorrect in relation to the bacterial enzymes,
but these predictions have a reasonable correlation with the bacterial crystal
structure. The extra residues at the amino terminus of the mammalian
enzymes may contribute to the ATP inhibition site. They are presumably
capable of contacting those residues at the carboxyl terminus identified as
being essential for ATP inhibition (Valiatis et ai, 1989). The first thirty five
residues of BPFK were examined with ELIAS and the prediction agrees with
the crystal structure data. The fourteen extra residues of HMPFK and HLPFK
are predicted to contain an a helix before the first p strand. HMPFK contains
two histidines and a lysine in this region, while HLPFK contains a lysine and
and an arginine which may be capable of binding to ATP.
The partial HPPFK amino acid sequence appears to have evolved
from a common ancestor PFK and to be more similar to the muscle than the
liver enzyme. Comparing HPPFK to the carboxyl halves of HMPFK and
HLPFK gives 71% and 63% identity respectively. If conserved mutations are
also scored as matching however, these figures increase to 83% and 80%
respectively. HMPFK compared to HLPFK gives an identity of 68% and 83%
similarity if conservative replacements are allowed as matches. The muscle
and platelet forms are therefore more similar to each other (and equidistant)
in comparison to the liver enzyme
6.4.1 Comparison of residues contributing to catalytic and
effector sites of PFK
Residues thought to contribute to the catalytic and effector sites in the
bacterial enzyme can be identified by aligning the mammalian sequences
with them as shown in figure 17. Usually the mammalian amino half
residues are identical or similar to the bacterial ones. The two yeast
sequences are included here (Heinisch etal., 1989). Approximately the first
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PPFK SPFDRNFdtKI ARAMElftTEKLKEAI^RG KFTTDlftICVLGI B-STRANDPREDICTION «■■rn..11.i.it.11ni « SPFDRNFdtKISARAMEtftTEKLKEAf^RGKKFTTDlfeICVLGI SPFDRNFdtKISARAMEtftTEKLKEAI^jRGKKFTTDdfeCVLG
Figure19.Secondarystructurepredictionfo HPPFKinthear aoflphhelixlev n.
two hundred residues of the yeast sequence are omitted as they have no
equivalence with the other sequences. The secondary structure of the
bacterial enzymes is from Shirakihara & Evans (1988).
TABLE 9. Comparison of catalytic residues.
S. citri and T.thermophilus are not included. N or C refers to amino or
carboxyl domains. Where no differences are noted, residues are conserved
across all species and domains. Residues are taken from Schirmer & Evans
(1990).
EFFECTOR SITE
Arg 21 H-bond to (3 phosphate of ADP
Arg 25 H-bond to a and p phosphates
Val 57 H-bond to p phosphate of ADP via water molecule
Asp 59 main-chain amide H-bond to p phosphate of ADP via water
molecule. Side chain H-bond to ribose 0-3.
Met in HMPFK-N and RMPFK-N. Asn in HLPFK-N, MLPFK-N and YPFK1-
C. Gly in other sequences.
Arg 154 H-bond to p phosphate of ADP
Thr in mammalian amino sequences, Asp in YPFK1-N, Glu in YPFK2-N, Lys
for all carboxyl sequences.
Glu 187 Coordinated to Mg2+ of ADP and H-bond to His 215 via water
molecule in R state only
Asp in all sequences except for Val in YPFK1-C and Gin in YPFK2-C
Arg 211 side-chain H-bonds to a phosphate of ADP and C-terminal residue
Thr in mammalian amino sequences. His in yeast amino sequences. Lys in
mammalian carboxyl sequences. Asp in YPFK1-C and Ala in YPFK2-C.
Lys 213 H-bond to a phosphate of ADP
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Lys 214 H-bond to 0'4 of ADP ribose
His 215 H-bond to Mg2+ of ADP via water
Gapping of sequences may be incorrect around this area. Three arginine
residues are available in mammalian amino sequences to form H-bonds.
The carboxyl sequences contain several basic residues in this region and as
with the amino domain, have more residues than the bacterial enzymes at
this point which may extend alpha helix 8.
ACTIVE SITE
Fructose 6-phosphate binding
Arg 72 H-bond to y phosphate of ATP or 6-phosphate of F16BP
Asp 127 Catalytic residue. Increases nucleophilicity of 1-OH of F6P towards
y phosphate of ATP. H-bond to 3-OH of F6P
Asp in all amino sequences, Asn in all carboxyl sequences
Arg 162 H-bonds to 6-phosphate of F6P
Arg 243 H-bonds to 6-phosphate of F6P
Arg in all sequences except Lys in YPFK1-N and YPFK2-C
Arg 252 H-bond to O of F6P and H-bond to 6-phosphate of F6P
Arg in all amino sequences, Gin in all carboxyl sequences
ATP binding site
Arg 72 H-bond to y phosphate of ATP or 6-phosphate of F16BP
Gly 11 Main chain amide H-bond to y phosphate of ATP
Gly in all amino sequences, Ala in all carboxyl sequences
Cys 73 Main chain amide and carbonyl H-bonds to ATP ribose ring
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HLPFK-N is Ser but this may be a sequencing error. The genomic sequence
(exon 4) does not show complete identity in this area but both have a Ser at
this point.
Asp 103 H-bonds to Mg2+ and p phosphate of ATP
Asp in all amino sequences, Phe in all carboxyl sequences
Gly 104 H-bonds to p phosphate of ATP
Gly in all amino sequences, Glu in all carboxyl sequences
Ser 105 H-bond to p phosphate of ATP
Ser in all amino sequences, Ala in all carboxyl sequences except for Ala
in YPFK2-C
Thr125 H-bond to p phosphate of ATP
Ser in all amino sequences, Thr in all carboxyl sequences
The mammalian residues assumed to participate in ligand binding
are virtually always conserved across species and isoenzymes. Differences
are more often found in carboxyl half residues which have mutated from the
amino type. Twenty two residues are thought to be involved at catalytic and
effector sites in the N and C halves, giving forty four residues in all from ~
780 residues in a mammalian subunit (Hellinga, & Evans, 1987; Schirmer &
Evans, 1990). The N half residues of the mammalian enzymes are identical
to the coH or bacillus enzyme ten times , and the mammalian enzymes have
the same residues but differ from the bacterial case once at position Thr-125.
At this position, the carboxyl domain residues are identical to the bacterial
enzymes. Where there are differences between the mammalian enzymes, it
is usually a split between isoenzymes across species where the liver type is
distinct from the muscle or platelet type. Differences caused by the SHPFK
and SLPFK sequences might be possibly discounted as the sequence is
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often different to the other enzymes at the ends of the peptide digests. The
sheep sequences were both described by amino acid sequencing. Only one
of the twenty two residues of the eukaryotic amino half shows a difference
between the bacterial and eukaryotic enymes. Asp-59 which gives two
hydrogen bonds to ADP, is methionine in HMPFK-N and RMPFK-N,
asparagine in FILPFK-N MLPFK-N and YPFK1-C and glycine (except for
unknown sequence for SFIPFK-N and SLPFK-N) in all the other enzymes.
Eleven residues are conserved between all the mammalian N and C halves
and BPFK. Residues are conserved between the mammalian amino half and
BPFK at seventeen locations. Differences in residue type between muscle
and liver isoenzymes occurs once at position Asp-59. This residue (in the
effector site) is proposed to make a hydrogen bond to ADP via a water
molecule and a hydrogen bond to the ribose ring of ADP. The residue is
methionine in HMPFK-N and RMPFK-N, and asparagine in MLPFK-N and
HLPFK-N. Another possible change is seen at Cys-73 which forms hydrogen
bonds with ATP in the active site. HLPFK-N is serine at this position but this
may be a sequencing error as although the cDNA and genomic sequences
have serine at this point, there are differences between the two sequences
in exon 4 as a whole.
6.4.2 Contribution of domains and subunits to catalytic and
effector sites in the mammalian tetramer.
The mammalian tetramer is known to possess D2 sywetry (Hesterberg
etal.,) which agrees with the observation of Klotz etal. (1975) that all known
tetrameric proteins possess D2sy«*etry. Poorman etal. (1984) proposed a
model for the quaternary structural organisation of RMPFK based on this
sy^etry arrangement and on its structural relationship to BSPFK.
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Hp^
Figure 2£>a. A model of the mammalian dimer showing the F6P binding site A, the
ATP catalytic binding site B, the proposed hexose bisphosphate binding site A', the
equivalent site for ATP binding B' and the ADP effector site C.
The dark red ball represents the large domain of the amino half of a subunit
and the white or purple balls represent a small domain. The orange ball represents
the large domain of a carboxyl half.
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Figure 20b.A model of the mammalian dimer showing the F6P binding site A, the
ATP catalytic binding site B, the proposed hexose bisphosphate binding site A', the
equivalent site for ATP binding B' and the proposed ATP inhibitor site C'.
The dark red ball represents the large domain of the amino half of a subunit
and the white or purple balls represent a small domain. The orange ball represents
the large domain of a carboxyl half.
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Figure 2.0c. A model of the mammalian tetramer. The connecting peptides
represented by white coils.
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Using crystal structure information from the bacterial enzymes
(Schirmer & Evans, 1990) as a guide, close examination of the model shows
that the catalytic F6P binding site and proposed F26BP site will be
composed of residues from dimers from two subunits. This can be seen most
readily by examining a model based on the structure of bacterial PFK,
comparative sequence alignments and the result of limited digests of
mammalian PFK with a variety of proteases.The model is shown in figures
20a,b and c
Table 10 gives the probable contribution of subunits to the various ligand
binding sites of mammalian PFK
F6P binding site F26BP binding site
Subunit Subunit
Arg-72 Large domain, amino half. 1 carboxyl half- 1
Thr-125 " ". 1 " 1
Asp-127 " "1 " 1
Arg-252 " "1 " 1
Arg-162 Small domain, carboxyl half. 2 amino half 2
Arg-243 " "2 " 2
Gly-170 Between domains. 1 Between domains 1
Glu-222 " 1 " 1
His-249 " 1 " 1
The ATP catalytic site is likely to be composed of residues from the
amino half of subunit one. The residues involved are:
Arg-72, Gly-11, Tyr-41, Phe-73. Asp-103, Gly-104, Ser-105. It is not clear if
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the ATP catalytic site has mutated to form a new effector site in subunit two.
The ADP effector site is composed of residues from subunit one
whereas subunit two may have residues contributing to the ATP inhibition
site.
ADP activation site
Subunit
ATP inhibition site
Subunit
Arg-21 Large domain carboxyl half
Arg-25
Ser-58
Asp-59
Arg-154 Small domain amino half
Gly-185
Glu-187
Lys-211
Lys-213
Lys-214
1 amino half
carboxyl half
2
2
2
2
2
2
2
2
2
2
Table 10. Contribution of mammalian subunits to ligand binding sites
Of the other residues identified by Hellinga & Evans (1987) as being
potentially important for PFK activity, HPPFK differs from all the other
subunits at one conserved position, 107C. Residue 107 is proposed to make
a hydrophobic contact to the adenine ring in the ATP catalytic site in the
bacterial enzymes. This residue is a methionine in E. coliand a glutamine in
B.stearothermophilus. Residue 107N in all mammalian PFK sequences is a
threonine. Residue 107C is threonine for FIMPFK-C and RMPFK-C,
glutamate for the liver carboxyl sequences while SH 107C is unknown. This
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residue is a leucine in HPPFK-C. The HPPFK DNA sequence has been
sequenced on both strands at this position. The ATP catalytic binding site
may perform no function in the carboxyl half of the eukaryotic enzyme,
although it may still be part of a nucleotide binding site Residues are
conserved between N and C halves of the mammalian enzymes, but differ
from the bacterial enzymes at position 187. Glu 187 is an aspartate in the
mammalian enzymes but this is essentially a conservative change. Asp 187
is one of the few residues in the effector site to show a conformational
change between the R and T states (Schirmer & Evans, 1990). In the R state,
Glu 187 is coordinated to the Mg2+ ion of ADP, and is rotated away from the
ligand in the T structure. The side chain adopts a new position between the
central p sheet of the small domain and helix 9. This movement might
presumably be part of the mechanism which changes the conformation of
the active site.
The carboxyl terminal residue is a valine for muscle and platelet
enzymes, phenylalanine for human liver and mouse liver, isoleucine for
sheep heart and arginine for sheep liver.
6.5 The carboxyl terminal tail
When mammalian PFK amino and carboxyl halves are aligned with
the bacterial enzymes there are two stretches at their carboxyl tails which
'overhang' by about 30 residues. The amino half overhang is considered to
be a connecting peptide between the two halves which are equivalent to a
bacterial dimer. This connecting peptide appears to be buried within a
mammalian tetramer at the dimer-dimer interface (Poorman et ai, 1984).
This idea is also favoured by model building studies. The carboxyl half
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overhang is 30-36 residues and is thought to contribute to the ATP inhibition
site not present in the bacterial enzymes and also to be the site of
phosphorylation. Gottschalk et al. (1983) partially digested RMPFK with
subtilisn and assumed that N-terminal regions contained an ATP inhibition
site which was a mutated ADP activation site, as amino terminal fragments
were released. Vafatis etal. (1987) briefly exposed RMPFK to S.aureus V8
protease. This resulted in an enzyme which exhibited markedly reduced
inhibition by ATP. This treatment resulted in the release of two carboxyl
terminal peptides that comprised the last 17 residues of the enzyme. Limited
proteolysis by trypsin which removes the last seven or eight residues of the
carboxyl terminus had no significant effect on ATP inhibition. This implies
that the RMPFK sequence His-Ala-His-Leu-Glu-Flis-lle-Ser-GIn is the
important site of ATP inhibition. Limited digestion of RMPFK with subtilisin
removes 50-60 residues from the N-terminus and removes the ability to bind
ATP at the inhibition site (Poorman et al., 1984). Previous studies have
indicated that three histidines were implicated in the binding of ATP to the
inhibitory site of SHPFK on the basis of modification by diethyl
pyrocarbonate. Three histidines are present in the RM, HM and SH
sequences at this point but only one is present in the HP, HL, SL and ML
sequences. The observed inhibition of human PFK by ATP is highest for
isoenzymes containing large amounts of platelet type subunit. Liver type
tetramers show less inhibition, with muscle type PFK being least inhibited by
rVrfc.. The platelet sequence is five residues shorter than the muscle
sequences and six residues shorter than the liver sequences. The missing
residues contain a serine which is believed to be the site of phosphorylation.
Foe and Kemp (1984) reported that phosphorylation of brain PFK was
possible. Although brain does contain the platelet type subunit, it also
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consists of 14% liver, and 58% muscle type subunits (Dunaway eta!., 1988).
The cloning and expression of a full length cDNA platelet clone would permit
in vitro studies on phosphorylation of platelet PFK. Sequences have been
reported with possible phosphorylation sites for all three rabbit enzymes
(Valiatis etai, 1989).
It is interesting to speculate on the role of phosphorylation, and the
binding of actin, calmodulin and ATP to mammalian PFK. The carboxy
terminal tail contains the low affinity binding site for calmodulin (Buschmeier
et al. 1987) and is also reported to contain the site of phosphorylation. It also
contributes residues to the ATP inhibition site and shows sequence
conservation of several residues in mammalian PFK. Phosphorylation
inhibits calmodulin binding and vice versa. A low affinity calmodulin binding
site has only been reported for the muscle enzyme and it is unknown if it is
present in the other isoenzymes.
It may be possible that high concentrations of calmodulin in
contracting muscle stabilise the active tetramer and may also promote the
formation of active polymeric PFK, although it has been reported that PFK in
contracting muscle is phosphorylated to a greater extent than in resting
muscle (Hofer & Sorenson-Ziganke, 1979). PFK bound to actin may form
part of a glycolytic complex of enzymes on the cytoskeleton and it is
interesting that active polymers of muscle PFK and actin bound PFK are less
sensitive to inhibition by ATP. Calmodulin and/or actin binding may prevent
access of ATP to the ATP inhibitory site and may also prevent citrate
inactivation. The citrate inhibition site might contact the carboxyl terminus as
citrate and ATP inhibition act synergistically to inhibit PFK.
It has been shown that PFK has a tendency to self-associate to
oligomeric forms higher than the tetramer (Uyeda, 1979). High Mr
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aggregates have a higher affinity for F6P than for MgATP. The reverse is true
for monomers and dimers (Reinhart & Lardy, 1980b). The quaternary
structure of pig liver PFK has been studied by electron microscopy (Foe &
Trujillo, 1980), and particles ranging from tetramers to long flexible chains
have been observed. The geometry of association of the pig liver enzyme
implied that chains are formed by end to end association of tetramers rather
than by tetramer stacking. It is likely from examination of the model that the
most terminal amino and carboxyl residues of PFK are important for polymer
chain formation. Liver PFK self associates to a larger extent than muscle
PFK under comparable conditions (Trujillo & Deal, 1977; Reinhart & Lardy,
1980b) while HPPFK does not self-associate beyond the active tetramer
(Foe & Kemp, 1985). Differences in the length and sequence of the carboxyl
terminal tail between isoenzymes may be responsible for these effects and it
is notable that HPPFK has a shorter carboxyl terminal tail than the other
isoenzymes.
The availability of a cloned and expressed HPPFK would be useful to
investigate its aggregation characteristics as a homotetramer, and in
association with the other two subunits as it has been reported that the
platelet enzyme does not aggregate beyond the active tetramer (Foe &
Kemp, 1985).
It is possible to make structural predictions for the carboxyl tail of the
platelet enzyme using the Elias program and the peptide structure program
of UWGCG. Beginning at 282C (B. stearothermophilus numbering) the
prediction is a continuation of a-helix to 319 + 10 folllowed by a p-sheet and
then a turn or coil. The human muscle and liver enzymes have the same
predicted structure (not shown). Figure 21 shows the prediction for the
carboxyl terminal residues of HPPFK.This prediction of the platelet structure
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PPFK TURNOCOILPREDICTION
J—
'■1I-iLif .»I HRIPKEQtf8LKLRPLMKftAKYKASY[f0SDSGQLEHTO WSV HRIPKEQVlftLKLRPLMKflAKYKASYlftSDSGQLEHWjPVSV HELIXPREDICT ON
-
plHLHh HRIPKEQtfftLKLRPLMld'LAKYKASYlftSDSGQLEHWaPVSV
Figure21.Secondarystr cturepredictionfo HPPFKinthear aofcarboxylerminil
is in complete agreement with the crystal structure of the bacterial enzyme.
The last 10 residues of the platelet enzyme are not predicted to have any
strong 2° structure. It is perfectly feasible for the C-terminal tail to contact the
ADP effector site of the C half and that this site has mutated to form the ATP
inhibition site. The C-terminal tail might also interact with the citrate binding
site. This was identified as around the sequence 154C-161C. The sequence
of all the mammalian PFK's is highly conserved in the citrate binding region.
The HPPFK sequence is
Arg-lle-Lys-Gln-Ser-Ala-Ser-Gly-Thr-Lys-Arg-Arg
+ + + + +
+ = positively charged residues
This sequence is identical to HLPFK and MLPFK. HMPFK and
RMPFK replace the second serine residue with an alanine residue. These
residues are present at the C-terminus of a-6 which is very close to the ADP
effector site of the bacterial enzyme and could be contacted by the C-
terminal tail of the mammalian enzyme.
It has already been noted (Section 1.4) that phosphorylation does not
appear to markedly influence the activity of mammalian PFK but that
phosphorylation activates PFK from Ascaris suum and Fasciola hepatica.
The phosphorylation site in Ascaris suum PFK has been isolated and
sequenced as Ata. Lys Gly Arg Ser Asp Ser(P) lie Val Pro Thr (Kamemoto &
Mansour, 1986). It is quite different from the phosphorylation site derived
from RMPFK.
A search of the NBRF protein database reveals that the Ascaris
sequence is similar to part of the bacterial enzymes beginning at position
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Ascaris AKGRSDSIVPT
E.coli A K G K K H A I V A I
Bacillus ERG KKHSI I I V
This area is proposed by Schirmer & Evans (1990), to be part of the
ADP effector site of the bacterial enzymes. By implication, Poorman et al.
(1984) have proposed that this has mutated to become an ATP inhibition site
in the carboxyl half of the eukaryotic enzymes. The alignment of the
eukaryotic and bacterial enzymes introduces an extra three residues
between Lys-214 and His-215. Examination of the crystal structures of the
bacterial enzymes shows that residue 216 is virtually buried in the enzyme
and is unlikely to be accessible to a protein kinase. The three extra residues
in the eukaryotic enzyme may change the position of this residue however.
The phosphorylation of this residue in the parasitic enzymes might be
responsible for preventing the access of ATP to this area and/or inducing a
conformational change which favours the R state. Residue 216 of the
bacterial enzymes is part of the 8H loop which shows the only major
conformational change in response to the change of ligand in the effector
site and the transition between the R and the T states (Schirmer & Evans,
1990).
6.6 The nucleoside binding site.
Kemp et al. (1987) proposed the position of the citrate binding site.
They also sequenced a peptide from SHPFK which was not involved in
citrate binding but may be part of a nucleoside phosphate binding site. The
RMPFK sequence is from 266 C —> 280C and has the sequence Met Gly
Ala Lys Ala Met Asn Trp Met Ala Gly Lys. In the carboxyl half, residue 266 is
an arginine proposed to be part of the ATP inhibition site (Poorman et al.,
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1984). This stretch of residues is present from the middle to the end of a-11.
The lysine which corresponds to the inhibition site arginine, present
just before Met-266-C is conserved throughout the mammalian C halves.
6.7 The Calmodulin binding sites
Buschmeier etal. (1987) found two binding sites for calmodulin after
digesting RMPFK with cyanogen bromide. A high affinity site is located in the
connecting peptide of the subunit where two dimers are proposed to make
contacts if associating to form an active tetramer. A low affinity site is present
at the C-terminus and contains the site which is phosphorylated by cAMP-
dependent protein kinase. Binding of CaM is known to prevent
phosphorylation and vice versa. The connecting peptide is not present in
this partial sequence of HPPFK and awaits discovery.The muscle and heart
enzymes are similar and the liver enzymes are similar to each other.
HM NNWEVYKLLAHVRPPVSKSGSHTVAVM
+ Jfc V K.
RM I A P Y
SH K L
*
HL N I TQK KE N-FSLIL
★ *
ML K QKVSKE N FS L I L
* * *
SL K KISKENTWNGAV
* *
Positively charged residues are marked with *.
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The low affinity binding site was identified as the residues from Arg-
288-C to the carboxyl terminus. This portion of RMPFK contains sixteen
basic residues out of a total of sixty seven. The calmodulin binding domains
appear to require a tryptophan residue and the low affinity site possesses
two tryptophans in an area of particularly high sequence conservation of all
the mammalian enzymes.
The percentage of basic residues in the proposed low affinity binding site of
mammalian PFK sequences is shown in table 12.
HM RM SH SL HL ML HP
25% 24% 22% 19% 22% 22% 21%
Table 12. Percentage of basic residues in the low affinity mammalian PFK
calmodulin binding site
6.8 The hexose bisphosphate binding site.
It seems probable that the doubling of the bacterial structure should
give a mammalian PFK tetramer with eight allosteric sites. Comparison of
the N half residues with the bacterial enzyme shows that conservation is
almost complete in those residues proposed by Schirmer and Evans (1990)
to be necessary for binding of ligands.The use of this paper and a pair of
stereo viewing glasses makes the sites much more accessible to
interpretation. The F6P binding site for the bacterial enzyme consists of
residues from both the small and large domains and from the other dimer.
Four differences can be seen, three of these are in the sheep heart and liver
sequences and may be due to incorrect sequencing. Position 241 in the
bacterial enzymes is Glu while the mammalian enzymes have Asp. The
function of Glu 241 in the bacterial enzymes is to form a salt bridge with Arg
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72 from another subunit, in the T state. This Arg 72 bridges the two
substrates F6P and ATP in the R state. This change of Glu-241 --> Asp-241
is relatively conservative and presumably reflects a very slight difference in
the mammalian catalytic site.
The C half of the mammalian enzymes shows several differences at
these residues. The main difference is at the catalytic residue Asp-127 in
bacterial and mammalian N half. This is a serine in the C half of all the
mammalian enzymes. The aspartate is thought to increase the
nucleophilicity of the '0'-1 hydroxyl of F6P for attack on the y phosphate of
ATP and then repulsion of F16BP. Serine has half the negative charge and is
not likely to repel FBP.
This site is a likely candidate for the binding of sugar bisphosphates.
It may be the binding site of F26BP, R15BP, F16BP and G16BP. R15BP has
only been found to be an in vivo activator of rat brain PFK and may have a
certain affinity for the platelet isoenzyme which is the major component
(-62%) of the rat brain isoenzyme pool. Twelve residues are reported as
being important to the FBP binding site (Ishikawa et al., 1990). The C-
terminal partial sequence includes all of these residues except for the
unsequenced Asp-12-N which is Pro-12-C in all other mammalian PFK's. If
the platelet isoenzyme is particularly responsive to R15BP then perhaps
some other long range structural difference might account for this. The in
vitro expression of full length isoenzyme clones might explain a difference, if
any, between the isoenzymes in their response to these effectors.
6.9 Subunit interactions
Six deletions from mammalian PFK can be seen in the gapped
alignment to bacterial PFK. These occur at positions 81-C, 86-C, 87-C and
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271-C but not in the amino half of the mammalian enzymes. An additional
two deletions are present in the platelet sequence at 91-C and 92-C. Many
additional residues are present in the mammalian enzymes, the majority
being in the amino half. It may be possible that some of these additional
residues contribute to further subunit interactions. Arg 252 which is central to
the subunit interface in the bacterial enzymes lies in oc-10 which is in an area
showing a high degree of conservation between mammalian and bacterial
enzymes. This residue is a glutamine in all of the carboxyl halves and lies in
an area of particularly high sequence conservation. The meaning of such
conservation must await the availability of crystal structure data.
6.10 Chromosomal localisation of the platelet clone.
The fragment containing HPPFK DNA in pCS11 was subcloned into
pKS+ and named pCS16. This was due to problems with background in
hybridisation experiments when pCS11 was used as a probe. Attempts to
further verify the position of human muscle PFK using the insert of pCS10 as
a probe ran into the same problem and this work was not succesful. The
biotin hybridisation work was kindly done by Norma Morrison of the Duncan
Guthrie Institute for Medical Genetics, YorkhiII, Glasgow. pCS16 was
labelled with biotin-11-dUTP and used for in-situ hybridisation on human
chromosome spreads. Eighty eight metaphases were scored following
hybridisation and the positions of three hundred and thirty six hybridisation
signals recorded as shown in Figure 22a. Of these, a highly significant
(P<0.005) thirty nine signals (11.6%) were located on chromosome ten with
seventeen (5.1%) comprising a single peak on 10p15. For confirmation and
refinement, the probe was hybrised to longer chromosomes (example Figure
23) obtained from human lymphocyte cultures synchronised with the
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mitogen phytohaemagglutinin. The positions of thirty six signals which fell
within 10p15 and which could be assigned with confidence to a single sub-
band are shown in Figure 22b. Thirty three signals (91.7%) were located at
10p15.2-p15.3 with twenty four signals (66.7%) at 10p15.3. Vora et al.
(1983) used a variety of human-rodent somatic cell hybrids to localise
HPPFK to chromosome 10p using polyspecific rodent antisera.
The localisation of this clone to 10p15.3 supports the contention that it
represents a sequence for HPPFK although it cannot be denied that it might
represent a processed pseudogene lying close to the gene for HPPFK. The
cloning and expression of a full length cDNA for HPPFK would resolve this
problem.
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Figure 22. a) hybridisation signal scores for FIPPFK
b) signal scores for HPPFK on chromosome ten
/
a
I
b
Figure 23. Chromosomal assignment of HPPFK to human
chromosome ten, a) before and b) after hybridisation
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SUMMMARY
Several methods were used to try to characterise PFK from
Onchocerca volvulus. Progress was not made due to the quality of the
onchocerca libraries, the lack of good quality heterologous probes and the
unexpected nature of onchocerca gene structure and sequence
characteristics. The use of a DNA probe from an organism with a similar
DNA structure and better quality onchocerca libraries might prove more
succesful in characterising genes from this parasite. The availability of
onchocerca tubulin as a probe will give an indication of the quality of any
library made available for screening.
A partial genomic clone of human muscle PFK was isolated using a
partial genomic clone of rabbit muscle PFK as a probe. This human genomic
clone was used to isolate a partial cDNA for human muscle PFK. This cDNA
clone was used to isolate a partial cDNA for human platelet PFK. The
identity of the clone was further established by localising its position to
human chromosome ten. The isolation of a complete clone encoding human
platelet PFK would allow further characterisation of the isoenzymes of
human PFK as the full length muscle and liver sequences have already
been reported. The availability of crystal structure data for the bacterial
enzyme makes mammalian phosphofructokinase an interesting target for
site directed mutagenesis.
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Appendix.
The sequence of the putative human platelet phosphofructokinase has been
submitted to the EMBL/GENBANK database under the accession number
M64784 and is reported in Simpson & Fothergill-Gilmore (1991) Biochem.
Biophys. Res. Comm. (in preparation). The chromosomal localisation of the
putative human platelet phosphofructokinase clone has been submitted to
Human Genetics (Morrison etal., 1991). This work has been supported by a
grant from the World Health Organisation, grant number 08/181/230.
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